UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended ~~September~~June 30, ~~2020~~2021


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from to

Commission File Number 001-36189

Tandem Diabetes Care, Inc.

(Exact name of registrant as specified in its charter)


Delaware		20-4327508
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
11075 Roselle Street		92121
San Diego,	California	(Zip Code)
(Address of principal executive offices)

(858) 366-6900

(Registrant’s telephone number, including area ~~code~~code)

Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class	~~Symbol~~Trading Symbol(s)	Name of Exchange on Which Registered
Common Stock, par value $0.001 per share	TNDM	~~NASDAQ~~Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~October~~July 30, ~~2020,~~2021, there were ~~62,194,609~~63,029,361 shares of the registrant’s Common Stock outstanding.

Table of contents

TABLE OF CONTENTS


Part I	Financial Information	1
Item 1	Financial Statements	1
	Condensed Consolidated Balance Sheets at ~~September~~June 30, ~~2020~~2021 (Unaudited) and December 31, ~~2019~~ 2020	1
	Condensed Consolidated Statements of Operations and Comprehensive ~~Loss~~Income (Loss) for the Three and ~~Nine~~Six Months Ended ~~September~~June 30, 2021 and 2020 ~~and 2019~~ (Unaudited)	2
	Condensed Consolidated Statements of Stockholders’ Equity for the Three and ~~Nine~~Six Months Ended ~~September~~June 30, 2021 and 2020 ~~and 2019~~ (Unaudited)	3
	Condensed Consolidated Statements of Cash Flows for the ~~Nine~~Six Months Ended ~~September~~June 30, 2021 and 2020 ~~and 2019~~ (Unaudited)	5
	Notes to Unaudited Condensed Consolidated Financial Statements	6
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 3	Quantitative and Qualitative Disclosures About Market Risk	41
Item 4	Controls and Procedures	4243

Part II	Other Information	4344
Item 1	Legal Proceedings	4344
Item 1A	Risk Factors	4445
Item 6	Exhibits	7982

Table of contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

TANDEM DIABETES CARE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value)


		September 30,		December 31,			June 30,		December 31,
		2020		2019			2021		2020
		(Unaudited)		(Note 1)			(Unaudited)		(Note 1)
Assets	Assets					Assets
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	129,481	$	51,175	Cash and cash equivalents	$	98,578	$	94,613
Short-term investments	Short-term investments	335,041		125,283		Short-term investments	446,724		390,323
Accounts receivable, net	Accounts receivable, net	52,104		46,585		Accounts receivable, net	80,212		82,195
Inventories	Inventories	70,644		49,073		Inventories	66,705		63,721
Prepaid and other current assets	Prepaid and other current assets	5,023		4,025		Prepaid and other current assets	6,066		6,383
Total current assets	Total current assets	592,293		276,141		Total current assets	698,285		637,235
Property and equipment, net	Property and equipment, net	49,320		32,923		Property and equipment, net	48,890		50,022
Operating lease right-of-use assets	Operating lease right-of-use assets	21,325		15,561		Operating lease right-of-use assets	31,499		19,773
Other long-term assets	Other long-term assets	10,050		1,485		Other long-term assets	16,576		9,385
Total assets	Total assets	$	672,988	$	326,110	Total assets	$	795,250	$	716,415
Liabilities and Stockholders’ Equity	Liabilities and Stockholders’ Equity					Liabilities and Stockholders’ Equity
Current liabilities:	Current liabilities:					Current liabilities:
Accounts payable	Accounts payable	$	20,499	$	17,745	Accounts payable	$	27,504	$	17,805
Accrued expenses	Accrued expenses	6,349		8,014		Accrued expenses	6,405		4,783
Employee-related liabilities	Employee-related liabilities	30,526		28,320		Employee-related liabilities	36,476		34,159
Deferred revenue	Deferred revenue	5,210		3,869		Deferred revenue	7,953		6,082
Common stock warrants	Common stock warrants	17,404		23,509		Common stock warrants	2,789		14,261
Operating lease liabilities	Operating lease liabilities	9,365		6,320		Operating lease liabilities	9,260		9,421
Other current liabilities	Other current liabilities	16,153		11,619		Other current liabilities	18,336		17,341
Total current liabilities	Total current liabilities	105,506		99,396		Total current liabilities	108,723		103,852
Convertible senior notes, net - long-term	Convertible senior notes, net - long-term	199,120		0		Convertible senior notes, net - long-term	280,599		202,984
Operating lease liabilities - long-term	Operating lease liabilities - long-term	17,893		14,063		Operating lease liabilities - long-term	27,376		15,914
Other long-term liabilities	Other long-term liabilities	23,925		17,672		Other long-term liabilities	32,467		27,360
Total liabilities	Total liabilities	346,444		131,131		Total liabilities	449,165		350,110
Commitments and contingencies (Note 10)
Commitments and contingencies (Note 11)						Commitments and contingencies (Note 11)	0		0
Stockholders’ equity:	Stockholders’ equity:					Stockholders’ equity:
Common stock, $0.001 par value; 200,000 shares authorized, 62,116 and 59,396 shares issued and outstanding at September 30, 2020 (unaudited) and December 31, 2019, respectively.		62		59
Common stock, $0.001 par value; 200,000 shares authorized, 62,952 and 62,335 shares issued and outstanding at June 30, 2021 (unaudited) and December 31, 2020, respectively.						Common stock, $0.001 par value; 200,000 shares authorized, 62,952 and 62,335 shares issued and outstanding at June 30, 2021 (unaudited) and December 31, 2020, respectively.	63		62
Additional paid-in capital	Additional paid-in capital	1,002,502		819,626		Additional paid-in capital	997,190		1,025,233
Accumulated other comprehensive income	Accumulated other comprehensive income	190		122		Accumulated other comprehensive income	29		220
Accumulated deficit	Accumulated deficit	(676,210)		(624,828)		Accumulated deficit	(651,197)		(659,210)
Total stockholders’ equity	Total stockholders’ equity	326,544		194,979		Total stockholders’ equity	346,085		366,305
Total liabilities and stockholders’ equity	Total liabilities and stockholders’ equity	$	672,988	$	326,110	Total liabilities and stockholders’ equity	$	795,250	$	716,415

See accompanying notes to unaudited condensed consolidated financial statements.

Table of contents

TANDEM DIABETES CARE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE ~~LOSS~~INCOME (LOSS)

(Unaudited)

(In thousands, except per share data)


		Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended June 30,				Six Months Ended June 30,
		2020		2019		2020		2019				2021		2020		2021		2020
Sales	Sales	$	123,603	$	94,657	$	330,765	$	253,907		Sales	$	172,139	$	109,236	$	313,176	$	207,162
Cost of sales	Cost of sales	58,290		43,974		160,801		119,967			Cost of sales	79,685		54,846		147,435		102,511
Gross profit	Gross profit	65,313		50,683		169,964		133,940			Gross profit	92,454		54,390		165,741		104,651
Operating expenses:	Operating expenses:										Operating expenses:
Selling, general and administrative	Selling, general and administrative	50,228		44,649		150,385		120,173			Selling, general and administrative	66,523		50,440		125,086		100,157
Research and development	Research and development	16,094		12,038		46,198		32,632			Research and development	20,499		15,987		38,460		30,104
Total operating expenses	Total operating expenses	66,322		56,687		196,583		152,805			Total operating expenses	87,022		66,427		163,546		130,261
Operating loss		(1,009)		(6,004)		(26,619)		(18,865)
Operating income (loss)											Operating income (loss)	5,432		(12,037)		2,195		(25,610)
Other income (expense), net:	Other income (expense), net:										Other income (expense), net:
Interest income and other, net	Interest income and other, net	143		854		1,235		2,381			Interest income and other, net	418		367		690		1,093
Interest expense	Interest expense	(4,855)		0		(8,030)		0			Interest expense	(1,509)		(3,176)		(3,015)		(3,176)

Change in fair value of common stock warrants	Change in fair value of common stock warrants	(3,648)		2,321		(19,906)		(10,849)			Change in fair value of common stock warrants	(272)		(14,336)		(962)		(16,258)
Total other income (expense), net		(8,360)		3,175		(26,701)		(8,468)
Loss before income taxes		(9,369)		(2,829)		(53,320)		(27,333)
Total other expense, net											Total other expense, net	(1,363)		(17,145)		(3,287)		(18,341)
Income (loss) before income taxes											Income (loss) before income taxes	4,069		(29,182)		(1,092)		(43,951)
Income tax expense (benefit)	Income tax expense (benefit)	39		72		(1,938)		72			Income tax expense (benefit)	61		(2,075)		(56)		(1,977)
Net loss		$	(9,408)	$	(2,901)	$	(51,382)	$	(27,405)
Other comprehensive loss:
Net income (loss)											Net income (loss)	$	4,008	$	(27,107)	$	(1,036)	$	(41,974)
Other comprehensive income (loss):											Other comprehensive income (loss):
Unrealized gain (loss) on short-term investments	Unrealized gain (loss) on short-term investments	$	(69)	$	(60)	$	78	$	91		Unrealized gain (loss) on short-term investments	$	(51)	$	105	$	(89)	$	147
Foreign currency translation gain (loss)	Foreign currency translation gain (loss)	216		(11)		(10)		13			Foreign currency translation gain (loss)	(26)		183		(102)		(226)
Comprehensive loss		$	(9,261)	$	(2,972)	$	(51,314)	$	(27,301)
Comprehensive income (loss)											Comprehensive income (loss)	$	3,931	$	(26,819)	$	(1,227)	$	(42,053)

Net loss per share, basic		$	(0.15)	$	(0.05)	$	(0.85)	$	(0.47)
Net loss per share, diluted		$	(0.15)	$	(0.09)	$	(0.85)	$	(0.47)
Net income (loss) per share, basic											Net income (loss) per share, basic	$	0.06	$	(0.45)	$	(0.02)	$	(0.70)
Net income (loss) per share, diluted											Net income (loss) per share, diluted	$	0.06	$	(0.45)	$	(0.02)	$	(0.70)

Weighted average shares used to compute basic net loss per share		61,529		58,801		60,568		58,268
Weighted average shares used to compute diluted net loss per share		61,529		59,196		60,568		58,268

Weighted average shares used to compute basic net income (loss) per share											Weighted average shares used to compute basic net income (loss) per share	62,717		60,424		62,583		60,082
Weighted average shares used to compute diluted net income (loss) per share											Weighted average shares used to compute diluted net income (loss) per share	65,663		60,424		62,583		60,082

See accompanying notes to unaudited condensed consolidated financial statements.

Table of contents

TANDEM DIABETES CARE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands)

Three Months Ended ~~September~~June 30, ~~2020~~2021

Common Stock Additional
Paid-in
Capital Accumulated
Other
Comprehensive
Income (Loss) Accumulated
Deficit Total
Stockholders’
Equity
Shares Amount
Balance at June 30, 2020 60,787 $ 61 $ 934,402 $ 43 $ (666,802) $ 267,704
Exercise of stock options 1,072 1 29,030 — — 29,031
Exercise of common stock warrants 257 — 899 — — 899
Fair value of common stock warrants at time of exercise — — 25,870 — — 25,870
Stock-based compensation — — 12,301 — — 12,301
Unrealized (loss) on short-term investments — — — (69) — (69)
Foreign currency translation adjustments — — — 216 — 216
Net loss — — — — (9,408) (9,408)
Balance at September 30, 2020 62,116 $ 62 $ 1,002,502 $ 190 $ (676,210) $ 326,544


	Common Stock			Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total Stockholders’ Equity
	Shares	Amount
Balance at March 31, 2021	62,571	$	63	$	968,450	$	106	$	(655,205)	$	313,414
Exercise of stock options	252	—		8,172		—		—		8,172
Vesting of restricted stock units, net of shares withheld for taxes	29	—		(867)		—		—		(867)
Issuance of common stock for Employee Stock Purchase Plan	100	—		6,317		—		—		6,317



Stock-based compensation expense	—	—		15,118		—		—		15,118
Unrealized loss on short-term investments	—	—		—		(51)		—		(51)
Foreign currency translation adjustments	—	—		—		(26)		—		(26)
Net income	—	—		—		—		4,008		4,008
Balance at June 30, 2021	62,952	$	63	$	997,190	$	29	$	(651,197)	$	346,085

~~Nine~~Six Months Ended ~~September~~June 30, ~~2020~~2021


		Common Stock			Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total Stockholders’ Equity			Common Stock			Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total Stockholders’ Equity
		Shares	Amount											Shares	Amount
Balance at December 31, 2019		59,396	$	59	$	819,626	$	122	$	(624,828)	$	194,979
Balance at December 31, 2020													Balance at December 31, 2020	62,335	$	62	$	1,025,233	$	220	$	(659,210)	$	366,305
Effect of change in accounting for convertible senior notes(1)													Effect of change in accounting for convertible senior notes(1)	—	—		(85,803)		—		9,049		(76,754)
Exercise of stock options	Exercise of stock options	2,199	3		52,759		—		—		52,762		Exercise of stock options	363	1		11,307		—		—		11,308
Vesting of restricted stock units, net of shares withheld for taxes													Vesting of restricted stock units, net of shares withheld for taxes	29	—		(867)		—		—		(867)
Issuance of common stock for Employee Stock Purchase Plan	Issuance of common stock for Employee Stock Purchase Plan	229	—		4,916		—		—		4,916		Issuance of common stock for Employee Stock Purchase Plan	100	—		6,317		—		—		6,317
Exercise of common stock warrants	Exercise of common stock warrants	292	—		2,935		—		—		2,935		Exercise of common stock warrants	125	—		437		—		—		437
Fair value of common stock warrants at time of exercise	Fair value of common stock warrants at time of exercise	—	—		26,011		—		—		26,011		Fair value of common stock warrants at time of exercise	—	—		12,434		—		—		12,434
Equity component of convertible note issuance, net of issuance cost		—	—		85,803		—		—		85,803
Purchase of capped call options related to convertible notes		—	—		(34,069)		—		—		(34,069)
Stock-based compensation		—	—		44,521		—		—		44,521
Unrealized gain on short-term investments		—	—		—		78		—		78
Stock-based compensation expense													Stock-based compensation expense	—	—		28,132		—		—		28,132
Unrealized loss on short-term investments													Unrealized loss on short-term investments	—	—		—		(89)		—		(89)
Foreign currency translation adjustments	Foreign currency translation adjustments	—	—		—		(10)		—		(10)		Foreign currency translation adjustments	—	—		—		(102)		—		(102)
Net loss	Net loss	—	—		—		—		(51,382)		(51,382)		Net loss	—	—		—		—		(1,036)		(1,036)
Balance at September 30, 2020		62,116	$	62	$	1,002,502	$	190	$	(676,210)	$	326,544
Balance at June 30, 2021													Balance at June 30, 2021	62,952	63		997,190		29		(651,197)		$	346,085

(1) The Company adopted ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity effective January 1, 2021 (see Note 2, “Summary of Significant Accounting Policies”).

See accompanying notes to unaudited condensed consolidated financial statements.

~~Three Months Ended September 30, 2019~~

Common Stock Additional
Paid-in
Capital Accumulated
Other
Comprehensive
Income (Loss) Accumulated
Deficit Total
Stockholders’
Equity
Shares Amount
Balance at June 30, 2019 58,589 $ 58 $ 769,704 $ 162 $ (624,579) $ 145,345
Exercise of stock options 440 1 7,033 — — 7,034
Fair value of common stock warrants at time of exercise — — 13 — — 13
Stock-based compensation — — 17,574 — — 17,574
Unrealized loss on short-term investments — — — (60) — (60)
Foreign currency translation adjustments — — — (11) — (11)
Net loss — — — — (2,901) (2,901)
Balance at September 30, 2019 59,029 $ 59 $ 794,324 $ 91 $ (627,480) $ 166,994
:AccountingStandardsUpdate202006Member

Table of contents

Three Months Ended June 30, 2020


	Common Stock			Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total Stockholders’ Equity
	Shares	Amount
Balance at March 31, 2020	60,071	$	60	$	847,056	$	(245)	$	(639,695)	$	207,176

Exercise of stock options	453	1		12,254		—		—		12,255
Issuance of common stock for Employee Stock Purchase Plan	229	—		4,916		—		—		4,916
Exercise of common stock warrants	34	—		2,029		—		—		2,029
Equity component of convertible senior notes issuance, net of issuance costs	—	—		85,803		—		—		85,803
Payment for capped call transactions related to convertible senior notes	—	—		(34,069)		—		—		(34,069)
Stock-based compensation expense	—	—		16,413		—		—		16,413
Unrealized gain on short-term investments	—	—		—		105		—		105
Foreign currency translation adjustments	—	—		—		183		—		183
Net loss	—	—		—		—		(27,107)		(27,107)
Balance at June 30, 2020	60,787	$	61	$	934,402	$	43	$	(666,802)	$	267,704

~~Nine~~Six Months Ended ~~September~~June 30, ~~2019~~2020


		Common Stock			Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total Stockholders’ Equity			Common Stock			Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total Stockholders’ Equity
		Shares	Amount											Shares	Amount
Balance at December 31, 2018		57,554	$	57	$	731,306	$	(13)	$	(600,075)	$	131,275
Balance at December 31, 2019													Balance at December 31, 2019	59,396	$	59	$	819,626	$	122	$	(624,828)	$	194,979

Exercise of stock options	Exercise of stock options	1,214	2		14,510		—		—		14,512		Exercise of stock options	1,126	2		23,728		—		—		23,730
Issuance of common stock for Employee Stock Purchase Plan	Issuance of common stock for Employee Stock Purchase Plan	168	—		2,951		—		—		2,951		Issuance of common stock for Employee Stock Purchase Plan	229	—		4,916		—		—		4,916
Exercise of common stock warrants	Exercise of common stock warrants	93	—		326		—		—		326		Exercise of common stock warrants	36	—		2,036		—		—		2,036
Fair value of common stock warrants at time of exercise	Fair value of common stock warrants at time of exercise	—	—		5,492		—		—		5,492		Fair value of common stock warrants at time of exercise	—	—		141		—		—		141
Stock-based compensation		—	—		39,739		—		—		39,739
Equity component of convertible senior notes issuance, net of issuance costs													Equity component of convertible senior notes issuance, net of issuance costs	—	—		85,803		—		—		85,803
Payment for capped call transactions related to convertible senior notes													Payment for capped call transactions related to convertible senior notes	—	—		(34,069)		—		—		(34,069)
Stock-based compensation expense													Stock-based compensation expense	—	—		32,221		—		—		32,221
Unrealized gain on short-term investments	Unrealized gain on short-term investments	—	—		—		91		—		91		Unrealized gain on short-term investments	—	—		—		147		—		147
Foreign currency translation adjustments	Foreign currency translation adjustments	—	—		—		13		—		13		Foreign currency translation adjustments	—	—		—		(226)		—		(226)
Net loss	Net loss	—	—		—		—		(27,405)		(27,405)		Net loss	—	—		—		—		(41,974)		(41,974)
Balance at September 30, 2019		59,029	$	59	$	794,324	$	91	$	(627,480)	$	166,994
Balance at June 30, 2020													Balance at June 30, 2020	60,787	$	61	$	934,402	$	43	$	(666,802)	$	267,704

See accompanying notes to unaudited condensed consolidated financial statements.

Table of contents

TANDEM DIABETES CARE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)


		Nine Months Ended September 30,					Six Months Ended June 30,
		2020		2019			2021		2020
Operating Activities	Operating Activities					Operating Activities
Net loss	Net loss	$	(51,382)	$	(27,405)	Net loss	$	(1,036)	$	(41,974)
Adjustments to reconcile net loss to net cash provided by operating activities:
Adjustments to reconcile net loss to net cash provided (used) by operating activities:						Adjustments to reconcile net loss to net cash provided (used) by operating activities:
Depreciation and amortization expense	Depreciation and amortization expense	7,024		4,430		Depreciation and amortization expense	6,925		4,035
Amortization of debt discount and debt issuance costs		6,233		0
Amortization of debt discount and issuance costs						Amortization of debt discount and issuance costs	859		2,457
Provision for expected credit losses	Provision for expected credit losses	2,181		1,468		Provision for expected credit losses	874		1,529
Provision (recovery) for inventory obsolescence		(109)		1,508
Provision for (recovery of) inventory obsolescence						Provision for (recovery of) inventory obsolescence	211		(81)
Change in fair value of common stock warrants	Change in fair value of common stock warrants	19,906		10,849		Change in fair value of common stock warrants	962		16,258
Amortization of discount on short-term investments	Amortization of discount on short-term investments	(1,446)		(302)		Amortization of discount on short-term investments	(306)		(1,127)
Benefit for deferred income taxes	Benefit for deferred income taxes	(2,126)		0		Benefit for deferred income taxes	0		(2,126)
Stock-based compensation expense	Stock-based compensation expense	45,123		39,386		Stock-based compensation expense	27,924		32,286

Other	Other	37		42		Other	(106)		36
Changes in operating assets and liabilities:	Changes in operating assets and liabilities:					Changes in operating assets and liabilities:
Accounts receivable, net	Accounts receivable, net	(7,820)		(11,588)		Accounts receivable, net	1,046		(50)
Inventories	Inventories	(22,052)		(21,990)		Inventories	(2,965)		(13,181)
Prepaid and other current assets	Prepaid and other current assets	(1,082)		(17)		Prepaid and other current assets	411		(2,101)
Other long-term assets	Other long-term assets	33		(387)		Other long-term assets	(159)		6
Accounts payable		3,268		7,131
Accrued expenses		(1,679)		4,045
Accounts payable and accrued expenses						Accounts payable and accrued expenses	11,957		(3,779)

Employee-related liabilities	Employee-related liabilities	1,704		4,173		Employee-related liabilities	2,318		(3,094)
Deferred revenue	Deferred revenue	4,215		3,587		Deferred revenue	5,288		2,668
Other current liabilities	Other current liabilities	5,023		2,335		Other current liabilities	1,170		2,428
Other long-term liabilities	Other long-term liabilities	2,381		5,198		Other long-term liabilities	2,207		678
Net cash provided by operating activities		9,432		22,463
Net cash provided (used) by operating activities						Net cash provided (used) by operating activities	57,580		(5,132)
Investing Activities	Investing Activities					Investing Activities
Purchases of short-term investments	Purchases of short-term investments	(331,968)		(126,307)		Purchases of short-term investments	(385,580)		(166,984)
Proceeds from maturities of short-term investments	Proceeds from maturities of short-term investments	82,709		96,495		Proceeds from maturities of short-term investments	308,607		54,709
Proceeds from sales of short-term investments	Proceeds from sales of short-term investments	41,027		6,550		Proceeds from sales of short-term investments	20,788		35,027
Purchases of property and equipment	Purchases of property and equipment	(23,312)		(12,792)		Purchases of property and equipment	(5,339)		(16,552)
Acquisition of intangible assets		(4,886)		0
Acquisition of intangible assets and equity investments						Acquisition of intangible assets and equity investments	(9,331)		(4,805)
Net cash used in investing activities	Net cash used in investing activities	(236,430)		(36,054)		Net cash used in investing activities	(70,855)		(98,605)
Financing Activities	Financing Activities					Financing Activities
Proceeds from issuance of convertible senior notes, net of $8,809 debt issuance costs	Proceeds from issuance of convertible senior notes, net of $8,809 debt issuance costs	278,691		0		Proceeds from issuance of convertible senior notes, net of $8,809 debt issuance costs	0		278,691
Purchase of capped call options related to convertible senior notes		(34,069)		0
Payment for capped call transactions related to convertible senior notes						Payment for capped call transactions related to convertible senior notes	0		(34,069)

Proceeds from issuance of common stock under Company stock plans		57,677		327
Proceeds from issuance of common stock under Company stock plans, net						Proceeds from issuance of common stock under Company stock plans, net	16,758		28,645

Proceeds from exercise of common stock warrants	Proceeds from exercise of common stock warrants	2,935		17,462		Proceeds from exercise of common stock warrants	438		2,036
Net cash provided by financing activities	Net cash provided by financing activities	305,234		17,789		Net cash provided by financing activities	17,196		275,303
Effect of foreign exchange rate changes on cash	Effect of foreign exchange rate changes on cash	70		36		Effect of foreign exchange rate changes on cash	44		(262)
Net increase in cash and cash equivalents	Net increase in cash and cash equivalents	78,306		4,234		Net increase in cash and cash equivalents	3,965		171,304
Cash and cash equivalents at beginning of period	Cash and cash equivalents at beginning of period	51,175		41,826		Cash and cash equivalents at beginning of period	94,613		51,175
Cash and cash equivalents at end of period	Cash and cash equivalents at end of period	$	129,481	$	46,060	Cash and cash equivalents at end of period	$	98,578	$	222,479
Supplemental disclosures of cash flow information	Supplemental disclosures of cash flow information					Supplemental disclosures of cash flow information

Income taxes paid	Income taxes paid	$	192	$	67	Income taxes paid	$	197	$	131
Supplemental schedule of non-cash investing and financing activities	Supplemental schedule of non-cash investing and financing activities					Supplemental schedule of non-cash investing and financing activities
Right-of-use assets obtained in exchange for operating lease obligations	Right-of-use assets obtained in exchange for operating lease obligations	$	11,022	$	11,445	Right-of-use assets obtained in exchange for operating lease obligations	$	15,087	$	8,805

Property and equipment included in accounts payable	Property and equipment included in accounts payable	$	1,618	$	2,484	Property and equipment included in accounts payable	$	452	$	977
Intangible costs in accounts payable and other long-term liabilities		$	2,348	$	0
Intangible costs in other current and other long-term liabilities						Intangible costs in other current and other long-term liabilities	$	1,029	$	2,348

See accompanying notes to unaudited condensed consolidated financial statements.

Table of contents

TANDEM DIABETES CARE, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Organization and Basis of Presentation

The Company

Tandem Diabetes Care, Inc. is a medical device company with ~~an innovative~~a positively different approach to the design, development and commercialization of products for people with insulin-dependent diabetes. ~~The Company~~Tandem Diabetes Care, Inc. is incorporated in the state of Delaware. Unless the context requires otherwise, the terms the “Company” or “Tandem” refer to Tandem Diabetes Care, Inc., together with its wholly-owned subsidiaries in the U.S. and Canada.

The Company manufactures, sells and supports insulin pump products that are designed to address the evolving needs and preferences of differentiated segments of the insulin-dependent diabetes market. The Company’s manufacturing, sales and support activities principally focus on the t:slim X2 Insulin Delivery System (t:slim X2), the Company’s flagship pump platform which is capable of remote ~~feature~~software updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. The Company’s insulin pump products are compatible with other complementary digital health offerings, such as the t:connect cloud-based ~~data~~diabetes management application (t:connect) and the Tandem Device Updater, a Mac and PC-compatible tool ~~for the remote update~~which offers and supports different updates of the Company’s insulin pump ~~software.~~software from a personal computer. The Company’s insulin pump products are generally considered durable medical equipment and have an expected lifespan of at least four years. In addition to insulin pumps, the Company sells disposable products that are used together with the pumps and are replaced every few days, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to a user’s ~~body.~~

The Company has commercially launched 7 insulin pumps in the United States since 2012 and 3 pumps outside the United States since 2018. Four of the insulin pumps have featured integration with CGM technology, of which two have also featured an automated insulin delivery (AID) algorithm. In June 2018, the t:slim X2 was the first insulin pump designatedbody, as compatible with integrated CGM (iCGM) devices; in February 2019, the t:slim X2 was the first insulin pump in a new device category called Alternate Controller Enabled Infusion Pumps (ACE pumps); and in December 2019, Control-IQ technologywell as other accessories for the t:slim X2 insulin pump was the first automated insulin dosing software in a new interoperable automated glycemic controller category. The Company believes that the three new classifications by the United States Food and Drug Administration (FDA) for the interoperability of devices for AID will help support continued rapid innovation by streamlining the regulatory pathway for integrated products in the United States.

As of September 30, 2020, the Company had $464.5 million in cash and cash equivalents and short-term investments. The Company has incurred operating losses since its inception and had an accumulated deficit of $676.2 million as of September 30, 2020, which included a net loss of $51.4 million for the nine months ended September 30, 2020. Management believes that the cash, cash equivalents and short-term investments on hand will be sufficient to satisfy the Company’s liquidity requirements for at least the next 12 months from the date of this filing.

The Company’s ability to execute on its business strategy, meet its future liquidity requirements, and achieve and maintain profitable operations, is dependent on a number of factors, including its ability to continue to gain market acceptance of its products and achieve a level of revenues adequate to support its cost structure, achieve renewal pump sales objectives, develop and launch new products, expand the commercialization of products into new international markets, maximize manufacturing efficiencies, satisfy increasing production requirements, leverage the investments made in its sales, clinical, marketing and customer support organizations, and operate its business and manufacture and sell products without infringing on third-party intellectual property rights.

The Company has funded its operations primarily through cash collected from product sales, private and public offerings of equity securities, and debt financing. The Company may in the future seek additional capital from public or private offerings of equity or debt securities, or it may elect to borrow capital under new credit arrangements or from other sources. If the Company issues equity or debt securities to raise additional funds, its existing stockholders may experience dilution, it may incur significant financing or debt service costs, and the new equity or debt securities may have rights, preferences and privileges senior to those of its existing stockholders. There can be no assurance that equity or debt financing will be available on acceptable terms, or at all.

~~Table of contents~~

enhanced usability.

Basis of Presentation and Principles of Consolidation

The Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments which are of a normal and recurring nature, considered necessary for a fair presentation of the financial information contained herein, have been included.

Interim financial results are not necessarily indicative of results anticipated for the full year or any other period(s). These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2019~~2020 (Annual Report), from which the balance sheet information herein was derived.

The condensed consolidated financial statements include the accounts of Tandem Diabetes Care, Inc. and its wholly-owned subsidiaries in the U.S. and Canada. All significant intercompany balances and transactions have been eliminated in consolidation.

The functional currency of the Company’s foreign subsidiary is the local currency. The Company translates the financial statements of its foreign subsidiary into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for each period for revenue, costs and expenses. Translation related adjustments are included in other comprehensive loss, and in accumulated other comprehensive income ~~(loss)~~ in the stockholders’ equity section of the Company’s condensed consolidated balance sheets. Foreign exchange gains or losses resulting from balances denominated in a currency other than the functional currency are recognized in interest income and other, net in the Company’s condensed consolidated statements of operations.

~~Reclassification~~Reclassifications

Prior year amounts related to the presentation of other income (expense), net on the Company’s condensed consolidated statement of operations and comprehensive loss, have been reclassified to conform to the current year presentation. Starting with the third quarter of 2020, the first full quarter in which the Company’s convertible senior notes were outstanding, the Company began to present non-operating expenses unrelated to the convertible senior notes with interest income and other, net. In prior periods, other non-operating expenses were combined with interest expense and reported as interest and other expense.

Table of contents

2. Summary of Significant Accounting Policies

There have been no material changes to the Company’s significant accounting policies during the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, as compared to those disclosed in the Annual Report, ~~with~~other than the ~~exception~~adoption of ~~policies put~~ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in ~~place with regards to its convertible senior notes issued in May 2020.~~an Entity’s Own Equity, effective January 1, 2021(see Note 7, “Convertible Senior Notes”).

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes as of the date of the consolidated financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions.

~~Segment Reporting~~

Operating segments are identified as components of an enterprise about which discrete financial information is available for evaluation by the chief operating decision-maker (CODM) in making decisions regarding resource allocation and assessing performance. The Company is organized based on its current product portfolio, which consists primarily of insulin pumps, disposable cartridges and infusion sets for the storage and delivery of insulin. The Company views its operations and manages its business as 1 segment because key operating decisions and resource allocations are made by the CODM using consolidated financial data.

~~Table of contents~~

Accounts Receivable

The Company grants credit to various customers in the ordinary course of business and is paid directly by customers who use the products, distributors and third-party insurance payors. The Company maintains an allowance for its current estimate of expected credit losses. Provisions for expected credit losses are estimated based on historical experience, assessment of specific risk, review of outstanding invoices, forecasts about the future, and various assumptions and estimates that are believed to be reasonable under the circumstances, which included the Company’s estimates of credit risks as a result of the ~~novel~~ coronavirus pandemic (COVID-19 global pandemic). Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible.

Fair Value of Financial Instruments

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, and employee-related liabilities are reasonable estimates of their fair values because of the short-term nature of these assets and liabilities. Short-term investments are carried at fair value. The Company determined the fair value of its convertible senior notes ~~at September 30, 2020~~ to be ~~$367.2~~$326.6 million at June 30, 2021, and $333.5 million at December 31, 2020, based on Level 2 quoted market prices ~~as of that date~~ (see Note 7, “Convertible Senior Notes”). The estimated fair value of certain of the Company’s common stock warrants was determined using the Black-Scholes pricing model as of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019~~2020 (see Note 5, “Fair Value Measurements”).

Operating Lease Right-of-Use Assets and Liabilities

~~In February 2016, the FASB issued~~ ~~ASU No. 2016-02~~, ~~Leases~~. The new standard and its related amendments (collectively referred to as ASC 842) require lessees to recognize right-of-use assets and corresponding lease liabilities for all leases with lease terms of greater than 12 months. The new standard was effective for the Company starting in the first quarter of 2019. The Company adopted the new standard using the modified retrospective approach and recognized right-of-use leased assets and corresponding operating lease liabilities of $12.4 million on the consolidated balance sheet as of January 1, 2019. The Company did not restate prior periods. Deferred rent of $1.0 million and $3.8 million as of January 1, 2019 was reclassified from other current liabilities and deferred rent long-term, respectively, to a reduction of the right-of-use leased assets in connection with the adoption of the standard.

Lease right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent ~~their~~its obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized when the Company takes possession of the leased property (the Commencement Date) based on the present value of lease payments over the lease term. For lease agreements entered into or reassessed after the adoption of ASC 842, the Company combines lease and non-lease components. Rent expense on ~~noncancelable~~noncancellable leases containing known future scheduled rent increases is recorded on a straight-line basis over the term of the respective leases beginning on the Commencement ~~Date.~~Date (see Note 6, “Leases”). The difference between rent expense and rent paid is accounted for as a component of operating lease right-of-use assets on the Company’s condensed consolidated balance ~~sheet.~~sheets. Landlord improvement allowances and other similar lease incentives are recorded as property and equipment and as a reduction of the right-of-use leased assets, and are amortized on a straight-line basis as a reduction to operating lease costs. ~~Leases with~~

Cost Basis Equity Investment

During the second quarter of 2021, the Company made an ~~initial term~~$8.1 million equity investment in a private company, which represented less than 5% of ~~12 months or less are expensed~~the outstanding equity of that company. The investment is accounted for using the cost method, as ~~incurred~~the investment does not have a readily determinable fair value, and ~~are not recorded~~is included as ~~right-of-use~~a component of other long-term assets on the condensed consolidated balance ~~sheets (see Note 6, “Leases”).~~sheet at June 30, 2021.

Intangible Assets Subject to Amortization

~~Intangible~~

Table of contents

Finite-lived intangible assets ~~subject to~~are recorded at cost, net of accumulated amortization ~~consist~~and, if applicable, impairment charges. Amortization of ~~developed technology~~finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis. The Company reviews its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company did not recognize any impairment losses during the six months ended June 30, 2021 and ~~patents purchased or licensed that are related to the Company’s commercialized products, and are included in other long-term assets on the consolidated balance sheets.~~2020.

On June 24, 2020, the Company acquired Sugarmate, Inc. (Sugarmate), the developer of a ~~popular~~ mobile app ~~for people with diabetes who use insulin, which is~~ designed to help people ~~with diabetes~~ visualize diabetes therapy data in innovative ways. The Sugarmate acquisition was accounted for as an acquisition of assets in accordance with Accounting Standards Update (ASU) No. 2017-01, Business Combinations (Topic 805) Clarifying the Definition of a ~~Business.~~Business. Substantially all of the ~~purchase price~~fair value was ~~allocated to~~concentrated in a single identifiable asset, a technology-based intangible asset. The purchased intangible asset ~~which~~ is being amortized on a straight-line basis over an estimated useful life of five years. The Company’s results of operations ~~for the three and nine months ended September 30, 2020 included~~include the operating results of Sugarmate since the date of acquisition, the amounts of which were not material.

~~Table of contents~~

~~Convertible Senior Notes~~

In accounting for the issuance of the convertible senior notes, the Company separated the notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments that do not have associated convertible features. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the respective notes. The equity component is not remeasured as long as it continues to meet the condition for equity classification. The excess of the principal amount of the liability component over its carrying amount (“debt discount”) is amortized to interest expense over the term of the notes.

The Company allocated the issuance costs incurred to the liability and equity components of the notes based on their relative fair values. Issuance costs attributable to the liability component were recorded as a reduction to the liability portion of the notes and are being amortized to interest expense over the term of the notes. Issuance costs attributable to the equity component, representing the conversion option, were netted with the equity component in stockholders' equity.

Revenue Recognition

Revenue is generated primarily from sales of insulin pumps, disposable cartridges and infusion sets to individual customers with third-party insurance coverage and ~~third-party~~through a network of distributors that resell the products to insulin-dependent diabetes customers. The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.

Revenue Recognition for Arrangements with Multiple Deliverables

The Company considers the individual deliverables in its product offering asto be separate performance obligations. The transaction price is determined based on the consideration expected to be received, based either on the stated value in contractual arrangements or the estimated cash to be collected in non-contracted arrangements. The Company allocates the consideration to the individual performance obligations and recognizes the consideration based on when the performance obligation is satisfied, considering whether or not this occurs at a point in time or over time. Generally, insulin pumps, cartridges, infusion sets and accessories are deemed performance obligations that are satisfied at a point in time when the customer obtains control of the promised good, which typically is upon ~~delivery.~~shipment for our distributor arrangements and upon receipt for sales directly to individual customers. Complementary products, such as t:connect and the Tandem Device Updater, are considered performance obligations that are satisfied over time, as access and support for these products is provided throughout the typical four-year warranty period of the insulin pumps. Accordingly, revenue related to the complementary products is deferred and recognized ratably over a four-year period. When there is no standalone value for the complementary product, the Company determines their value by applying the expected cost plus a margin approach and then allocates the residual to the insulin pumps. Deferred revenue related to these performance obligations that are satisfied over time was included in the following consolidated balance sheet accounts in the amounts shown as of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019~~2020 (in thousands):

September 30, 2020 December 31, 2019
Deferred revenue $ 4,608 $ 3,465
Other long-term liabilities 8,499 5,656
Total $ 13,107 $ 9,121

~~Sales Returns~~

The Company offers a 30-day right of return to customers in the U.S. and Canada from the date of shipment of its insulin pumps, provided a physician’s confirmation of the medical reason for the return is received. Estimated allowances for sales returns are based on historical returned quantities as compared to pump shipments in those same periods of return, adjusted for known or expected changes in the marketplace when appropriate. The amount recorded in deferred revenue on the Company’s consolidated balance sheets for allowances for sales returns was $0.6 million and $0.4 million at September 30, 2020 and December 31, 2019, respectively. Actual product returns have not differed materially from estimated amounts recorded in the accompanying condensed consolidated financial statements.

~~Table of contents~~


	June 30, 2021		December 31, 2020
Deferred revenue	$	7,471	$	5,508
Other long-term liabilities	13,841		10,426
Total	$	21,312	$	15,934

Warranty Reserve

The Company generally provides a four-year warranty on its insulin pumps to end-user customers and may replace any pumps that do not function in accordance with the product specifications. Insulin pumps returned to the Company may be refurbished and redeployed. Additionally, the Company offers a six-month warranty on disposable cartridges and infusion sets. Estimated warranty costs are recorded at the time of shipment. The Company evaluates the reserve quarterly. Warranty costs are primarily estimated based on the current expected product replacement cost and expected replacement rates utilizing historical experience. Recently released versions of the pump may not incur warranty costs in a manner similar to previously released pumps, on which the Company initially bases its warranty estimate of newer pumps. The Company may make further adjustments to the warranty reserve when deemed appropriate, giving additional consideration to the length of time the pump version has been in the field and future expectations of performance based on new features and capabilities that may become available through Tandem Device Updater.

Table of contents

The following table provides a reconciliation of the ~~change~~changes in product warranty liabilities ~~from December 31, 2019 through September~~for the three and six months ended June 30, 2021 and 2020 (in thousands):


~~Balance at December 31, 2019~~	$	~~16,724~~
~~Provision for warranties issued during the period~~	~~14,588~~
~~Settlements made during the period~~	~~(10,217)~~
~~Decreases in warranty estimates~~	~~(2,902)~~
~~Balance at September 30, 2020~~	$	~~18,193~~


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Balance at beginning of period	$	23,169	$	16,761	$	22,075	$	16,724
Provision for warranties issued during the period	8,020		4,844		13,916		9,658
Settlements made during the period	(4,751)		(3,331)		(9,007)		(6,721)
Decrease in warranty estimates	(770)		(451)		(1,316)		(1,838)
Balance at end of period	$	25,668	$	17,823	$	25,668	$	17,823

As of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, total product warranty reserves of ~~$18.2~~$25.7 million and ~~$16.7~~$22.1 million, respectively, were included in the following consolidated balance sheet accounts (in thousands):


		September 30, 2020		December 31, 2019			June 30, 2021		December 31, 2020
Other current liabilities	Other current liabilities	$	6,964	$	4,707	Other current liabilities	$	9,795	$	8,409
Other long-term liabilities	Other long-term liabilities	11,229		12,017		Other long-term liabilities	15,873		13,666
Total warranty reserve	Total warranty reserve	$	18,193	$	16,724	Total warranty reserve	$	25,668	$	22,075

Stock-Based Compensation

Stock-based compensation cost is measured at the grant date based on the estimated fair value of the award, and the portion that is ultimately expected to vest is recognized as compensation expense over the requisite service period on a straight-line basis. The Company estimates the fair value of stock options issued under the Company’s Amended and Restated 2013 Stock Incentive Plan (2013 Plan), and the fair value of the employees’ purchase rights under the Company’s 2013 Employee Stock Purchase Plan (ESPP), using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model requires the use of assumptions about a number of variables, including stock price volatility, expected term, dividend yield and risk-free interest rate (see Note 8, “Stockholders’ Equity”). The fair value of restricted stock unit (RSU) awards issued under the ~~Company’s~~ 2013 Plan that vest solely based on service is estimated based on the fair market value of the underlying stock on the date of grant.

~~Table~~ The fair value of ~~contents~~

RSU awards issued under the 2013 Plan that vest based upon the Company’s actual performance relative to predefined performance metrics is estimated based on the fair market value of the underlying stock on the date of grant and the probability that the specified performance criteria will be met, subject to the awardee’s continuing service through the measurement date. We update our assessment of the probability that the specified performance criteria will be achieved each quarter, and adjust our estimate of the fair value of the performance-based RSUs if necessary.

Net ~~Loss~~Income (Loss) Per Share

Basic net ~~loss~~income (loss) per share is calculated by dividing the net ~~loss~~income (loss) by the weighted average number of common shares ~~that were~~ outstanding for the period, without consideration for common stock equivalents. Diluted ~~loss~~net income per share reflects the potential dilution that would occur if securities exercisable for or convertible into common stock were exercised for or converted into common stock. Dilutive common share equivalents are comprised of ~~warrants,~~ stock options and unvested RSUs outstanding under the Company’s ~~equity incentive~~stock plans, ~~unvested RSUs, and~~ potential awards to be granted pursuant to the ESPP, and common stock warrants, each calculated using the treasury stock method; and shares issuable upon conversion of the convertible senior ~~convertible~~ notes, calculated using the if-converted method. For common stock warrants that are recorded as a liability in the accompanying condensed consolidated balance sheets, the calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of the warrants is dilutive to loss per share for the period, an adjustment is made to net loss used in the calculation to remove the change in fair value of the warrants from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method.

Table of contents

For ~~all periods presented other than~~ the three months ended ~~September~~June 30, ~~2019,~~2020, and the six months ended June 30, 2021 and 2020, there is no difference in the weighted average number of shares used to calculate basic and diluted ~~shares outstanding~~net loss per share due to the Company’s net loss position. For the three months ended ~~September~~June 30, ~~2019,~~2021, the ~~net loss used in~~numerator and denominator of the ~~calculation of~~ diluted net ~~loss~~income per share ~~was increased by $2.3 million to remove the decrease in fair value of common stock warrants based on the dilutive effect of assumed exercise, and the denominator was increased by 394,433 shares~~computation are calculated ~~under the treasury stock method.~~as follows:


	Three Months Ended June 30,
(in thousands)	2021
Net income - basic and diluted	$	4,008



Weighted average shares outstanding - basic	62,717
Dilutive common share equivalents:
Options to purchase common stock	2,550
Unvested restricted stock units	246
Warrants to purchase common stock	148
Awards to be granted under the ESPP	2
Convertible senior notes (if-converted)	0
Weighted average shares outstanding - diluted	65,663

Potentially dilutive securities outstanding and not included in the calculation of diluted net loss per share (because inclusion would be anti-dilutive) are as follows (in thousands, in common stock equivalent shares):


		Three Months Ended September 30,		Nine Months Ended September 30,			Three Months Ended June 30,		Six Months Ended June 30,
		2020	2019	2020	2019		2021	2020	2021	2020
Warrants to purchase common stock		383	293	383	710
Options to purchase common stock	Options to purchase common stock	5,548	6,234	5,128	5,868	Options to purchase common stock	0	6,195	5,136	5,992
Unvested restricted stock units	Unvested restricted stock units	134	N/A	61	N/A	Unvested restricted stock units	0	132	170	132
Awards granted under the ESPP		42	134	21	45
Warrants to purchase common stock						Warrants to purchase common stock	30	640	251	640
Awards to be granted under the ESPP						Awards to be granted under the ESPP	0	8	4	4
Convertible senior notes (if-converted)	Convertible senior notes (if-converted)	2,554	N/A	1,286	N/A	Convertible senior notes (if-converted)	2,554	1,375	2,554	688
		8,661	6,661	6,879	6,623		2,584	8,350	8,115	7,456

Recent Accounting Pronouncements

In ~~June 2016,~~December 2019, the Financial Accounting Standards Board (FASB) ~~issued Accounting Standards Update (ASU) No. 2016-13,~~ ~~Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,~~ which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income (loss) rather than reducing the carrying amount under the prior, other-than-temporary-impairment model. The new standard must be adopted using the modified retrospective approach and was effective for the Company starting in the first quarter of 2020. The Company determined there was no cumulative-effect transition adjustment to the opening balance of accumulated deficit for recognition of additional credit losses upon adoption of this standard as of January 1, 2020 based on its outstanding accounts receivable, the composition and credit quality of its short-term investments, and current economic conditions as of that date.

~~In August 2018, the FASB issued ASU No. 2018-13,~~ ~~Fair Value Measurement: Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement~~, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The updated guidance was effective for the Company starting in the first quarter of 2020. As a result, the Company modified certain fair value measurement disclosures primarily related to its Level 3 liabilities (see Note 5, “Fair Value Measurements”).

~~Table of contents~~

~~In December 2019, the FASB~~ issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. ASU 2019-12 is effective for public business entities for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, and early adoption is permitted. The Company early adopted the new guidance in the second quarter of 2020. As a result, the Company recognized, on a prospective basis, $13,000 of income tax expense in the second quarter of 2020 upon the reversal of tax benefits recorded in the first quarter of 2020 related to unrealized gains on short-term investments.

Table of contents

In June 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in

an Entity’s Own Equity, which is intended to simplify the accounting for convertible instruments. This new guidance eliminates certain models that require separate accounting for embedded conversion features, and eliminates certain of the conditions for equity classification for contracts in an entity’s own equity. Accordingly, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new guidance can be adopted through either a modified retrospective method of transition or a fully retrospective method of transition. ASU 2020-06 is effective for public business entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company ~~is in the process of determining the impact of the adoption of the standard on its consolidated financial statements as well as whether~~elected to early adopt the new ~~standard.~~standard on January 1, 2021 using the modified retrospective method, and recorded a net reduction to accumulated deficit of $9.0 million, a decrease to additional paid-in capital of $85.8 million, and an increase to convertible senior notes, net - long-term of $76.8 million to reflect the impact of the accounting change (see Note 7, “Convertible Senior Notes”).

3. Short-Term Investments

The Company invests in marketable securities primarily consisting of debt instruments of the U.S. Government, U.S. Government-sponsored enterprises, and financial institutions and corporations with strong credit ratings. The following represents a summary of the estimated fair value of short-term investments as of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019~~2020 (in thousands):


At September 30, 2020		Maturity (in years)	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Estimated Fair Value
At June 30, 2021											At June 30, 2021	Maturity (in years)	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Estimated Fair Value
Available-for-sale securities:	Available-for-sale securities:										Available-for-sale securities:
Commercial paper	Commercial paper	Less than 1	$	94,076	$	9	$	(1)	$	94,084	Commercial paper	Less than 1	$	222,319	$	11	$	(2)	$	222,328
U.S. Government-sponsored enterprise	U.S. Government-sponsored enterprise	Less than 2	32,157		23		(1)		32,179		U.S. Government-sponsored enterprise	Less than 2	63,175		18		(19)		63,174
U.S. Treasury securities	U.S. Treasury securities	Less than 1	105,779		36		0		105,815		U.S. Treasury securities	Less than 2	104,937		2		(23)		104,916
Corporate debt securities	Corporate debt securities	Less than 2	102,862		107		(6)		102,963		Corporate debt securities	Less than 2	53,303		6		(13)		53,296
Supranational bonds											Supranational bonds	Less than 1	3,010		0		0		3,010
Total	Total		$	334,874	$	175	$	(8)	$	335,041	Total		$	446,744	$	37	$	(57)	$	446,724


At December 31, 2019		Maturity (in years)	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Estimated Fair Value
At December 31, 2020											At December 31, 2020	Maturity (in years)	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Estimated Fair Value
Available-for-sale securities:	Available-for-sale securities:										Available-for-sale securities:
Commercial paper	Commercial paper	Less than 1	$	24,147	$	10	$	0	$	24,157	Commercial paper	Less than 1	$	108,892	$	5	$	(1)	$	108,896
U.S. Government-sponsored enterprise	U.S. Government-sponsored enterprise	Less than 2	33,073		26		0		33,099		U.S. Government-sponsored enterprise	Less than 2	52,330		21		(1)		52,350
U.S. Treasury securities	U.S. Treasury securities	Less than 2	17,963		17		(1)		17,979		U.S. Treasury securities	Less than 2	143,244		12		(2)		143,254
Corporate debt securities	Corporate debt securities	Less than 2	50,011		42		(5)		50,048		Corporate debt securities	Less than 2	85,788		48		(13)		85,823
Total	Total		$	125,194	$	95	$	(6)	$	125,283	Total		$	390,254	$	86	$	(17)	$	390,323

The Company has classified all marketable securities, regardless of maturity, as short-term investments based upon the Company’s ability and intent to use any of those marketable securities to satisfy the Company’s liquidity requirements.

~~Table of contents~~

The Company periodically reviews the portfolio of available-for-sale debt securities to determine if any investment is impaired due to changes in credit risk or other potential valuation concerns. Unrealized losses on available-for-sale debt securities at ~~September~~June 30, ~~2020~~2021 were not significant and were due to changes in interest rates, including credit spreads from perceived increased credit risks as a result of the COVID-19 global pandemic. The Company does not intend to sell the available-for-sale debt securities that are in an unrealized loss position, and it is not more likely than not that the Company will be required to sell these debt securities before recovery of their amortized cost bases, which may be at maturity. Based on the credit quality of the available-for-sale debt securities ~~that are~~ in an unrealized loss position, and the Company’s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, the Company ~~has~~did not ~~recognized~~recognize any impairment losses related to its available-for-sale debt securities at ~~September~~June 30, ~~2020.~~2021.

Table of contents

4. Accounts Receivable and Inventories

Accounts Receivable

Accounts receivable consisted of the following (in thousands):


		September 30,		December 31,
		2020		2019			June 30, 2021		December 31, 2020
Accounts receivable	Accounts receivable	$	55,568	$	49,889	Accounts receivable	$	83,885	$	86,052
Less: allowance for credit losses	Less: allowance for credit losses	(3,464)		(3,304)		Less: allowance for credit losses	(3,673)		(3,857)
Accounts receivable, net	Accounts receivable, net	$	52,104	$	46,585	Accounts receivable, net	$	80,212	$	82,195

Allowance for Credit Losses

The following table provides a reconciliation of the ~~change~~changes in the estimated allowance for expected accounts receivable credit losses for the three and ~~nine month periods~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019~~2020 (in thousands):


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
		2020		2019		2020		2019			2021		2020		2021		2020
Balance at beginning of the period	Balance at beginning of the period	$	3,139	$	2,194	$	3,304	$	1,837	Balance at beginning of the period	$	3,559	$	3,384	$	3,857	$	3,304
Provision for expected credit losses	Provision for expected credit losses	653		671		2,181		1,468		Provision for expected credit losses	731		666		874		1,529
Write-offs and adjustments, net of recoveries	Write-offs and adjustments, net of recoveries	(328)		(173)		(2,021)		(613)		Write-offs and adjustments, net of recoveries	(617)		(911)		(1,058)		(1,694)
Balance at end of the period	Balance at end of the period	$	3,464	$	2,692	$	3,464	$	2,692	Balance at end of the period	$	3,673	$	3,139	$	3,673	$	3,139

Inventories

Inventories consisted of the following as of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019~~2020 (in thousands):


		September 30, 2020		December 31, 2019			June 30, 2021		December 31, 2020
Raw materials	Raw materials	$	36,111	$	20,699	Raw materials	$	22,684	$	30,880
Work-in-process	Work-in-process	14,316		16,532		Work-in-process	16,360		15,664
Finished goods	Finished goods	20,217		11,842		Finished goods	27,661		17,177
Total Inventories		$	70,644	$	49,073
Total inventories						Total inventories	$	66,705	$	63,721

~~Table of contents~~

5. Fair Value Measurements

Authoritative guidance on fair value measurements defines fair value, and provides a consistent framework for measuring fair value and for disclosures of each major asset and liability category measured at fair value on either a recurring or a nonrecurring basis. Fair value is intended to reflect an assumed exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Observable inputs such as unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly for substantially the full term of the asset or liability.

Level 3: Unobservable inputs in which there is little or no market data and that are significant to the fair value of the assets or liabilities, which require the reporting entity to develop its own valuation techniques that require input assumptions.

Table of contents

The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis as of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, and indicates the fair value hierarchy of the valuation techniques utilized by the Company to determine such fair value (in thousands):


				Fair Value Measurements at September 30, 2020									Fair Value Measurements at June 30, 2021
				(Level 1)		(Level 2)		(Level 3)					(Level 1)		(Level 2)		(Level 3)
Assets	Assets									Assets
Cash equivalents(1)	Cash equivalents(1)	$	127,732	$	127,732	$	0	$	0	Cash equivalents(1)	$	94,966	$	94,966	$	0	$	0
Commercial paper	Commercial paper	94,084		0		94,084		0		Commercial paper	222,328		0		222,328		0
U.S. Government-sponsored enterprise	U.S. Government-sponsored enterprise	32,179		0		32,179		0		U.S. Government-sponsored enterprise	63,174		0		63,174		0
U.S. Treasury securities	U.S. Treasury securities	105,815		105,815		0		0		U.S. Treasury securities	104,916		104,916		0		0
Corporate debt securities	Corporate debt securities	102,963		0		102,963		0		Corporate debt securities	53,296		0		53,296		0
Supranational bonds										Supranational bonds	3,010		0		3,010		0
Total assets	Total assets	$	462,773	$	233,547	$	229,226	$	0	Total assets	$	541,690	$	199,882	$	341,808	$	0

Liabilities	Liabilities									Liabilities
Common stock warrants	Common stock warrants	$	17,404	$	0	$	0	$	17,404	Common stock warrants	$	2,789	$	0	$	0	$	2,789

Total liabilities	Total liabilities	$	17,404	$	0	$	0	$	17,404	Total liabilities	$	2,789	$	0	$	0	$	2,789

Fair Value Measurements at December 31, 2019
(Level 1) (Level 2) (Level 3)
Assets
Cash equivalents(1)
$ 33,844 $ 33,844 $ 0 $ 0
Commercial paper 24,157 0 24,157 0
U.S. Government-sponsored enterprise 33,099 0 33,099 0
U.S. Treasury securities 17,979 17,979 0 0
Corporate debt securities 50,048 0 50,048 0
Total assets $ 159,127 $ 51,823 $ 107,304 $ 0
Liabilities
Common stock warrants $ 23,509 $ 0 $ 0 $ 23,509
Total liabilities $ 23,509 $ 0 $ 0 $ 23,509

~~Table of contents~~


			Fair Value Measurements at December 31, 2020
			(Level 1)		(Level 2)		(Level 3)
Assets
Cash equivalents(1)	$	87,300	$	87,300	$	0	$	0
Commercial paper	108,896		0		108,896		0
U.S. Government-sponsored enterprise	52,350		0		52,350		0
U.S. Treasury securities	143,254		143,254		0		0
Corporate debt securities	85,823		0		85,823		0
Total assets	$	477,623	$	230,554	$	247,069	$	0

Liabilities
Common stock warrants	$	14,261	$	0	$	0	$	14,261
Total liabilities	$	14,261	$	0	$	0	$	14,261

(1)Generally, cash equivalents include money market funds and investments with a maturity of three months or less from the date of purchase.

The Company’s Level 2 financial instruments are valued using market prices on less active markets with observable valuation inputs such as interest rates and yield curves. The Company obtains the fair value of Level 2 financial instruments from quoted market prices, calculated prices or quotes from third-party pricing services. The Company validates these prices through independent valuation testing and review of portfolio valuations provided by the Company’s investment managers.

The Company’s Level 3 liabilities at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019~~2020 include the remaining Series A warrants issued by the Company in connection with the public offering of common stock in October ~~2017. The Series A warrants,~~2017, and which expire in October 2022, initially provided holders the right to purchase 4,630,000 shares of the Company’s common stock at an exercise price of $3.50 per share. The Series A warrants were initially valued in the aggregate amount of $5.2 million on the date of issuance utilizing a Black-Scholes pricing model.

~~During the nine months ended September 30, 2020 and 2019, the Company issued 259,115 shares and 93,470 shares of common stock, respectively, upon the exercise of Series A warrants.~~2022. As of ~~September~~June 30, ~~2020~~2021 and ~~2019,~~2020, there were Series A warrants outstanding to purchase ~~158,200~~29,700 shares and ~~417,315~~415,200 shares, respectively, of the Company’s common stock (see Note 8, “Stockholders’ Equity”).

Table of contents

The Company reassesses the fair value of the outstanding Series A warrants at each reporting date utilizing a Black-Scholes pricing model. Variables used in the pricing model include the closing market price of the Company’s common stock at the balance sheet date, and estimates of stock price volatility, dividend yield, ~~expected~~remaining warrant term and risk-free interest rate. The Company develops its estimates based on publicly available historical data. A significant increase (decrease) in any of these inputs in isolation, particularly the market price of the Company’s common stock, would have resulted in a significantly higher (lower) fair value measurement. The assumptions used to estimate the fair values of the outstanding Series A warrants at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019~~2020 are presented below:


							Series A Warrants
		September 30, 2020		December 31, 2019			June 30, 2021		December 31, 2020
Risk-free interest rate	Risk-free interest rate	0.1	%	1.6	%	Risk-free interest rate	0.1	%	0.1	%
Expected dividend yield	Expected dividend yield	0.0	%	0.0	%	Expected dividend yield	0.0	%	0.0	%
Expected volatility	Expected volatility	64.1	%	77.2	%	Expected volatility	50.3	%	55.3	%
Expected term (in years)		2.0		2.8
Remaining term (in years)						Remaining term (in years)	1.3		1.8

The following table presents a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019:~~2020:


		Nine Months Ended September 30,					Six Months Ended June 30,
		2020		2019			2021		2020
Balance at beginning of the period	Balance at beginning of the period	$	23,509	$	17,926	Balance at beginning of the period	$	14,261	$	23,509
Loss recognized from the change in fair value of common stock warrants	Loss recognized from the change in fair value of common stock warrants	19,906		10,849		Loss recognized from the change in fair value of common stock warrants	962		16,258
Decrease in fair value from warrants exercised during the period		(26,011)		(5,492)
Common stock warrants exercised during the period						Common stock warrants exercised during the period	(12,434)		(142)
Balance at end of the period	Balance at end of the period	$	17,404	$	23,283	Balance at end of the period	$	2,789	$	39,625

Of the loss recognized from the change in fair value of common stock warrants for the ~~nine~~six months ended ~~September~~June 30, 2021 and 2020, ~~and 2019, $8.5~~$0.1 million and ~~$8.6~~$16.2 million, respectively, was attributable to warrants outstanding as of ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

~~Table of contents~~

6. Leases

The Company’s leases consist of operating leases for general office space, laboratory, manufacturing and warehouse facilities, and equipment. These noncancellable operating leases have initial lease terms ranging from one year to seven years. Leases with an initial term of 12 months or less are expensed as incurred and are not recorded as right-of-use assets on the Company’s condensed consolidated balance sheets. Certain leases include an option to renew, with renewal terms that can extend the lease term for additional periods. The exercise of lease renewal options is at the Company’s sole discretion. For renewal options that are reasonably certain at the lease Commencement Date of being exercised, the Company includes the renewal option period in the lease term. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option that is reasonably certain to be exercised.

The Company recognizes lease expense for these leases on a straight-line basis over the lease term. Because the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease Commencement Date in determining the present value of future lease payments. The Company used the incremental borrowing rate on January 1, 2019 for operating leases that commenced prior to that date. ~~For lease agreements entered into or reassessed after the adoption of ASC 842, the Company combines lease and non-lease components.~~

Certain leases include an option to renew, with renewal terms that can extend the lease term for additional periods. The exercise of lease renewal options is at the Company’s sole discretion. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option that is reasonably certain to be exercised.

In ~~January 2019,~~March 2021, the Company entered into a second amendment (Second Amendment) to its lease agreement ~~for~~covering approximately ~~25,332~~59,013 square feet of ~~additional~~ general administrative office space ~~(Initial~~(Existing Premises) located on Vista Sorrento Parkway, in San Diego, California (Vista Sorrento Lease). The ~~lease term for~~Second Amendment expanded the ~~Initial~~Existing Premises ~~commenced in March 2019 and expires in September 2022. In May 2019, the Company entered into a First Amendment to the Vista Sorrento Lease (First Amendment) to expand the leased premises~~ by adding approximately ~~33,681~~14,916 square feet of ~~additional~~ general administrative office space (Expansion Space), and ~~to extend~~extended the lease term for the ~~Initial~~Existing Premises through January ~~2023.~~2028. The ~~lease term for the~~ Expansion Space ~~commenced~~lease Commencement Date occurred in ~~May 2019~~March 2021, and the lease term expires in January ~~2023.~~2028. The Company has ~~a 1-time option~~2 options to extend the term of the Vista Sorrento Lease, covering both the ~~Initial~~Existing Premises and the Expansion Space, with each option providing for aan additional period of ~~four~~five years. The Vista Sorrento Lease term was determined assuming the renewal options would not be exercised. The Company recognized right-of-use leased assets and corresponding operating lease liabilities of ~~$3.1~~$15.1 million on the condensed consolidated balance sheet in the first quarter of ~~2019~~2021 related to the ~~Initial Premises, and $4.7 million related to the First~~Second Amendment.

~~In March 2019, the Company entered into a lease agreement for approximately 40,490 square feet~~

Table of space located on Marindustry Place, San Diego, California to house additional operations functions, including warehousing and shipping (Marindustry Place Lease). The lease term commenced in May 2019 and expires in April 2026. The Company has a one-time option to extend the term of the Marindustry Place Lease for a period of no less than three years and no more than five years. The Company recognized right-of-use leased assets and corresponding operating lease liabilities of $3.4 million on the consolidated balance sheet on the Commencement Date in the second quarter of 2019.contents

In November 2019, the Company entered into a lease agreement for approximately 94,562 square feet of additional general office space located on Shoreline Drive, in Boise, Idaho (Shoreline Lease). The lease term commenced on July 1, 2020, and expires in June 2027. The Company has a 1-time option to extend the term of the Shoreline Lease for a period of three years. The Company recognized right-of-use leased assets and corresponding operating lease liabilities of approximately $6.5 million on the consolidated balance sheet on the Commencement Date in the first quarter of 2020.

In January 2020, the Company entered into a sub-lease agreement for approximately 30,703 square feet of general office space located on High Bluff Drive, in San Diego, California. The lease term began in April 2020 and expires in March 2022. The Company recognized right-of-use leased assets and corresponding operating lease liabilities of approximately $2.3 million on the consolidated balance sheet on the Commencement Date in the first quarter of 2020.

In September 2020, the Company amended certain leases covering approximately 77,000 square feet of general office and laboratory space located on Roselle Street in San Diego, California (Roselle Street Leases). The lease amendments extended the term of each lease for an additional period of one year, and included a rent increase during the additional lease term. The Roselle Street Leases, which would have expired in May 2022, are now scheduled to expire in May 2023. The Company recognized additional right-of-use leased assets and corresponding operating lease liabilities of $2.2 million on the consolidated balance sheet in the third quarter of 2020 related to the amendment of the Roselle Street Leases.

The Company’s lease cost recorded in the condensed consolidated statements of operations was as follows (in thousands):

~~Table of contents~~


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
		2020		2019		2020		2019			2021		2020		2021		2020
Operating lease cost	Operating lease cost	$	1,914	$	1,372	$	5,569	$	3,208	Operating lease cost	$	2,197	$	1,899	$	4,203	$	3,655
Short-term lease cost	Short-term lease cost	63		39		198		84		Short-term lease cost	22		71		44		135
Total lease cost	Total lease cost	$	1,977	$	1,411	$	5,767	$	3,292	Total lease cost	$	2,219	$	1,970	$	4,247	$	3,790

Maturities of operating lease liabilities at ~~September~~June 30, ~~2020~~2021 were as follows (in thousands):

Years Ending December 31,
2020 (remaining) $ 2,314
2021 9,421
2022 8,710
2023 4,386
2024 1,881
Thereafter 3,975
Total undiscounted lease payments 30,687
Less: amount representing interest (3,429)
Present value of operating lease liabilities 27,258
Less: current portion of operating lease liabilities (9,365)
Operating lease liabilities - long-term $ 17,893


Years Ending December 31,
2021 (remaining)	$	4,742
2022	9,129
2023	6,856
2024	5,691
2025	5,801
Thereafter	10,654
Total undiscounted lease payments	42,873
Less: amount representing interest	(6,237)
Present value of operating lease liabilities	36,636
Less: current portion of operating lease liabilities	(9,260)
Operating lease liabilities - long term	$	27,376

The weighted-average remaining lease term and weighted-average discount rate for operating leases were as follows:


		September 30, 2020		December 31, 2019			June 30, 2021		December 31, 2020
Weighted-average remaining lease term (in years)	Weighted-average remaining lease term (in years)	3.9		3.6		Weighted-average remaining lease term (in years)	5.3		3.6
Weighted-average discount rate used to determine operating lease liabilities	Weighted-average discount rate used to determine operating lease liabilities	5.9	%	6.6	%	Weighted-average discount rate used to determine operating lease liabilities	5.6	%	6.6	%

Cash paid for amounts included in the measurement of lease liabilities, representing operating cash flows ~~from~~used for operating leases, was ~~$5.9~~$4.7 million and ~~$3.1~~$2.9 million for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019,~~2020, respectively.

7. Convertible Senior Notes

In May 2020, the Company entered into a purchase agreement with certain counterparties for the sale of an aggregate of ~~$250.0~~$287.5 million principal amount of 1.50% Convertible Senior Notes due 2025 (Notes) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The notes consisted of a $250.0 million initial placement (Base Notes) and an over-allotment option that provided the initial purchasers of the Base Notes with the option to purchase an additional $37.5 million aggregate principal amount of notes (together with the Base Notes, the Notes), which was fully exercised. The Notes were issued pursuant to an Indenture, dated May 15, 2020, between the Company and U.S. Bank National Association, as trustee (Indenture). The net proceeds from the issuance of the Notes were $244.6 million, net of debt issuance costs and cash used to ~~purchase~~pay the cost of the capped call transactions (Capped Call Transactions) discussed below.

The Notes are the Company’s senior unsecured obligations. Interest is payable in cash semi-annually in arrears beginning on November 1, 2020 at a rate of 1.50% per year. The Notes mature on May 1, 2025 unless repurchased, redeemed, or converted in accordance with their terms prior to the maturity date.

1715

Table of contents

The Notes are convertible into cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, at the Company’s election, at an initial conversion rate of 8.8836 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $112.57 (Conversion Price) per share of the Company’s common stock. The conversion rate is subject to customary adjustments for certain events as described in the Indenture. It is the Company’s intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion.

The Company may not redeem the Notes prior to May 6, 2023. The Company has the option to redeem for cash all or any portion of the Notes on or after May 6, 2023 if the last reported sale price of the Company’s common stock has been at least 130% of the Conversion Price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period, at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest. No sinking fund is provided for the Notes.

Holders of the Notes may convert all or a portion of their Notes at their option prior to November 1, 2024, in multiples of $1,000 principal amounts, only under the following circumstances:

•if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the applicable ~~conversion price~~Conversion Price of the Notes on each such trading day;

•during the 5 business day period after any 5 consecutive trading day period in which the trading price per $1,000 principal amount of the Notes for each day of that 5 consecutive trading day period was less than 98% of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate of the Notes on such trading day;

•if the Company calls any or all of the Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or

•on the occurrence of specified corporate events.

On or after November 1, 2024, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their Notes at any time, regardless of the foregoing circumstances.

Holders of the Notes who convert in connection with a make-whole fundamental change ~~as defined in the Indenture,~~ or in connection with a redemption are entitled to an increase in the conversion rate. Additionally, in the event of a fundamental change, ~~as defined in the Indenture,~~ holders of the Notes may require us to repurchase all or a portion of the Notes at a price equal to 100% of the principal amount of the Notes, plus any accrued and unpaid interest.

InInitially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the ~~conversion~~conversion option for the Notes was $85.8 million and was recorded as a debt discount, ~~which is~~to be amortized to interest expense at an effective interest rate of 9.9%. ~~The~~In addition, the Company allocated $2.7 million of debt issuance costs to the equity component and the remaining debt issuance costs of $6.1 million were allocated to the liability component, ~~which are~~to be amortized to interest expense under the effective interest rate method.

On January 1, 2021, the Company early adopted ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which is intended to simplify the accounting for convertible instruments. The ~~equity~~ASU eliminates the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, an issuer will account for these securities as a single unit of account, unless the ~~Notes will not be remeasured as long as it continues~~conversion feature meets certain criteria. The Company adopted the new standard using the modified retrospective method, and recorded a net reduction to ~~meet~~accumulated deficit of $9.0 million, a decrease to additional paid-in capital of $85.8 million, and an increase to convertible senior notes, net - long-term of $76.8 million to reflect the conditions for equity classification. It is the Company’s intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excessimpact of the ~~conversion value over the principal portion.~~accounting change. The Notes are now accounted for as a single liability measured at amortized cost, as no other embedded features require bifurcation and recognition as derivatives.

1816

Table of contents

The liability and equity components of the Notes consisted of the following (in thousands): at June 30, 2021 and December 31, 2020:


	As of September 30, 2020
~~Liability:~~
~~Principal~~	$	~~287,500~~
~~Unamortized debt discount and debt issuance costs~~	~~(88,380)~~
~~Net carrying amount~~	$	~~199,120~~
~~Carrying amount of the equity component~~	$	~~85,803~~


	June 30, 2021		December 31, 2020
Liability:
Principal amount	$	287,500	$	287,500
Unamortized debt issuance costs	(6,901)		(5,446)
Unamortized debt discount	0		(79,070)
Net carrying amount	$	280,599	$	202,984
Carrying amount of the equity component	$	0	$	85,803

As of ~~September~~June 30, ~~2020,~~2021, the ~~debt discount and~~unamortized debt issuance costs of $6.9 million associated with the Notes will be amortized to interest expense, at an effective interest rate of 2.2%, over the remaining ~~period~~term of the Notes of approximately ~~4.6~~3.8 years.

The following table details interest expense recognized related to the Notes for the three and ~~nine~~six months ended ~~September~~June 30, 2021 and 2020 (in thousands):


							Three Months Ended June 30,				Six Months Ended June 30,
		Three Months Ended September 30, 2020		Nine Months Ended September 30, 2020			2021		2020		2021		2020
Contractual interest expense	Contractual interest expense	$	1,078	$	1,797	Contractual interest expense	$	1,078	$	719	$	2,156	$	719
Amortization of debt issuance costs	Amortization of debt issuance costs	244		403		Amortization of debt issuance costs	431		159		859		159
Amortization of debt discount	Amortization of debt discount	3,533		5,830		Amortization of debt discount	N/A		2,298		N/A		2,298
Total interest expense	Total interest expense	$	4,855	$	8,030	Total interest expense	$	1,509	$	3,176	$	3,015	$	3,176

The ~~notes~~Notes will have a dilutive effect to the extent the average market price per share of the Company’s common stock for a given reporting period exceeds the ~~conversion price~~Conversion Price of $112.57. As of ~~September~~June 30, ~~2020,~~2021, the “if-converted value” did not exceed the principal amount of the Notes.

Capped Call Transactions

In connection with the issuance of the Notes, the Company entered into Capped Call Transactions in May of 2020 with certain counterparties at a net cost of $34.1 million. The Capped Call Transactions are intended to reduce potential dilution to holders of the Company’s common stock beyond the ~~conversion price~~Conversion Price of $112.57, up to a ~~conversion price~~Conversion Price of $173.18 on any conversion of the Notes, or to offset any cash payments the Company is required to make in excess of the principal amount of such converted Notes, as the case may be, with such reduction or offset subject to a cap. The cap price of the Capped Call Transactions is initially $173.18 per share of the Company’s common stock, representing a premium of 100% above the last reported sale price of $86.59 per share of the Company’s common stock on May 12, 2020, and is subject to certain adjustments under the terms of the Capped Call Transactions. Conditions that cause adjustments to the initial strike price of the Capped Call Transactions mirror conditions that result in corresponding adjustments for the Notes.

For accounting purposes, the Capped ~~Calls~~Call Transactions are separate transactions, and not part of the terms of the Notes. As these transactions meet certain criteria under the applicable accounting guidance, the Capped ~~Calls~~Call Transactions are recorded in stockholders' equity and are not accounted for as derivatives. The cost of the Capped Call Transactions was recorded as a reduction of the Company’s additional paid-in capital in the Company’s consolidated balance sheet and will not be remeasured.

1917

Table of contents

8. Stockholders’ Equity

Shares Reserved for Future Issuance

The following shares of the Company’s common stock were reserved for future issuance as of ~~September~~June 30, ~~2020~~2021 (in thousands):


Shares reserved for issuance upon conversion of Convertible Senior Notes			2,554
Shares underlying outstanding warrants			~~383~~251
Shares underlying outstanding stock options			~~5,866~~5,691
Shares underlying unvested restricted stock units			~~135~~
~~Shares authorized for future equity award grants~~			~~2,117~~453
Shares authorized for issuance pursuant to awards granted under the ESPP			~~1,462~~1,289
Shares authorized for future equity award grants			1,440
			~~9,963~~11,678

Common Stock Warrants

Warrants outstanding to purchase shares of the Company's common stock as of ~~September~~June 30, ~~2020~~2021 were as follows:


Issue Date	Issue Date	Exercise Price Per Share	Warrants Outstanding	Expiration Date	Issue Date	Exercise Price Per Share		Warrants Outstanding	Expiration Date
October 2017	October 2017	$3.50	158,200	October 2022	October 2017	$	3.50	29,700	October 2022
March 2017	March 2017	$23.50	193,788	March 2027	March 2017	$	23.50	193,788	March 2027
August 2011 - August 2012	August 2011 - August 2012	$73.73	31,166	August 2021 - August 2022	August 2011 - August 2012	$	73.73	27,704	August 2021 - August 2022
			383,154					251,192

Each warrant allows the holder to purchase 1 share of the Company's common stock at the exercise price per share of the respective warrant. The Company issued ~~257,000~~522 and ~~291,894~~125,522 shares of its common stock, respectively, upon the exercise of warrants during the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, and ~~200~~32,574 and ~~93,470~~34,689 shares of its common stock, respectively, upon the exercise of warrants during the three and ~~nine~~six months ended ~~September~~June 30, ~~2019.~~2020.

Stock Plans

The Company’s Amended and Restated 2013 Stock Incentive Plan (2013 Plan) was originally approved by the Company’s board of directors in October 2013. Under the 2013 Plan, the Company ~~issued 1,072,499 and 2,198,986 shares, respectively, of its common stock upon the exercise of~~may grant stock options, ~~during~~stock appreciation rights, restricted stock and restricted stock units to individuals who are then employees, officers, directors or consultants of the three and nine months ended September 30, 2020. The Company issued 439,646 and 1,213,428 shares, respectively, of its common stock upon the exercise of stock options during the three and nine months ended September 30, 2019.Company.

The ESPP enables eligible employees to purchase shares of the Company’s common stock using their after-tax payroll deductions, subject to certain conditions. Generally, offerings under the ESPP consist of a two-year offering period with 4 six-month purchase periods which begin in May and November of each year. During the nine months ended September 30, 2020 and 2019, 229,320 and 168,165 shares of the Company’s common stock, respectively, were purchased under the ESPP for proceeds of $4.9 million and $3.0 million, respectively.

Stock-Based Compensation

Common Stock Options

The Company granted options to purchase ~~1,010,996~~239,608 and 355,008 shares of common stock, ~~under the 2013 Plan~~respectively, during the ~~nine~~three and six months ended ~~September~~June 30, ~~2020. During the nine months ended September 30, 2019, the Company granted~~2021, and options to purchase ~~2,916,906~~621,045 and 850,956 shares of common stock, ~~under~~respectively, during the ~~2013 Plan, of which 1,644,715 were originally awarded between February 2019~~three and six months ended June 2019, subject to and conditioned upon the approval by its stockholders of an increase in the number of shares of common stock reserved for issuance under the 2013 Plan. Stock-based compensation expense was not recognized for these contingent stock option grants prior to the approval by the Company’s stockholders of the increase in the number of shares of common stock reserved for issuance under the 2013 Plan, which occurred in June 2019.30, 2020. These options have an exercise price equal to the closing price of the Company’s common stock on the applicable award date, and generally vest as to 25% of the underlying shares on the first anniversary of the award, with the balance of the options vesting monthly over the following three years.

2018

Table of contents

The Company ~~also~~estimates the fair value of stock options using the Black-Scholes option-pricing model on the grant date. The assumptions used in the Black-Scholes option-pricing model for common stock options were as follows:


	Stock Options
	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Weighted average grant date fair value (per share)	$54.92		$52.50		$56.89		$50.04
Risk-free interest rate	1.1	%	0.4	%	1.0	%	0.6	%
Expected dividend yield	0.0	%	0.0	%	0.0	%	0.0	%
Expected volatility	74.9	%	75.0	%	75.1	%	74.3	%
Expected term (in years)	6.1		6.0		6.1		6.0

Restricted Stock Units (RSUs)

The Company granted ~~2,846~~339,386 and ~~134,694~~342,594 restricted stock units (RSUs), respectively, during the three and ~~nine~~six months ended ~~September~~June 30, 2021, and 131,848 RSUs during the three and six months ended 2020. These RSUs have a grant ~~price~~value equal to the closing price of the Company’s common stock on the award date, and generally vest based only on service as to 25% of the underlying shares on the first anniversary of the award, with the balance of the RSUs vesting quarterly over the following three ~~years, except for 17,857~~years. The Company also granted 25,674 performance-based RSUs ~~which~~during the three months ended June 30, 2021. The performance-based RSUs have a grant value equal to the closing price of the Company’s common stock on the award date, and vest ~~in annual installments over a period~~upon the Company’s actual performance relative to predefined performance metrics and subject to the awardee’s continuing service through the December 31, 2024 measurement date. The weighted average grant date fair value of ~~one~~ ~~to three years.~~

~~The assumptions used in the Black-Scholes option-pricing model are~~RSUs granted were as follows:

Stock Options
Three Months Ended
September 30, Nine Months Ended
September 30,
2020 2019 2020 2019
Weighted average grant date fair value (per share) $67.64 $38.74 $52.83 $39.08
Risk-free interest rate 0.4 % 1.7 % 0.6 % 2.1 %
Expected dividend yield 0.0 % 0.0 % 0.0 % 0.0 %
Expected volatility 75.3 % 71.8 % 74.5 % 71.8 %
Expected term (in years) 6.1 6.1 6.1 6.0


	Restricted Stock Units
	Three Months Ended June 30,		Six Months Ended June 30,
	2021	2020	2021	2020
Weighted average grant date fair value (per share)	$82.31	$82.33	$82.41	$82.33

ESPP
Nine Months Ended
September 30,
2020 2019
Weighted average grant date fair value (per share) $36.18 $33.49
Risk-free interest rate 0.2 % 2.3 %
Expected dividend yield 0.0 % 0.0 %
Expected volatility 65.7 % 75.9 %
Expected term (in years) 1.3 1.3
Employee Stock Purchase Plan

The Company records stock-based compensation expense associated with the ESPP using the Black-Scholes option-pricing model. Valuations are performed on the grant date at the beginning of the purchase period, which generally occurs in May and November of each year. The assumptions used in the Black-Scholes option-pricing model for the ESPP were as follows:


	ESPP
	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Weighted average grant date fair value (per share)	$29.24		$36.18		$29.24		$36.18
Risk-free interest rate	0.1	%	0.2	%	0.1	%	0.2	%
Expected dividend yield	0.0	%	0.0	%	0.0	%	0.0	%
Expected volatility	47.5	%	65.7	%	47.5	%	65.7	%
Expected term (in years)	1.3		1.3		1.3		1.3

Table of contents

The following table summarizes the allocation of stock-based compensation expense included in the condensed consolidated ~~statement~~statements of operations for all stock-based compensation arrangements (in thousands):


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
		2020		2019		2020		2019			2021		2020		2021		2020
Cost of sales	Cost of sales	$	2,138	$	1,751	$	6,464	$	4,178	Cost of sales	$	1,591	$	2,162	$	3,067	$	4,326
Selling, general & administrative	Selling, general & administrative	8,866		13,110		32,077		29,060		Selling, general & administrative	10,881		11,707		20,292		23,210
Research and development	Research and development	1,833		2,369		6,582		6,148		Research and development	2,505		2,552		4,565		4,750
Total		$	12,837	$	17,230	$	45,123	$	39,386
Total stock-based compensation expense										Total stock-based compensation expense	$	14,977	$	16,421	$	27,924	$	32,286

The total stock-based compensation expense capitalized as part of the cost of the Company’s inventories was ~~$0.7~~$0.8 million at June 30, 2021, and ~~$1.3~~$0.6 million ~~as of September 30, 2020 and~~at December 31, ~~2019, respectively.~~2020.

9. Income Taxes

For the three and ~~nine~~six months ended ~~September~~June 30, ~~2020 and 2019,~~2021, the ~~Company’s~~Company recognized income tax expense of $0.1 million on pre-tax income of $4.1 million, and an income tax benefit of $0.1 million on pre-tax loss of $1.1 million, respectively. The income tax benefit for the six months ended June 30, 2021 was primarily attributable to the pre-tax loss position and excess tax benefits from stock compensation recorded discretely during the period, partially offset by state and foreign income tax expense as a result of current taxable income in certain jurisdictions.

For the three and six months ended June 30, 2020, the Company recognized an income tax benefit of $2.1 million on a pre-tax loss of $29.2 million, and an income tax benefit of $2.0 million on a pre-tax loss of $44.0 million, respectively. The income tax benefit for three and six months ended June 30, 2020 was primarily due to benefit associated with the release of valuation allowance related to the acquisition of Sugarmate, partially offset by state and foreign income tax expense as a result of current taxable income in those jurisdictions. ~~The nine months ended September 30, 2020 also included a benefit associated with release of valuation allowance related to the acquisition of Sugarmate during the second quarter of 2020.~~

~~Table of contents~~

The Company ~~used~~calculated the ~~year-to-date effective tax rate method to determine its interim~~provision (benefit) for income ~~tax expense~~taxes for ~~federal~~the three and ~~state jurisdictions where a reliable~~six months ended June 30, 2021 by applying an estimate of the annual effective tax rate ~~could~~for the full year to ordinary income (loss) adjusted by the tax impact of discrete items. For the three and six months ended June 30, 2020, the Company calculated the provision for income taxes using a discrete effective tax rate method as the annual effective tax rate method would not ~~be made.~~provide a reliable estimate.

The Company ~~maintains~~continues to maintain a full valuation allowance against its net deferred tax assets as of ~~September~~June 30, ~~2020~~2021, based on the current assessment that it is not more likely than not these future benefits will be realized before expiration.

On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of the COVID-19 global pandemic. While the CARES Act provides sweeping tax changes in response to the COVID-19 global pandemic, some of the more significant provisions which are expected to impact the Company’s financial statements include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. Due to the recent enactment of the CARES Act, the Company is unable to quantify the impact, if any, that the CARES Act will have on its financial position, results of operations or cash flows but it is not anticipated to be significant.

10. Business Segment and Geographic Information

Segment Reporting

Operating segments are identified as components of an enterprise about which discrete financial information is available for evaluation by the chief operating decision-maker (CODM) in making decisions regarding resource allocation and assessing performance. The Company is organized based on its current product portfolio, which consists primarily of insulin pumps, disposable cartridges and infusion sets for the storage and delivery of insulin. The Company views its operations and manages its business as 1 segment and a single reporting unit because key operating decisions and resource allocations are made by the CODM using consolidated financial data.

Disaggregation of Revenue

The Company primarily sells its products through national and regional distributors in the United States on a non-exclusive basis, and through distribution partners outside the United States, including in select European countries, Canada, Australia, New Zealand, and South Africa. In the United States and Canada, the Company utilizes a direct sales force. The Company disaggregates its revenue by geography and by major sales channel as management believes these categories best depict how the nature, amount and timing of revenues and cash flows are affected by economic factors.

Table of contents

Revenues by Geographic Region and Customer Sales Channels

During the three and six months ended June 30, 2021 and 2020, no individual country outside the United States generated revenue that represented more than 10% of total revenue. The table below sets forth revenues for the Company’s two primary geographical markets, based on the geographic location to which its products are shipped.


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
United States	$	127,580	$	89,277	$	230,919	$	168,823
International	44,559		19,959		82,257		38,339
Total Sales	$	172,139	$	109,236	$	313,176	$	207,162

Sales to distributors accounted for 68% and 71% of the Company’s total domestic sales for the three months ended June 30, 2021 and 2020, respectively, and 68% and 70% of total domestic sales for the six months ended June 30, 2021 and 2020, respectively.

Sales to distributors accounted for 95% and 96% of the Company’s total international sales for the three months ended June 30, 2021 and 2020, respectively, and 95% of the Company’s total international sales for both the six months ended June 30, 2021 and 2020.

11. Commitments and Contingencies

Legal and Regulatory Matters

In April 2020, the Company was named as a defendant in 4 federal class action lawsuits relating to a data breach it experienced in January 2020, each of which was subsequently dismissed.

In addition, in May 2020 the Company was named as a defendant in 3 California state court class action lawsuits arising from the same data breach. Collectively, these lawsuits seek statutory, compensatory, actual, and punitive damages; equitable relief, including restitution; pre- and post-judgment interest; injunctive relief; and attorney fees, costs, and expenses from the Company. On July 24, 2020, these 3 pending lawsuits were consolidated into a single case in the Superior Court of the State of California in the County of San Bernardino entitled Joseph Deluna et al v. Tandem Diabetes Care, Inc. The consolidated case alleges violations of the Confidentiality of Medical Information Act (CMIA), California Consumer Privacy Act (CCPA), California’s Unfair Competition Law (UCL), and breach of contract. The Company filed a demurrer seeking dismissal of all claims, which was heard by the Court on October 27, 2020, and which resulted in the following outcome: (i) the demurrer of the CMIA claim was denied; (ii) the demurrer of the CCPA claim was sustained; and (iii) the demurrer of the UCL and contract claims were sustained with leave to amend the pending complaint. A second demurrer was heard by the Court on March 29, 2021 with the following outcome: (i) the demurrer of the CMIA claim was denied; and (ii) the demurrer of the UCL and contract claims were narrowed in scope to dismiss three plaintiffs for either failing to allege cognizable damages or injuries-in-fact, resulting in two remaining plaintiffs. Although the Company intends to vigorously defend against these claims, there is no guarantee that the Company will prevail. The Company presently is unable to determine the ultimate outcome of these lawsuits or determine the amount (or range) of possible losses associated with the lawsuits.

In September 2020, the Company was named as a defendant in a lawsuit entitled Buck Walsh, individually and on behalf of others similarly situated v. Tandem Diabetes Care, Inc., which was filed in the Superior Court of the State of California in the County of San Diego. The alleged violations include business and professions code and labor code violations for failure to compensate wages, unpaid meal and rest periods, and failure to reimburse for necessary business-related expenses. The class of plaintiffs includes hourly paid or non-exempt employees of the Company who were employed from April 6, 2016 through the date of adjudication. The parties recently agreed to resolve the matter on a class-wide basis. The settlement is intended to resolve the claims of the individual plaintiff, as well as the remaining members of the class, unless an individual class member submits a timely request for exclusion. The material terms of the settlement are set forth in a binding Memorandum of Agreement dated as of July 1, 2021, which is subject to the completion of a number of conditions, as well as final approval by the court. There is no guarantee that the conditions will be met or that court approval will be obtained. If the court does not approve the settlement, or if other conditions to approval of the settlement are not met, the case will continue and the Company will continue to vigorously defend against the claims.

Table of contents

From time to time, the Company ~~may be subject to~~is involved in various other legal proceedings, or regulatory matters, and other disputes or claims arising infrom or related to the ~~ordinary~~normal course of our business activities, including actions with respect to intellectual property, data privacy, employment, regulatory, product liability and contractual matters. In connection with these proceedings or matters, the Company regularly assesses the probability and amount (or range) of possible losses based on the developments in these proceedings or matters. A liability is recorded in the consolidated financial statements if it is determined that it is probable that a loss has been incurred, and that the amount (or range) of the loss can be reasonably estimated. Because of the uncertainties related to any pending proceedings or matters, the Company is currently unable to predict their ultimate outcome and, with respect to any ~~legal~~ proceeding or ~~regulatory~~ matter where no liability has been accrued, to make a reasonable estimate of the possible loss (or range of loss) that could result from an adverse outcome.

AsExcept as set forth above, as of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, there were 0 legal proceedings, regulatory matters, or other disputes or claims for which a material loss was considered probable or for which the amount (or range) of loss was ~~deemed to be~~ reasonably estimable. However, regardless of the merits of the claims raised or the outcome, legal proceedings, regulatory matters, and other disputes and claims ~~can~~may have an adverse impact on the Company because of ~~legal~~as a result of defense and settlement costs, diversion of management time and resources, and other factors.

Table of contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis together with our financial statements and related notes in Part I, Item 1 of this Quarterly Report on Form 10-Q for the quarter ended ~~September~~June 30, ~~2020~~2021 (Quarterly Report).

This Quarterly Report contains forward-looking statements within the meaning of the federal securities laws, which statements are subject to considerable risks and uncertainties. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements included or incorporated by reference in this Quarterly Report, other than statements of historical fact, are forward-looking statements. You can identify forward-looking statements by the use of words such as “may,” “will,” “could,” “anticipate,” “expect,” “intend,” “believe,” “continue” or the negative of such terms, or other comparable terminology. Forward-looking statements also include the assumptions underlying or relating to such statements. In particular, forward-looking statements contained in this Quarterly Report may relate to, among other things, our future or assumed financial condition, results of operations, liquidity, trends impacting our financial results, business forecasts and plans, research and product development plans, manufacturing plans, strategic plans and objectives, capital needs and financing plans, ~~and objectives,~~ product launches, geographic expansion, distribution plans, production capacity, clinical trials, regulatory approvals, competitive position and the impact of changes in the competitive ~~environment.~~environment, the impact of the COVID-19 global pandemic, integration of acquisitions and partner technologies, and the application of accounting guidance. We caution you that the foregoing list may not include all of the forward-looking statements made in this Quarterly Report.

Our forward-looking statements are based on our management’s current assumptions and expectations about future events and trends, which affect or may affect our business, strategy, operations or financial performance. Although we believe that these forward-looking statements are based upon reasonable assumptions, they are subject to numerous known and unknown risks and uncertainties and are made in light of information currently available to us. Our actual financial condition and results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below in the section entitled “Risk Factors” in Part II, Item 1A, and elsewhere in this Quarterly Report, as well as the other public filings we make with the Securities and Exchange Commission. In particular, as discussed in greater detail below, our financial condition, operating results, liquidity and business prospects could be materially adversely affected by the impacts and disruptions caused by the novel coronavirus pandemic (COVID-19 global pandemic). You should read this Quarterly Report with the understanding that our actual future financial condition and results may be materially different from and worse than what we expect.

Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Forward-looking statements speak only as of the date they were made and, except to the extent required by law or the rules of the ~~NASDAQ~~Nasdaq Global Market, we undertake no obligation to update or review any forward-looking statement because of new information, future events or other factors.

We qualify all of our forward-looking statements by these cautionary statements.

Overview

We are a medical device company with ~~an innovative~~a positively different approach to the design, development and commercialization of products for people with insulin-dependent diabetes. Diabetes management can vary greatly from person-to-person, creating multiple market segments based on clinical needs and personal preferences. We aim to improve and simplify the lives of all people living with insulin-dependent diabetes and those of their healthcare providers, by delivering innovative hardware and software solutions, as well as best-in-class customer support. Our goal is to lead in insulin therapy management by building a robust ecosystem and portfolio of data-driven products and services around our flagship insulin pumps. We believe our competitive advantage is rooted in our consumer-focused approach and the incorporation of modern and innovative technology into our product offerings. Our manufacturing, sales and support activities principally focus on our flagship pump platform, the t:slim X2 Insulin Delivery System (t:slim X2)~~, which is capable of remote feature updates~~ and ~~is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen, as well as~~ our complementary product offerings, such as our cloud-based t:connect data management application (t:connect) and the Tandem Device Updater. We aim to improve and simplify the lives of people with diabetes and those of their healthcare providers, by delivering innovative hardware and software solutions, as well as best-in-class customer support.

~~Table of contents~~

offerings.

Since our initial commercial launch, we have ~~been able to~~ rapidly ~~innovate~~innovated and ~~bring~~brought more products to market than our competitors. We have commercially launched seven insulin ~~pumps~~pump configurations in the United States since 2012 and three ~~of which we also launched~~insulin pump configurations outside the United States since 2018. ~~Four of~~Today, our insulin pumps have featured integration with CGM technology, of which two have also featured an automated insulin delivery (AID) algorithm. The United States Food and Drug Administration (FDA) has defined requirements for the interoperability of devices as a complete AID system, which we believe will help support continued rapid innovation by streamlining the regulatory pathway for integrated products in the United States. This interoperability designation is comprised of three categories: alternate controller enabled (ACE) infusion pumps, integrated continuous glucose monitor (iCGM) devices, and interoperable automated glycemic controller (iAGC) technology. In June 2018, the t:slim X2 was the first insulin pump designated as compatible with iCGM devices; in February 2019 the t:slim X2 was the first insulin pump to receive ACE pump designation, and in December 2019 our Control-IQ technology for the t:slim X2 was cleared as the first iAGC.

In the four-year period ended September 30, 2020, we shipped approximately 188,000 insulin pumps, which is representative of our estimated global installed customer base, assuming the typical four-year reimbursement cycle. Approximately 152,000 of these pumps were shipped to customers in the United States and approximately 36,000 were shipped to international markets.

~~Today, our~~software-updatable t:slim X2 hardware platform represents 100% of our new pump ~~shipments and~~shipments. We now have nearly ~~all~~270,000 customers in our global installed base, assuming a typical four year reimbursement cycle, of ~~our in-warranty customers benefit from having the X2 platform. The~~which 25% are in international markets.

Table of contents

Our simple-to-use t:slim X2 is based on our proprietary technology platform and is the smallest durable insulin pump ~~available, and~~available. We have commercially offered our pump technology integrated with three generations of Dexcom’s continuous glucose monitoring (CGM) sensors. The t:slim X2 is the only ~~commercial insulin~~ pump ~~that allows users to update their pumps’~~on which remote software updates have been made commercially available in the United States. This experience, which offers and supports different software updates quickly and easily from a personal computer ~~using~~through the use of our revolutionary tool referred to as Tandem Device Updater ~~tool. This~~(TDU), provides us with a unique ~~offering has allowed us to bring future innovations, including~~competitive advantage. Two of our ~~next generation AID algorithms,~~updates provided our users access to our in-warranty t:slim X2 customers faster than the industry was able to in the past and independent of the typical four-year insurance pump reimbursement cycle. We have offered in-warranty t:slim customers in the United States four different software updates for no-cost since the Tandem Device Updater was approved in July 2016, including our two AIDautomated insulin delivery (AID) algorithms, Basal-IQ technology and Control-IQ technology. Basal-IQ technology launched in August 2018 and is a predictive low glucose suspend feature that is designed to temporarily suspend insulin delivery to help reduce the frequency and duration of hypoglycemic events. Control-IQ technology launched in January 2020 and is an advanced hybrid-closed loop feature, designed to help increase a ~~user’s~~user's time in their targeted glycemic range. It is the first and only system cleared by the U.S. Food and Drug Administration (FDA) to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar. Outside the United States we began selling ~~efforts with~~ t:slim X2 with Dexcom G5 ~~CGM~~ integration in the third quarter of 2018, ~~and began~~ offering no-cost software updates for Basal-IQ technology beginning in the third quarter of ~~2019. In July 2020, we initiated~~2019 and for Control-IQ technology beginning in the third quarter of 2020. We intend to continue our scaled launch of Control-IQ technology ~~in select geographies, which we plan to continue~~outside the United States throughout the remainder of 2021, subject to ~~required~~securing necessary regulatory ~~and reimbursement~~clearances or approvals. We continue to offer both AID algorithms on the market to support the varying needs of people living with diabetes.

Our insulin pump products are generally considered durable medical equipment and have an expected lifespan of at least four years. In addition to insulin pumps, we sell disposable products that are used together with our pumps and are replaced every few days, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to a user’s ~~body.~~body, as well as a variety of accessories designed for enhanced usability. We also offer t:connect, a web-based data management application that provides users, their caregivers and their healthcare providers with a fast, easy and visual way to display diabetes therapy management data from our pumps, integrated CGMs and supported blood glucose meters.

In support of our digital health strategy, we continue to offer and improve t:connect and TDU, and also develop and launch other complementary ~~offerings beyond t:connect and the Tandem Device Updater.~~offerings. In the first quarter of 2020, we began a limited launch in the United States of our first-generation t:connect mobile application, followed by general availability in July 2020. This mobile app wirelessly uploads pump data to our t:connect diabetes management application, receives notification of pump alerts and alarms, and provides a discrete, secondary display of glucose and insulin data. The availability of this mobile app is intended to reduce patient burden and increase healthcare provider office efficiency by reducing the manual and more time-consuming steps historically required for data extraction. In addition, in the second quarter of 2020, we acquired Sugarmate, the developer of a popular app designed to help people visualize diabetes therapy data in innovative ~~ways.~~ways that also connects with many other popular, consumer-friendly devices. We ~~intend~~continue to support the Sugarmate app in addition to our t:connect mobile app to provide a wide variety of features intended to benefit a broad community of people with diabetes. In the second quarter of 2021, we began limited testing of an initial version of Tandem Source, our second-generation data management platform, in the United Kingdom.

For the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019,~~2020, our consolidated sales were ~~$330.8~~$313.2 million and ~~$253.9~~$207.2 million, respectively. For the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019,~~2020, our net loss was ~~$51.4~~$1.0 million and ~~$27.4~~$42.0 million, respectively. Worldwide pump sales accounted for ~~62%~~61% and ~~69%~~60% of our total sales ~~respectively,~~ for the ~~nine~~six months ended ~~September~~June 30, 2021 and 2020, ~~and 2019,~~respectively, while pump-related supplies and accessories accounted for the remainder in each year. Our accumulated deficit as of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019~~2020 was ~~$676.2~~$651.2 million and ~~$624.8~~$659.2 million, respectively. These amounts included ~~$281.6~~$321.2 million and ~~$216.6~~$292.1 million of accumulated non-cash stock-based compensation charges and non-cash charges from the change in fair value of common stock warrants as of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively.

Table of contents

In the United States, we have rapidly increased sales since the commercial launch of our first product by expanding our sales, clinical and marketing organization, by developing, commercializing and marketing multiple differentiated products that utilize our proprietary technology platform and consumer-focused approach, and by providing strong customer support. Our sales have further increased following our scaled product launches in an expanding number of geographies outside the United States. We believe that by demonstrating our product benefits and the shortcomings of existing insulin therapies, more people will choose our insulin pumps for their therapy needs, allowing us to further penetrate and expand the market worldwide. In addition, we believe publications, such as the results from studies using Control-IQ technology that were published in the New England Journal of Medicine in October 2019 and August 2020, and post-market real-world data will be valuable in demonstrating the clinical outcome benefits derived from our system to healthcare providers and payors. We also believe we are positioned well to address consumers’ needs and preferences with our current products and products under development and by offering customers access to our future innovations through ~~the Tandem Device Updater,~~TDU, as they are approved by the local regulating bodies. At the same time, by innovating and offering new product features and benefits using our t:slim X2 platform, we are able to leverage a shared global manufacturing and supply chain infrastructure. In the United States, we are able to leverage a single sales, marketing, and clinical organization, as well as our ~~domestic~~ customer support services. In Canada, we have a separate sales organization and our customer support infrastructure benefits from close collaboration with our United States organization. In other international geographies, we have contracted with experienced distribution partners to commercialize and support our t:slim X2 platform.

COVID-19 Global Pandemic Impact and Considerations

We are deemed an essential healthcare business under applicable governmental orders based on the critical nature of the products we offer and the communities we serve. We experienced a modest ~~impact~~impacts from the COVID-19 global pandemic during the first quarter of 2020, which became more pronounced beginning in the second quarter and ~~third quarters. We originally anticipated that our sales outside~~continuing through the ~~United States would experience a greater proportional impact due to differences in the sales process in domestic versus international markets.~~current period. Initially, the impact toon our business was relatively consistent worldwide but we have since seen varying degrees of impact in international markets based on local conditions. ~~The impact from COVID-19 on our~~During the first half of 2021, we saw a gradual increase in the amount of in-person sales ~~outside~~and training activities in the United States ~~during~~as vaccination availability expanded and social-distancing requirements were relaxed. However, we continue to see variability across the ~~fourth quarter of 2020 may be even more difficult to estimate due to the recent announcements of additional restrictions and lock-downs in multiple European countries.~~ country.

We anticipate that our sales and operating results will continue to be adversely impacted and subject to unpredictable variability for the duration of the pandemic. For example, during the early stages of the pandemic, we experienced delays in certain programs of up to six months from when they were originally planned, ~~to begin in the second quarter of 2020 were delayed until the second half of the year,~~ such as human factors studies associated with our product development efforts. ~~Programs originally planned~~More recently, recruiting and hiring new employees has proven more difficult due to ~~be begin or to be completed~~generalized labor shortages. There is substantial competition for talent in the ~~second half of 2020 may also be delayed until future periods.~~ markets in which we operate as the economy is entering a recovery phase and businesses increase hiring in general. In addition, regulatory timelines have been and may continue to be difficult to predict as the FDA has stated that its review process may take longer than normal due to the impact of the COVID-19 global ~~pandemic.~~ pandemic, and we have experienced delays in the review of pending submissions. The full extent of the impact of the COVID-19 global pandemic on our future business and operations is difficult to estimate and will depend on a number of factors including the scope and duration of the COVID-19 global pandemic, and the relative impact of COVID-19 on the business operations of our contract manufacturers, suppliers and competitors.

Table of contents

We have taken steps to prioritize the health and safety of our employees and customers during the COVID-19 global pandemic, while working to maintain a continuous supply of products, training and customer support. To that end, we have increased the frequency of our communications to employees, suppliers, customers, and healthcare providers. ~~Since March 2020,~~Until recently, we ~~have~~ restricted nearly all non-essential employee travel and banned non-essential visitors from all of our facilities. We have recently modified those restrictions to allow for some limited employee travel and visitors to our facilities ~~and transitioned~~with controls. For example at our facilities in San Diego, California, those employees who are able to perform their job ~~function~~functions outside of our facilities continue to work in a remote ~~work environment.~~environment, while employees at our facility in Boise, Idaho began a gradual return to the office during the second quarter. For our field-based sales and clinical employees, we initially discontinued all in-person activities and began utilizing technology to remotely engage healthcare providers and customers. We continue to work closely with our healthcare providers and customers, remaining flexible in our method of ~~interaction.~~interaction, but during the second quarter of 2021 we began seeing an increase in the amount of in-person interactions among our field-based staff. To help ensure the safety and health of our employees in manufacturing and warehousing positions involved in production and fulfillment operations, we have implemented preventative measures to comply with social distancing requirements and require temperature checks of our employees before each shift.

In response to developments surrounding the COVID-19 global pandemic, we initiated discussions with our key suppliers in early 2020 regarding their abilities to fulfill existing orders, and we have continued to regularly assess their capacity. At this time, we believe many of our suppliers are deemed essential businesses under applicable governmental orders, and we have not experienced, and do not anticipate experiencing, disruption in our ability to manufacture insulin pumps and cartridges due to component procurement limitations. Our finished goods and raw material inventory for insulin pumps, as well as available manufacturing capacity, position us well to respond to unforeseen disruptions in the near term.

~~Table of contents~~

During the first six months of 2020, we experienced certain challenges managing our inventory, primarily due to the impacts of the COVID-19 global pandemic. For example, in the first quarter of 2020, we observed customers purchasing cartridges and infusion sets at a higher rate than ~~anticipated. In addition, during the second quarter of 2020,~~anticipated; however, we have not observed similar patterns in more recent periods. Nevertheless, our ~~primary~~ infusion set manufacturer ~~experienced~~continues to experience certain inventory constraints which have resulted in ~~our having to ask~~us asking some customers to accept substitutions of similar products to prevent delays in order fulfillment. ~~Our infusion set inventory has returned to more normal levels~~At this time, we believe many of our suppliers are deemed essential businesses under applicable governmental orders, and we ~~continue~~have not experienced, and do not anticipate experiencing, disruption in our ability to ~~focus on building~~manufacture insulin pumps and ~~maintaining adequate levels~~cartridges due to component procurement limitations in general. However, we are closely monitoring global shortages for semiconductors and copper, which are essential for the production of our insulin pumps and accessories. Our finished goods and raw material inventory, ~~for finished cartridges. Our third-party cartridge manufacturer completed validation and commenced commercial-scale manufacturing near the end of the first quarter to supplement our existing cartridge~~as well as available manufacturing capacity, ~~which~~position us well to respond to unforeseen disruptions in the near term but we ~~believe will assist us in meeting product~~could experience greater challenges with our supply chain if pump demand ~~in future periods.~~meaningfully exceeds our current forecasts.

Commercially, we have been communicating with our customers and healthcare providers through social media, direct email outreach and our website, in addition to regular communications sent by our sales and clinical employees. We are also leveraging our technology platforms, such as our t:connect diabetes management application, to support healthcare providers ~~as many of them are increasingly~~ utilizing telehealth capabilities in their practices. By the end of the first quarter of 2020, we expanded our remote new pump training offering to all customers who purchased a t:slim X2 insulin pump, and in the third quarter of 2020, we resumed offering in-person trainings under specific conditions. During the second quarter of 2021 we began seeing an increase in the amount of in-person interactions among our field-based staff with customers and healthcare providers in the United States. During the same period, we also began observing more pronounced rates of travel and vacations by both customers and healthcare providers in the United States, coinciding with the increase in vaccination trends and relaxation of COVID-19 related restrictions on travel and social-distancing. Historically we have seen similar summer vacation seasonality in Europe, but it is possible that we could also experience a more significant summer seasonality in the United States during 2021 due to the lifting of COVID-19 related restrictions.

We are prudently managing our use of cash and completed a convertible debt financing in May 2020 to further strengthen our balance sheet. We believe that our total cash and investments on hand are sufficient to sustain our existing operations for at least the next 12 months from the date of this filing. In the meantime, we are focused on making necessary investments in the organization as originally planned to continue to progress against our long-term sales and profitability initiatives, including through the recruitment of key employees, advancement of our ~~R&D~~research and development pipeline, and implementation of technology solutions. We will continue to evaluate our business operations and strategy based on new information as it becomes available and ~~we intend to~~will make changes that we consider necessary in light of this information.

Products Under Development

Our products under development support our strategy of focusing on both consumer and clinical needs, and include a connected (mobile) health offering, a next-generation hardware platform, which we refer to as the t:sport Insulin Delivery System (t:sport), AID system enhancements, and additional CGM integrations with our current and future products. We intend to leverage our consumer-focused approach and proprietary technology platform to continue to develop products that have the features and functionality that will allow us to meet the needs of people in differentiated segments of the insulin-dependent diabetes market, including the following:

Table of contents

•Connected (Mobile) Health Offerings – In July of 2020, we began offering the first version of our t:connect mobile application that wirelessly uploads pump data to our cloud-based t:connect diabetes management application, receives notification of pump alerts and alarms, and provides a discrete, secondary display of glucose and insulin data. Future updates of our mobile application are planned to include mobile bolus delivery, additional pump control features, integrate other health-related information from third-party sources and support future capabilities for our products under development. We plan to transition our mobile health offerings to a single, global digital platform, which is intended to provide all users, including pump users, caregivers and healthcare providers, with a simplified and tailored user experience. The platform is being designed to enhance the user experience, streamline the pump and supplies purchasing process, and provide internal efficiencies. In the future, data from our centralized system may be used for new product development, continuous product improvement, and for the generation of health economic outcomes data, and may ultimately support other advanced technology and patient monitoring services.

•t:sport Insulin Delivery System – Approximately half the size of our t:slim X2 pump, the t:sport pump is being designed for people who seek even greater discretion and flexibility with the use of their insulin pump. We anticipate that t:sport will feature a 200-unit cartridge, an on-pump bolus button, a rechargeable battery, an AID algorithm, and a Bluetooth radio. t:sport is being designed for use with leading U-100 insulins, and we are evaluating the use of insulin concentrates to provide to people with greater insulin needs. We anticipate that t:sport will be our first insulin pump to support full pump-control from our mobile application, subject to FDA review and approval. A separate controller may be offered in addition to full mobile control availability.

•AID Enhancements – We intend to further enhance our automated insulin delivery system and are considering alternative strategies to deliver new features and benefits to our customers on a regular basis. In addition to algorithm enhancements intended to improve clinical outcomes, we are also developing new features for greater personalization and refinements to the overall system usability.

~~Table of contents~~

•Additional CGM Integration – In June 2020 we announced an agreement with Abbott to develop and commercialize integrated diabetes solutions that combine Abbott’s CGM technology with our insulin delivery systems to provide more options for people to manage their diabetes. Following the completion of our integrated product development work, and after obtaining required regulatory clearances or approvals, we intend to focus our initial commercial activities ~~for~~on integrated products in the U.S. and Canada, with additional geographies considered in the future. In November 2020, we entered into an agreement with Dexcom to extend our current collaboration to include integration with Dexcom’s future G7 CGM technology. Following integrated product development work, and required regulatory clearances or approvals, this will be the fourth generation of Dexcom CGM that we intend to integrate with our devices.

Pump Shipments

From inception through June 2018, we derived nearly all of our sales from the shipment of insulin pumps and associated supplies to customers in the United States. Starting in the third quarter of 2018, we commenced sales of our t:slim X2 insulin pump in select international geographies. We consider the number of insulin pump units shipped per quarter domestically and internationally to be an important metric for managing our business.

In the four-year period ended ~~September~~June 30, ~~2020,~~2021, we shipped approximately ~~188,000~~269,000 insulin pumps, of which approximately ~~152,000~~203,000 were shipped to customers in the United States and approximately ~~36,000~~66,000 were shipped to international markets.

Table of contents

Pump shipments to customers in the United States by fiscal quarter were as follows:


		Pump Units Shipped for Each of the Three Months Ended in Respective Years - U.S.						Pump Units Shipped for Each of the Three Months Ended in Respective Years - U.S.
		March 31	June 30	September 30	December 31	Total		March 31	June 30	September 30	December 31	Total
2012	2012	—	9	204	844	1,057	2012	0	9	204	844	1,057
2013	2013	852	1,363	1,851	2,406	6,472	2013	852	1,363	1,851	2,406	6,472
2014	2014	1,723	2,235	2,935	3,929	10,822	2014	1,723	2,235	2,935	3,929	10,822
2015	2015	2,487	3,331	3,431	6,234	15,483	2015	2,487	3,331	3,431	6,234	15,483
2016	2016	4,042	4,582	3,896	4,418	16,938	2016	4,042	4,582	3,896	4,418	16,938
2017	2017	2,816	3,427	3,868	6,950	17,061	2017	2,816	3,427	3,868	6,950	17,061
2018	2018	4,444	5,447	7,379	12,935	30,205	2018	4,444	5,447	7,379	12,935	30,205
2019	2019	9,669	12,799	13,814	17,453	53,735	2019	9,669	12,799	13,814	17,453	53,735
2020	2020	13,158	14,735	18,380	N/A	46,273	2020	13,158	14,735	18,380	24,552	70,825
2021							2021	16,644	20,665	N/A	N/A	37,309

Pump shipments to international customers by fiscal quarter were as follows:


		Pump Units Shipped for Each of the Three Months Ended in Respective Years - International						Pump Units Shipped for Each of the Three Months Ended in Respective Years - International
		March 31	June 30	September 30	December 31	Total		March 31	June 30	September 30	December 31	Total
2018	2018	N/A	N/A	1,055	3,233	4,288	2018	N/A	N/A	1,055	3,233	4,288
2019	2019	5,063	8,459	4,025	2,149	19,696	2019	5,063	8,459	4,025	2,149	19,696
2020	2020	4,220	3,952	3,641	N/A	11,813	2020	4,220	3,952	3,641	8,133	19,946
2021							2021	8,708	13,152	N/A	N/A	21,860

Trends Impacting Financial Condition and Operating Results

Overall, we have experienced considerable sales growth since the commercial launch of our first product in the third quarter of 2012, while incurring operating losses since our inception. Our operating results have historically fluctuated on a quarterly or annual basis, particularly in periods surrounding anticipated regulatory approvals, the commercial launch of new products by us and our competitors, the commercial launch of our products in geographies outside of the United States and due to general seasonality in the United States. We expect these periodic fluctuations in our operating results to continue.

We believe that our financial condition and operating results, as well as the decision-making process of our current and potential customers, has been and will continue to be impacted by a number of general trends, including the following:

•market acceptance of our products and competitive products by people with insulin-dependent diabetes, their caregivers and healthcare providers;

~~Table of contents~~

•the introduction of new products, treatment techniques or technologies for the treatment of diabetes, including the timing of the commercialization of new products by us and our competitors;

•seasonality in the United States associated with annual insurance deductibles and coinsurance requirements associated with the medical insurance plans utilized by our customers and the customers of our distributors;

•incidence of disease or illness, including the COVID-19 global pandemic, that may impact customer purchasing patterns or disrupt our supply chain;

•timing of holidays and summer vacations, which may vary by ~~geography;~~geography and may be further influenced by the lifting or relaxation of COVID-19 related restrictions during 2021;

•the buying patterns of our distributors and other customers, both domestically and internationally;

Table of contents

•changes in the competitive landscape, including as a result of companies entering or exiting the diabetes therapy market;

•access to adequate coverage and reimbursement for our current and future products by third-party payors, and reimbursement decisions by third-party payors;

•the magnitude and timing of any changes to our facilities, manufacturing operations and other infrastructure, and factors impacting our ability to access our facilities;

•the impact of any privacy breaches, which may subject us to legal and regulatory proceedings and substantial fines, penalties and expenses, as well as significant reputational harm;

•anticipated and actual regulatory approvals of our products and competitive products; and

•product recalls impacting, or the suspension or withdrawal of regulatory clearance or approval relating to, our products or the products of our competitors.

In addition to these general trends, we believe the following specific factors have materially impacted, and could continue to materially impact, our business going forward:

•the disruptions caused by the COVID-19 global pandemic on suppliers, third-party manufacturers, healthcare providers, distributors and our existing or potential customers;

•continued increase in demand following the commercial launch of t:slim X2 with Control-IQ technology in additional geographies, and the demonstrated success of our Tandem Device Updater;

•anticipated new product launches;

•increased opportunity to achieve customer renewals as customers become eligible for insurance reimbursement to purchase a new insulin pump at the end of the typical four-year reimbursement cycle;

•opportunity to transition former customers of Animas Corporation (Animas) to our t:slim X2 insulin pump in 2018 and 2019 following the announcement by Johnson & Johnson that it had discontinued the operations of Animas and discontinued the availability of Animas pump supplies in September 2019;

•designation by UnitedHealthcare of one of our competitors as its preferred, in-network durable medical equipment provider of insulin pumps for most customers age seven and above from July 2016 through June 2020;

•ability to enter into and maintain agreements with CGM partners for CGM integration;

•expansion and new product launches in select international geographies, including initial orders to stock inventories; and

~~Table of contents~~

•ability to effectively scale our operations to support rapid growth, including expanding our facilities, advancing our research and development efforts, increasing manufacturing capacity through third-party manufacturers, and hiring and retaining employees in customer service and support functions.

In addition to working to achieve our sales growth expectations, in the long-term we intend to continue to leverage our infrastructure investments to realize additional manufacturing, sales, marketing and administration cost efficiencies with the goal of improving our operating margins and ultimately achieving sustained profitability. We achieved profitability for the first time in the fourth ~~quarter~~quarters of 2018, 2019 and 2020, and again in the ~~fourth~~second quarter of ~~2019.~~2021. Though we ~~may be unable~~have yet to achieve profitability consistently from period to period, we believe we can ultimately achieve sustained profitability by driving incremental sales growth in U.S. and international markets, meeting our pump renewal sales objectives, maximizing manufacturing efficiencies on increased production volumes, and leveraging the investments made in our sales, clinical, marketing and customer support organizations.

Table of contents

~~Recent Developments~~

~~NEJM Publication of Pediatric Study Demonstrating Increased Time-In-Range Using the t:slim X2 Insulin Pump with Control-IQ Technology~~

In August 2020, we announced publication by the New England Journal of Medicine (NEJM) of results from the Protocol 5 study (DCLP5) of the International Diabetes Closed Loop (iDCL) trial. Results demonstrated increased time spent in range (70-180 mg/dL) in children ages six to 13 years old using the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology.

Components of Results of Operations

Sales

We offer products for people with insulin-dependent diabetes. We commenced commercial sales of our original t:slim insulin pump platform in the United States in the third quarter of 2012 and continued to launch various iterations of that platform during the following years. In October 2016, we began shipping our flagship pump platform, the t:slim X2 insulin pump. The t:slim X2 insulin pump platform with ~~advanced software algorithms and~~ remote software update capabilities, now represents 100% of our new pump shipments and is used by nearly all of our in-warranty customers. Our products also include disposable cartridges and infusion sets, as well as our complementary t:connect, Tandem Device Updater and mobile application products. We also offer additional accessories including protective cases, belt clips, and power adapters, although sales of these products are not significant.

We primarily sell our products through national and regional distributors in the United States on a non-exclusive basis. These distributors are generally providers of medical equipment and supplies to individuals with diabetes. Our primary end customers are people with insulin-dependent diabetes. Similar to other durable medical equipment, the primary payor is generally a third-party insurance carrier and the customer is usually responsible for any medical insurance plan copay or coinsurance requirements. We believe our existing sales, clinical, and marketing infrastructure will allow us to continue to increase sales by allowing us to promote our products to a greater number of potential customers, caregivers and healthcare providers, although the COVID-19 global pandemic has had, and may continue to have, an adverse impact on our sales.

In the third quarter of 2018, we began the launch of our t:slim X2 hardware platform through distribution partners outside the United ~~States,~~States. Our products are now sold in more than 20 countries, including in ~~select European countries, Australia, New Zealand,~~Canada, France and ~~South Africa.~~Germany. The software version on the t:slim X2 hardware platform has progressed from Dexcom G5 CGM integration at initial launch, followed by Basal-IQ technology scaling across various international markets beginning in the second quarter of 2019, and most recently we commenced the launch of our Control-IQ technology in ~~limited~~select geographies. Our launch of Control-IQ technology in international markets will continue to scale ~~through the remainder of 2020, contingent upon~~across additional geographies throughout 2021 subject to applicable regulatory and reimbursement approvals.

In the first quarter of 2020, we expanded into additional international markets by delivering initial orders to support product launches in France and Germany occurring in the second and third quarters of 2020, respectively. Our independent international distributor partners perform all sales, customer support and training in their respective markets. In Canada, we market with a direct sales force and, similar to the United States, use a distributor partner for certain billing and fulfillment activities. Historically, we have experienced consistent levels of reimbursement for our products in the United States, but we expect the average sales price will vary in international markets based on a number of factors, such as the geographical mix, nature of the reimbursement environment, government regulations and the extent to which we rely on distributor relationships to provide sales, clinical and marketing support.

~~Table of contents~~

In general, in the United States we have experienced pump shipments being weighted heavily towards the second half of the year, with the highest percentage of pump shipments expected in the fourth quarter due to the nature of the reimbursement environment. Consistent with these historical seasonality trends, our domestic pump shipments have typically decreased significantly from the fourth quarter to the following first quarter. Internationally, we do not expect this same impact from seasonality associated with reimbursement, although the quarterly sales trends may be impacted by a number of other factors, including summer vacations and product launches into new geographies. While the opportunity to transition former Animas customers positively impacted our 2019 quarterly sales trends worldwide, we do not anticipate that this trend will continue to have a significant impact.

Table of contents

During 2020, the COVID-19 global pandemic had a major impact on businesses around the world. While we experienced only a modest negative impact from the pandemic during the first quarter of 2020, ~~the negative impact during~~which became more pronounced in the second quarter and ~~third quarters~~remained through the end of ~~2020 was more pronounced, and~~the year, we anticipate that our sales and operating results will continue to be adversely impacted ~~in future periods.~~for the duration of the pandemic. Starting in March 2020, we ceased nearly all in-person sales, marketing and training activities and adopted numerous other changes to our daily business operations. These changes ~~primarily remain~~remained in effect asduring the majority of the ~~date~~first half of ~~this report~~2021, but during the second quarter of 2021 we began seeing an increase in the amount of in-person interactions among our field-based staff with customers and healthcare providers in the United States coincident with the increase in vaccination trends and relaxation of COVID-19 related restrictions on travel and social-distancing. Beginning in the second quarter of 2021 we also began observing more pronounced rates of travel and vacations by both customers and healthcare providers in the United States. Historically we have seen similar summer vacation seasonality in Europe, but it ~~remains uncertain when~~is possible that we ~~may be able~~could also experience more significant summer seasonality in the United States during 2021 due to ~~resume our normal operations.~~the lifting of COVID-19 related restrictions. Accordingly, we anticipate that our sales ~~will~~may not follow historical trends and ~~will~~may be ~~adversely impacted~~subject to unpredictable variability in the coming months ~~as customers delay their purchasing decisions or physicians pause their prescriptions~~based on varying levels of ~~new products.~~impact of the global pandemic across the markets in which we operate. Our sales outside the United States have been negatively impacted due to similar disruptions. Initially, the impact was relatively consistent worldwide but we have since seen varying degrees of impact in international markets based on local conditions. The full extent of the impact of the COVID-19 global pandemic on our business and operations will depend on a number of factors, including the scope and duration of the pandemic, varying government responses to the pandemic and potential delays to product development timelines.

Separate from any impacts of the COVID-19 global pandemic, our quarterly sales have historically fluctuated, and may continue to fluctuate substantially in the periods surrounding anticipated and actual regulatory approvals and commercial launches of new products by us or our competitors. We believe customers may defer purchasing decisions if they believe a new product may be launched in the future. Additionally, upon the announcement of FDA approval or commercial launch of a new product, either by us or one of our competitors, potential new customers may reconsider their purchasing decisions or take additional time to consider such FDA approval or product launch before making their purchasing decisions. For instance, we believe certain customers paused their decision-making during the second half of 2019 in anticipation of the commercial availability of the t:slim X2 with Control-IQ technology. However, it is difficult to quantify the extent of the impact of these or similar events on future purchasing decisions.

Cost of Sales

Historically, we have manufactured our pumps and disposable cartridges at our manufacturing facility in San Diego, California. Near the end of the first quarter of 2020, our third-party cartridge manufacturer completed validation and commenced commercial-scale manufacturing to supplement our existing cartridge manufacturing capacity. We expect to increase production capacity and volumes at our third-party cartridge manufacturer over the next 24 months and concurrently reduce our t:slim cartridge manufacturing capacity in our existing facility in order to create capacity for t:sport cartridge manufacturing in the future. Infusion sets and pump accessories are manufactured by third-party suppliers. Cost of sales includes raw materials, labor costs, manufacturing overhead expenses, product training costs, royalties, freight, reserves for expected warranty costs, costs of supporting our digital health platforms, scrap and charges for excess and obsolete inventories. Manufacturing overhead expenses include expenses relating to quality assurance, manufacturing engineering, material procurement, inventory control, facilities, equipment, information technology and operations supervision and management. We anticipate that our cost of sales will continue to increase as our product sales increase.

3031

Table of contents

Over the long term, we expect our overall gross margin percentage, which for any given period is calculated as sales less cost of sales divided by sales, to improve, as our sales increase and our overhead costs are spread over larger production volumes. We expect we will be able to leverage our manufacturing cost structure across our products that utilize the same technology platform and manufacturing infrastructure and will be able to further reduce per unit costs with increased automation, process improvements and raw materials cost reductions. We also expect our warranty cost per unit to decrease as we release additional product features and functionality utilizing the Tandem Device Updater. Pumps have, and are expected to continue to have, a higher gross margin percentage than our pump-related supplies. Therefore, the percentage of pump sales relative to total sales will have a significant impact on our overall gross margin percentage. In the event that customers delay their pump purchasing decisions or physicians pause in prescribing new pumps, whether as a result of the COVID-19 global pandemic, or for other reasons, it is possible that we may experience a higher percentage of pump-related supply sales than anticipated, which in turn could adversely impact our overall gross margin percentage. ~~We also expect our warranty cost per unit to decrease as we release additional product features and functionality utilizing the Tandem Device Updater.~~ However, our overall gross margin percentage may fluctuate in future quarterly periods as a result of numerous factors aside from those associated with production volumes and product mix. For instance, as a result of the COVID-19 global pandemic we ~~have~~ implemented temporary operational changes that ~~may introduce unpredictable~~introduced variability to our cost of sales, such as supplemental staffing, incremental expenses to protect the health, safety and welfare of our employees working on-site and to enable other employees to work remotely. In addition, as demand for our products increases, we may continue to make additional investments in manufacturing capacity or increase our reliance on third parties for manufacturing-related services, either of which could have a negative impact on our gross margins. Specifically, in 2020 and 2021, we ~~began~~have and will continue to evaluate investing in additional manufacturing equipment ~~that will double~~to substantially increase our existing capacity in order to meet anticipated long-term demand for our cartridges, which may initially place downward pressure on the gross margin percentage associated with our pump-related supplies.

Other factors impacting our overall gross margin percentage may include the changing percentage of products sold to distributors versus directly to individual customers, varying levels of reimbursement among third-party payors in domestic and international markets, the timing and success of new regulatory approvals and product launches, the impact of the valuation and amortization of employee stock awards on non-cash stock-based compensation expense allocated to cost of sales, changes in warranty estimates, training costs, licensing and royalty costs, ~~increased costs~~cost to support our digital health platforms, cost associated with excess and obsolete inventories, and changes in our manufacturing processes, capacity, costs or output.

Selling, General and Administrative

Our selling, general and administrative (SG&A) expenses primarily consist of salary, cash-based incentive compensation, fringe benefits and non-cash stock-based compensation for our executive, financial, legal, marketing, sales, clinical, customer support, technical services, insurance verification, regulatory affairs and other administrative functions. We began expanding our U.S. field sales and clinical organization during the third quarter of 2019 to support an expected increase in demand for our products. We ~~had~~have approximately 9095 sales territories in the United States as of ~~September~~June 30, ~~2020.~~2021. Our existing territories are generally maintained by sales representatives and field clinical specialists, and supported by managed care liaisons, additional sales management and other customer support personnel, which have also been rapidly expanding to support our growing installed base. Our operations in Canada are comprised of approximately ten sales territories. Other significant SG&A expenses include those incurred for product demonstration samples, commercialization activities associated with new product launches, travel, trade shows, outside legal fees, independent auditor fees, outside consultant fees, insurance premiums, facilities costs and information technology costs. Overall, we expect our SG&A expenses, including the cost of our customer support infrastructure, to increase as our customer base grows in the United States and international markets. We may experience additional costs as our employees return to work at our offices and as we adapt to alternative hybrid work models, or as needed to respond to general labor shortages and heightened competition for employees with specialized skills. In addition, we will continue to evaluate, and may further increase, the number of our field sales and clinical personnel in order to optimize the coverage of our existing territories. Additionally, we realized a notable increase in non-cash stock-based compensation expense allocated to SG&A beginning in the third quarter of 2018, and again in the second quarter of 2019, due to the valuation of certain 2018 and 2019 employee stock option grants and the impact on the valuation of the significant increase in our stock price over the previous year. We recognized higher non-cash stock-based compensation expense through the first half of 2020, and experienced a reduction in expense beginning in the third quarter of 2020 as certain 2018 employee stock option grants ~~are now~~became fully amortized. We anticipate that we will continue to see improvement in non-cash stock-based compensation expense as a percent of sales in future years. Our SG&A expenses may be affected by our response to the COVID-19 global pandemic, including reduced spending in areas such as non-essential employee travel, which may be offset by increased spending to support measures designed to prioritize the retention, health, safety and welfare of our employees. In the longer term, SG&A expenses may also increase due to anticipated costs associated with additional compliance and regulatory reporting requirements.

3132

Table of contents

Research and Development

Our research and development (R&D) activities primarily consist of engineering and research programs associated with our hardware, software and digital health products under development, as well as activities associated with our core technologies and processes. R&D expenses are primarily related to employee compensation, including salary, cash-based incentive compensation, fringe benefits, non-cash stock-based compensation and temporary employee expenses. We also incur R&D expenses for supplies, development prototypes, outside design and testing services, depreciation, allocated facilities and information services, clinical trial costs, payments under our licensing, development and commercialization agreements and other indirect costs. We expect our R&D expenses to increase as we advance our products under development, ~~and~~ develop new products and technologies ~~partially offset by future expected declines in non-cash stock-based compensation.~~and support more clinical trials. Similar to our SG&A expenses, our future R&D spending may be impacted by the COVID-19 global pandemic. For instance, we may experience lower spending associated with delays in the advancement of particular programs, which may be offset by increased spending to support the retention, health, safety and welfare of our employees or to enable development activities under alternative conditions.

Other Income and Expense

Other income and expense primarily consists of changes in the fair value of certain warrants issued in connection with our public offering of common stock in October 2017, interest expense which includes the amortization of debt ~~discount and debt~~ issuance costs related to our 1.50% Convertible Senior Notes due 2025, issued in May 2020 (our Notes), and interest earned on our cash equivalents and short-term investments. We expect interest expense in future quarters to be comparable with that of the ~~third quarter~~first and second quarters of ~~2020 as our~~2021, assuming that none of the Notes ~~were outstanding for the entire period,~~are converted or redeemed, and total other income and expense, net to fluctuate from period to period primarily due to the revaluation of the outstanding Series A warrants, which expire in the fourth quarter of 2022.

Income Tax Expense (Benefit)

Because ~~we are in~~the Company maintains a full valuation allowance against its net ~~loss position with respect to federal income taxes,~~deferred tax assets, income tax expense is expected to primarily consist of current state and foreign ~~income~~cash tax expense as a result of ~~current~~ taxable income anticipated or incurred in those jurisdictions. Income tax expense (benefit) may fluctuate in future quarters due to adjustments related to non-recurring transactions and changes in certain tax assessments.

3233

Table of contents

Results of Operations


		Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended June 30,					Six Months Ended June 30,
(in thousands, except percentages)	(in thousands, except percentages)	2020			2019			2020			2019				(in thousands, except percentages)	2021			2020			2021			2020
Sales:	Sales:														Sales:
Domestic	Domestic	$	107,517		$	78,842		$	276,340		$	203,867			Domestic	$	127,580		$	89,277		$	230,919		$	168,823
International	International	16,086			15,815			54,425			50,040				International	44,559			19,959			82,257			38,339
Total sales	Total sales	123,603			94,657			330,765			253,907				Total sales	172,139			109,236			313,176			207,162
Cost of sales	Cost of sales	58,290			43,974			160,801			119,967				Cost of sales	79,685			54,846			147,435			102,511
Gross profit	Gross profit	65,313			50,683			169,964			133,940				Gross profit	92,454			54,390			165,741			104,651
Gross margin	Gross margin	53		%	54		%	51		%	53		%		Gross margin	54		%	50		%	53		%	51		%
Operating expenses:	Operating expenses:														Operating expenses:
Selling, general and administrative	Selling, general and administrative	50,228			44,649			150,385			120,173				Selling, general and administrative	66,523			50,440			125,086			100,157
Research and development	Research and development	16,094			12,038			46,198			32,632				Research and development	20,499			15,987			38,460			30,104
Total operating expenses	Total operating expenses	66,322			56,687			196,583			152,805				Total operating expenses	87,022			66,427			163,546			130,261
Operating loss		(1,009)			(6,004)			(26,619)			(18,865)
Operating income (loss)															Operating income (loss)	5,432			(12,037)			2,195			(25,610)
Other income (expense), net:	Other income (expense), net:														Other income (expense), net:
Interest income and other, net	Interest income and other, net	143			854			1,235			2,381				Interest income and other, net	418			367			690			1,093
Interest expense	Interest expense	(4,855)			—			(8,030)			—				Interest expense	(1,509)			(3,176)			(3,015)			(3,176)

Change in fair value of common stock warrants	Change in fair value of common stock warrants	(3,648)			2,321			(19,906)			(10,849)				Change in fair value of common stock warrants	(272)			(14,336)			(962)			(16,258)
Total other income (expense), net		(8,360)			3,175			(26,701)			(8,468)
Loss before income taxes		(9,369)			(2,829)			(53,320)			(27,333)
Total other expense, net															Total other expense, net	(1,363)			(17,145)			(3,287)			(18,341)
Income (loss) before income taxes															Income (loss) before income taxes	4,069			(29,182)			(1,092)			(43,951)
Income tax expense (benefit)	Income tax expense (benefit)	39			72			(1,938)			72				Income tax expense (benefit)	61			(2,075)			(56)			(1,977)
Net loss		$	(9,408)		$	(2,901)		$	(51,382)		$	(27,405)
Net income (loss)															Net income (loss)	$	4,008		$	(27,107)		$	(1,036)		$	(41,974)

Comparison of the Three Months Ended ~~September~~June 30, ~~2020~~2021 and ~~2019~~2020

Sales. For the three months ended ~~September~~June 30, ~~2020,~~2021, sales were ~~$123.6~~$172.1 million, which included ~~$16.1~~$44.6 million of international sales. Sales were ~~$94.7~~$109.2 million for the same period in ~~2019,~~2020, which included ~~$15.8~~$20.0 million of international sales.

The increase in worldwide sales of ~~$28.9~~$62.9 million in the ~~third~~second quarter of 2021 compared to the second quarter of 2020 ~~compared to the third quarter of 2019~~ was ~~primarily~~ driven by ~~a 23%~~an 81% increase in worldwide pump shipments to ~~22,021~~33,817 in the ~~third~~second quarter of 2021, compared to 18,687 in the second quarter of 2020, ~~compared to 17,839 in the third quarter of 2019,~~ and a ~~43%~~47% increase in pump-related supply sales. Sales of pump-related supplies increased primarily due to ~~a 46% increase~~59% growth in our estimated worldwide installed base of customers.

Domestic sales by product were as follows (in thousands):


		Three Months Ended September 30,					Three Months Ended June 30,
		2020		2019			2021		2020
Pump	Pump	$	69,464	$	52,914	Pump	$	80,041	$	56,367
Infusion sets	Infusion sets	26,133		17,646		Infusion sets	32,134		22,536
Cartridges	Cartridges	11,767		8,149		Cartridges	15,082		10,196
Other	Other	153		133		Other	323		178
Total Domestic Sales	Total Domestic Sales	$	107,517	$	78,842	Total Domestic Sales	$	127,580	$	89,277

3334

Table of contents

Domestic pump sales were ~~$69.5~~$80.0 million for the ~~third~~second quarter of ~~2020,~~2021, compared to ~~$52.9~~$56.4 million in the ~~third~~second quarter of ~~2019,~~2020, as pump shipments increased ~~31%~~40% compared to the same period in the prior year due to continued strong demand for our products following the January 2020 domestic launch of our t:slim X2 insulin pump with Control-IQ technology. Domestic pump shipments were ~~18,380~~20,665 in the ~~third~~second quarter of ~~2020~~2021, compared to ~~13,814~~14,735 in the ~~third~~second quarter of ~~2019.~~2020. Sales of pump-related supplies increased primarily due to a ~~42%~~48% increase in our estimated domestic installed base of customers. Sales to distributors accounted for ~~74%~~68% and ~~72%~~71% of our total domestic sales for the three months ended ~~September~~June 30, ~~2020~~2021 and ~~2019,~~2020, respectively. Our percentage of sales to distributors versus individual customers is principally determined by the mix of customers ordering our products within the period and whether or not we have a contractual arrangement with their underlying third-party insurance payor.

International sales by product were as follows (in thousands):


		Three Months Ended September 30,					Three Months Ended June 30,
		2020		2019			2021		2020
Pump	Pump	$	9,045	$	10,310	Pump	$	27,630	$	9,124
Infusion sets	Infusion sets	5,118		3,444		Infusion sets	12,165		7,430
Cartridges	Cartridges	1,761		2,018		Cartridges	4,660		3,321
Other	Other	162		43		Other	104		84
Total International Sales	Total International Sales	$	16,086	$	15,815	Total International Sales	$	44,559	$	19,959

International pump sales were ~~$9.0~~$27.6 million for the ~~third~~second quarter of 2021, compared to $9.1 million in the second quarter of 2020, ~~compared to $10.3 million in the third quarter of 2019,~~ as pump shipments ~~declined 10%~~increased 233% compared to the same period in the prior ~~year.~~year due to strong demand for our products as we continue to expand the launch of Control-IQ technology, which began in the third quarter of 2020, outside the United States, as well as the varying impact of the global pandemic. Sales of pump-related supplies benefited from a 105% increase in our estimated international installed base of customers. The ordering patterns of our international distributors for pumps and supplies is highly variable from period to period. This variability was compounded by the varying levels of impact of the global pandemic across the international markets in which we operate. Sales to distributors accounted for 95% and 96% of our total international sales for the three months ended June 30, 2021 and 2020, respectively.

Cost of Sales and Gross Profit.Our cost of sales for the three monthsended June 30, 2021was $79.7 million, resulting in gross profit of $92.5 million, compared to cost of sales of $54.8 million for the same period in 2020 resulting in gross profit of $54.4 million. The gross margin for the three monthsended June 30, 2021 was 54%, compared to 50% in the same period in 2020.

The increase in our gross profit for the three months ended June 30, 2021 was primarily the result of the $62.9 million increase in total sales. Gross profit and gross margin both benefited from improvement in the per unit manufacturing costs for pumps and cartridges from efficiencies in the manufacturing process, leverage of fixed overhead and increased volumes from our third-party cartridge manufacturer. On an aggregate basis, non-manufacturing costs, which primarily consist of warranty, royalty, freight, training and digital health product support costs, also reflected improvement on a per unit basis. To a lesser extent, overall average selling prices slightly pressured gross margin as international pump sales comprised a greater portion of total pump sales compared to the prior year, while supply average selling prices reflected modest benefit from the growth of our international installed base. Royalty expense was $1.9 million for the three months ended June 30, 2021, compared to $1.7 million in the same period in 2020. Other factors that have and may continue to have an impact on the gross margin percentage are changes in product and customer mix. Pump sales, which have the highest gross margin, were 63% of total worldwide sales in the second quarter of 2021 versus 60% in the second quarter of 2020. Non-cash stock-based compensation expense allocated to cost of sales was $1.6 million for the three months ended June 30, 2021, compared to $2.2 million in the same period in 2020.

Table of contents

Selling, General and Administrative Expenses. SG&A expenses increased 32% to $66.5 million for the three months ended June 30, 2021 from $50.4 million for the same period in 2020.Employee-related expenses for ourSG&Afunctions comprise the majority of SG&A expenses.The increase compared to 2020 was primarily the result of a $9.6 million increase in salaries, incentive compensation and other employee benefits due to an increase in personnel to support additional sales territories, higher sales and other services in support of our growing installed customer base, offset by a $0.8 million decrease in non-cash stock-based compensation expense. Non-cash stock-based compensation expense allocated to SG&A was $10.9 million for the three months ended June 30, 2021, compared to $11.7 million in the same period in 2020. The increase in non-cash stock-based compensation expense associated with increased headcount in 2020 and 2021 was more than offset by a decrease in non-cash stock-based compensation expense from the valuation of certain 2018 employee stock option grants which are now fully amortized. We also experienced a $5.8 million increase in other non-employee discretionary spending, including outside services, outside consulting, equipment and travel costs.

Research and Development Expenses. R&D expenses increased 28% to $20.5 million for the three months ended June 30, 2021 from $16.0 million for the same period in 2020. The increase in R&D expenses was primarily the result of an increase of $4.5 million in salaries, incentive compensation and other employee benefits due to an increase in personnel to support our product development efforts. Non-cash stock-based compensation expense allocated to R&D was $2.5 million for the three months endedJune 30, 2021, compared to $2.6 million in the same period in 2020.

Other Income (Expense), Net. Total other expense, net for the three months ended June 30, 2021 was $1.4 million compared to $17.1 million in the same period in 2020. Total other expense, net for the three months ended June 30, 2021 primarily consisted of $1.5 million of interest expense which included the amortization of debt issuance costs related to our Notes issued in the second quarter of 2020, and a $0.3 million revaluation loss from the change in the fair value of certain warrants. Total other expense, net for the three months ended June 30, 2020consisted of a $14.3 million loss on revaluation from the change in the fair value of certain warrants, and $3.2 million of interest expense which included the amortization of debt discount and debt issuance costs related to our Notes. The decrease in interest expense was primarily due to the adoption of ASU No. 2020-06 in the first quarter of 2021 (see Note 7, “Convertible Senior Notes”).

Comparison of the Six Months Ended June 30, 2021 and 2020

Sales.For the six monthsended June 30, 2021,sales were $313.2 million, which included $82.3 million of international sales. For the six months ended June 30, 2020, sales were $207.2 million, which included $38.3 million of international sales.

The increase in worldwide sales of $106.0 million in the first six months of 2021 compared to the first six months of 2020 was driven by a 64% increase in worldwide pump shipments to 59,169 in the first six months of 2021, compared to 36,065 in the first six months of 2020, and a 51% increase in pump-related supply sales. Sales of pump-related supplies increased primarily due to a 59% growth in our estimated worldwide installed base of customers.

Domestic sales by product were as follows (in thousands):


	Six Months Ended June 30,
	2021		2020
Pump	$	142,953	$	106,086
Infusion sets	59,526		42,750
Cartridges	27,847		19,651
Other	593		336
Total Domestic Sales	$	230,919	$	168,823

Table of contents

Domestic pump sales were $143.0 million for the first six months of 2021, compared to $106.1 million in the first six months of 2020, as pump shipments increased 34% compared to the same period in the prior year due to continued strong demand for our products following the January 2020 domestic launch of our t:slim X2 insulin pump with Control-IQ technology. Domestic pump shipments were 37,309 in the first six months of 2021 compared to 27,893 in the first six months of 2020. Sales of pump-related supplies increased primarily due to a 48% increase in our estimated domestic installed base of customers. Sales to distributors accounted for 68% and 70% of our total domestic sales for the six months ended June 30, 2021 and 2020, respectively. Our percentage of sales to distributors versus individual customers is principally determined by the mix of customers ordering our products within the period and whether or not we have a contractual arrangement with their underlying third-party insurance payor.

International sales by product were as follows (in thousands):


	Six Months Ended June 30,
	2021		2020
Pump	$	46,538	$	18,940
Infusion sets	24,899		13,676
Cartridges	10,609		5,553
Other	211		170
Total International Sales	$	82,257	$	38,339

International pump sales were $46.5 million for the first six months of 2021, compared to $18.9 million in the first six months of 2020, as pump shipments increased 167% compared to the same period in the prior year due to strong demand for our products as we continue to expand the launch of Control-IQ technology, which began in the third quarter of 2020, outside the United States. Sales of pump-related supplies increased primarily due to an 105% increase in our estimated international installed base of customers. The ordering patterns of our international distributors for pumps and supplies is highly variable from period to period, particularly during the typical third quarter European holiday season. This variability was compounded by the varying levels of impact of the global pandemic across the international markets in which we operate. Sales to distributors accounted for ~~91% and 89%~~95% of our total international sales for both of the ~~three months~~six month periods ended ~~September~~June 30, ~~2020~~2021 and ~~2019, respectively.~~2020.

Cost of Sales and Gross Profit. Our cost of sales for the ~~three~~six months ended ~~September~~June 30, ~~2020~~2021 was ~~$58.3~~$147.4 million, resulting in gross profit of ~~$65.3~~$165.7 million, compared to cost of sales of ~~$44.0~~$102.5 million for the same period in ~~2019~~2020 resulting in gross profit of ~~$50.7~~$104.7 million. The gross margin ~~percentage~~ for the ~~three~~six months ended ~~September~~June 30, ~~2020~~2021 was 53%, compared to ~~54%~~51% in the same period in ~~2019.~~2020.

The increase in our gross profit for the ~~three~~six months ended ~~September~~June 30, ~~2020~~2021 was primarily the result of the ~~$28.9~~$106.0 million increase in total sales. Gross profit and gross margin ~~were negatively impacted by royalty~~both benefited from improvement in the per unit manufacturing costs for ~~which there was no comparable expense~~pumps and supplies from efficiencies in the ~~prior year. We recognized $1.7 million~~manufacturing process, leverage of ~~product royalty costs in the third quarter of 2020 associated with sales of products with Control-IQ technology~~fixed overhead, increased volumes from our third-party cartridge manufacturer and ~~free software updates downloaded by existing customers in the United States, as well as in certain international markets where we launched Control-IQ in the third quarter.~~material cost reductions. On an aggregate basis, ~~other~~ non-manufacturing costs, which primarily consist of warranty, royalty, freight, training and digital health product support costs, also reflected improvement on a per unit basis. ~~Gross margin was also pressured to~~To a lesser extent, ~~by other factors that are more temporary~~overall average selling prices slightly pressured gross margin as international pump sales comprised a greater portion of total pump sales compared to the prior year, while supply average selling prices reflected modest benefit from the growth of our international installed base. Royalty expense was $3.5 million for the six months ended June 30, 2021, compared to $3.0 million in ~~nature or anticipated to be leveraged through growth~~the same period in future quarters, including costs associated with COVID-19 risk mitigation, managing pump production to achieve desired stocking levels, the expansion of cartridge manufacturing capacity and increased spending to support our digital health product offerings.2020. Other factors that have and may continue to impact the gross margin percentage are changes in product and geographical mix and the level of non-cash stock-based compensation allocated to cost of sales. Pump sales, which have the highest gross margin, were ~~64%~~61% of total worldwide sales in the ~~third quarter~~first six months of ~~2020 versus 67%~~2021 compared to 60% in the ~~third quarter of 2019.~~same period in 2020. Non-cash stock-based compensation expense allocated to cost of sales was ~~$2.1~~$3.1 million for the ~~three~~six months ended ~~September~~June 30, ~~2020,~~2021, compared to ~~$1.8~~$4.3 million in the same period ~~of 2019, representing 2% of sales~~ in ~~both periods.~~2020.

3437

Table of contents

Selling, General and Administrative Expenses.SG&A expenses increased ~~12%~~25% to ~~$50.2~~$125.1 million for the ~~three~~six months ended ~~September~~June 30, ~~2020~~2021 from ~~$44.6~~$100.2 million for the same period in ~~2019.~~2020. Employee-related expenses for ourSG&Afunctions comprise the majority of SG&A expenses.The increase compared to ~~2019~~2020 was primarily the result of ~~an $8.5~~a $19.7 million increase in salaries, incentive compensation and other employee benefits due to an increase in personnel to support additional sales territories, higher sales and other services in support of our growing installed customer base, offset by a $2.9 million decrease ~~of $4.2 million~~ in non-cash stock-based ~~compensation.~~compensation expense. Non-cash stock-based compensation expense allocated to SG&A was ~~$8.9~~$20.3 million for the ~~three~~six months ended ~~September~~June 30, ~~2020,~~2021, compared to ~~$13.1~~$23.2 million in the same period in ~~2019.~~2020. The ~~higher~~increase in non-cash stock-based compensation expense associated with increased headcount in ~~the prior year~~2020 and 2021 was ~~primarily due to~~more than offset by a decrease in non-cash stock-based compensation expense from the valuation of certain 2018 employee stock option grants which are now fully ~~amortized, partially offset by non-cash stock-based compensation expense associated with increased headcount in 2020.~~amortized. We also experienced ~~increased costs for~~an $8.2 million increase in other non-employee discretionary spending, including outside consulting, software ~~maintenance, facilities~~ maintenance and outside ~~consulting of $3.1 million, offset by a $1.2 million decrease in travel and entertainment, and outside services expenses.~~services.

Research and Development Expenses. R&D expenses increased ~~34%~~28% to ~~$16.1~~$38.5 million for the ~~three~~six months ended ~~September~~June 30, ~~2020~~2021 from ~~$12.0~~$30.1 million for the same period in ~~2019.~~2020. The increase in R&D expenses was primarily the result of an increase of ~~$2.2~~$8.0 million in salaries, incentive compensation and other employee benefits due to an increase in personnel to support our product development ~~efforts, offset by a decrease of $0.6 million in non-cash stock-based compensation.~~efforts. Non-cash stock-based compensation expense allocated to R&D was ~~$1.8~~$4.6 million for the ~~three~~six months ended~~September~~ June 30, ~~2020~~, 2021, compared to ~~$2.4~~$4.8 million in the same period in ~~2019. We also experienced increased costs for consulting services and equipment and maintenance attributable to R&D of $2.3 million.~~2020.

Other Income (Expense), Net. Total other expense, net for the ~~three~~six months ended ~~September~~June 30, 2021 and 2020 was ~~$8.4~~$3.3 million ~~compared to total other income, net of $3.2~~and $18.3 million, ~~in the same period in 2019. Total other~~respectively. Other expense ~~net~~ for the ~~three~~six months ended ~~September~~June 30, ~~2020~~2021 primarily consisted of $3.0 million of interest expense which includes the amortization of debt issuance costs related to our Notes issued in the second quarter of 2020, and a ~~$3.6~~$1.0 million revaluation loss from the change in the fair value of certain warrants. Other expense for the six months ended June 30, 2020 primarilyconsisted of a $16.3 million revaluation loss from the change in the fair value of certain warrants ~~due to the appreciation of our stock price,~~ and ~~$4.9~~$3.2 million of interest expense which ~~includes~~included the amortization of debt discount and debt issuance costs related to our ~~Notes issued in the second quarter of 2020. Total other income, net for the three months ended September 30, 2019 primarilyconsisted of a $2.3 million gain on revaluation from the change in the fair value of certain warrants, and interest earned on our cash equivalents and short-term investments.~~

~~Comparison of the Nine Months Ended September 30, 2020 and 2019~~

~~Sales~~.~~For the nine monthsended September 30, 2020,~~sales were $330.8 million, which included $54.4 million of international sales. For the nine months ended September 30, 2019, sales were $253.9 million, which included $50.0 million of international sales.

The increase in worldwide sales of $76.9 million in the first nine months of 2020 compared to the first nine months of 2019 was primarily driven by $127.2 million in pump-related supplies sales from a 46% growth in the worldwide installed base and an increase in domestic pump sales of $36.9 million, offset by the effect of international product mix and non-recurring market dynamics in the prior year.

~~Domestic sales by product were as follows (in thousands):~~

Nine Months Ended
September 30,
2020 2019
Pump $ 175,550 $ 138,624
Infusion sets 68,883 44,335
Cartridges 31,418 20,530
Other 489 378
Total Domestic Sales $ 276,340 $ 203,867

~~Table of contents~~

Domestic pump sales were $175.6 million for the first nine months of 2020, compared to $138.6 million in the first nine months of 2019, as pump shipments increased 28% compared to the same period in the prior year due to continued strong demand for our products following the January 2020 domestic launch of our t:slim X2 insulin pump with Control-IQ technology. Domestic pump shipments were 46,273 in the first nine months of 2020 compared to 36,282 in the first nine months of 2019. Sales of pump-related supplies increased primarily due to a 42% increase in our estimated domestic installed base of customers. Sales to distributors accounted for 72% and 73% of our total domestic sales for the nine months ended September 30, 2020 and 2019, respectively. Our percentage of sales to distributors versus individual customers is principally determined by the mix of customers ordering our products within the period and whether or not we have a contractual arrangement with their underlying third-party insurance payor.

~~International sales by product were as follows (in thousands):~~

Nine Months Ended
September 30,
2020 2019
Pump $ 27,985 $ 36,472
Infusion sets 18,794 8,225
Cartridges 7,315 5,130
Other 331 213
Total International Sales $ 54,425 $ 50,040

International pump sales were $28.0 million for the first nine months of 2020, compared to $36.5 million in the first nine months of 2019. The first half of 2019 was positively impacted by the transition of former Animas customers to our products and the fulfillment of certain international pump demand from backlog that existed at the end of 2018 due to supply constraints in prior periods. Sales of pump-related supplies increased primarily due to an 64% increase in our estimated international installed base of customers. The ordering patterns of our international distributors for pumps and supplies is highly variable from period to period, particularly during the typical third quarter European holiday season. This variability was compounded by the varying levels of impact of the global pandemic across the international markets in which we operate. Sales to distributors accounted for 93% and 93% of our total international sales for the nine months ended September 30, 2020 and 2019, respectively.

~~Cost of Sales and Gross Profit~~.~~Our cost of sales for the nine monthsended September 30, 2020was $160.8 million~~resulting in gross profit of $170.0 million, compared to $120.0 million of cost of sales for the same period in 2019 resulting in gross profit of $133.9 million. The gross margin percentage for the nine months~~ended September 30, 2020 was 51% compared to 53% in the same period in 2019.~~

The increase in our gross profit for the nine months ended September 30, 2020 was primarily the result of the $76.9 million increase in total sales, including higher volumes shipped and improvement in pump average selling prices. Gross profit and gross margin were negatively impacted by royalty costs, for which there was no comparable expense in the prior year. We recognized $4.7 million of product royalty costs in the first nine months of 2020 associated with the first quarter launch of Control-IQ technology in the United States and a staged introduction in international markets beginning in the third quarter. On an aggregate basis, other non-manufacturing costs, which primarily consist of warranty, freight, training and digital health product support costs, reflected improvement on a per unit basis, as well as per unit manufacturing costs for pumps. Other factors that have and may continue to impact the gross margin percentage are changes in product and geographical mix and the level of non-cash stock-based compensation allocated to cost of sales. Pump sales, which have the highest gross margin, were 62% of total worldwide sales in the first nine months of 2020 compared to 69% in the same period in 2019. Non-cash stock-based compensation expense allocated to cost of sales was $6.5 million for the nine months ended September 30, 2020, compared to $4.2 million in the same period in 2019.

~~Table of contents~~

~~Selling, General and Administrative Expenses.~~ SG&A expenses increased 25% to $150.4 million for the nine months ended September 30, 2020 from $120.2 million for the same period in 2019. Employee-related expenses for our SG&A functions comprise the majority of SG&A expenses. The increase compared to 2019 was primarily the result of a $25.4 million increase in salaries, incentive compensation and other employee benefits due to an increase in personnel to support additional sales territories, higher sales and our growing installed customer base, which included an increase of $3.0 million in non-cash stock-based compensation. Non-cash stock-based compensation expense allocated to SG&A was $32.1 million for the nine months ended September 30, 2020, compared to $29.1 million in the same period in 2019. The increase in non-cash stock-based compensation expense was primarily due to increased headcount, as well as the valuation of certain 2019 employee stock option grants and the impact on the valuation of the significant increase in our stock price over the previous year. We also experienced increased costs for software maintenance, supplies, and outside consulting of $7.6 million, offset by decreased costs for travel and outside services of $2.3 million.

~~Research and Development Expenses~~. R&D expenses increased 42% to $46.2 million for the nine months ended September 30, 2020 from $32.6 million for the same period in 2019. The increase in R&D expenses was primarily the result of an increase of $6.1 million in salaries, incentive compensation and other employee benefits due to an increase in personnel to support our product development efforts, as well as an increase of $7.5 million in consulting services, supplies, and equipment and maintenance costs attributable to R&D. Non-cash stock-based compensation expense allocated to R&D was $6.6 million for the nine months ended September 30, 2020, compared to $6.1 million in the same period in 2019.

~~Other Income (Expense), Net~~. Total other expense, net for the nine months ended September 30, 2020 and 2019 was $26.7 million and $8.5 million, respectively. Other expense for the nine months ended September 30, 2020 primarily consisted of a $19.9 million revaluation loss from the change in the fair value of certain warrants due to the significant appreciation of our stock price during the first nine months of 2020, and $8.0 million of interest expense which includes the amortization of debt discount and debt issuance costs related to our Notes issued in the second quarter of 2020. Other expense for the nine months ended September 30, 2019 primarily~~consisted of a $10.8 million revaluation loss from the change in the fair value of certain warrants.~~Notes. Interest income and other, net for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019~~2020 primarily consisted of interest earned on our cash equivalents and short-term investments.

Income Tax Expense (Benefit). We recognized an income tax benefit of ~~$1.9~~$0.1 million on pre-tax loss of ~~$53.3~~$1.1 million for the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, compared to an income tax ~~expense~~benefit of ~~$0.1~~$2.0 million on a pre-tax loss of ~~$27.3~~$44.0 million for the ~~nine~~six months ended ~~September~~June 30, ~~2019.~~2020. The income tax benefit for the ~~nine~~six months ended ~~September~~June 30, 2021 was primarily attributable to the pre-tax loss position and excess tax benefits from stock compensation recorded discretely during the period. The income tax benefit for the six months ended June 30, 2020 was primarily due to benefit associated with the release of valuation allowance related to the acquisition of ~~certain intangible assets,~~Sugarmate, partially offset by ~~state and foreign income tax expense as a result of current taxable income in those jurisdictions. Income tax expense for the nine months ended September 30, 2019 was primarily attributable to~~ state and foreign income tax expense as a result of current taxable income in those jurisdictions.

Liquidity and Capital Resources

As of ~~September~~June 30, ~~2020,~~2021, we had ~~$464.5~~$545.3 million in cash and cash equivalents and short-term investments. We believe that our cash and cash equivalents and short-term investments balance is sufficient to satisfy our liquidity requirements for at least the next 12 months from the date of this filing.

Historically, our principal sources of cash have included cash collected from product sales, private and public offerings of equity securities, exercises of employee stock awards, and debt financing. Since the beginning of ~~2019,~~2020, we completed the following financing activities:

•In May 2020, we raised $278.7 million in net proceeds from the issuance of the Notes, and used $34.1 ~~$34.1~~ million of the net proceeds to ~~purchase capped call options in connection with~~pay the ~~transaction~~cost of the Capped Call Transactions related to the Notes (see Note 7, “Convertible Senior Notes”).

•From January ~~2019~~2020 through ~~September 2020,~~June 2021, we issued ~~3,617,939~~2,702,444 shares of common stock upon the exercise of stock options, and ~~558,392~~402,312 shares of common stock were purchased under our 2013 Employee Stock Purchase Plan, which generated aggregate proceeds of ~~$81.6~~$83.6 million.

•From January ~~2019~~2020 through ~~September 2020,~~June 2021, we received proceeds of ~~$1.2~~$1.4 million from the exercise of ~~352,585~~387,615 outstanding warrants which were originally issued in connection with our registered public offering of common stock in October 2017. As of ~~September~~June 30, ~~2020,~~2021, there were warrants to purchase ~~158,200~~29,700 shares outstanding relating to the October 2017 offering.

3738

Table of contents

•From January 2020 through ~~September 2020,~~June 2021, we received proceeds of $2.0 million from the exercise of ~~67,799~~71,261 outstanding warrants which were originally issued between August 2011 and August 2012. As of ~~September~~June 30, ~~2020,~~2021, there were warrants to purchase ~~31,166~~27,704 shares outstanding relating to these issuances.

Our historical cash outflows have primarily been associated with cash used for operating activities such as the development and commercialization of our products, the expansion and support of our sales, marketing, clinical and customer support organizations, the expansion of our R&D activities, the expansion of our commercial activities to select international geographies, the acquisition of intellectual property, expenditures related to increases in our manufacturing capacity and improvements to our manufacturing efficiency, overall expansion of our facilities and operations, and other working capital needs.

We expect our sales performance and the resulting operating income or loss, as well as the status of each of our new product development programs, will significantly impact our cash flow from operations, liquidity position and cash management decisions. In light of the COVID-19 global pandemic, we are prudently managing our use of cash. We will continue to evaluate new information as it becomes available and make changes as are considered necessary.

The following table shows a summary of our cash flows for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019:~~2020:


		Nine Months Ended September 30,					Six Months Ended June 30,
(in thousands)	(in thousands)	2020		2019		(in thousands)	2021		2020
Net cash provided by (used in):	Net cash provided by (used in):					Net cash provided by (used in):
Operating activities	Operating activities	$	9,432	$	22,463	Operating activities	$	57,580	$	(5,132)
Investing activities	Investing activities	(236,430)		(36,054)		Investing activities	(70,855)		(98,605)
Financing activities	Financing activities	305,234		17,789		Financing activities	17,196		275,303
Effect of foreign exchange rate changes on cash	Effect of foreign exchange rate changes on cash	70		36		Effect of foreign exchange rate changes on cash	44		(262)
Net increase in cash and cash equivalents	Net increase in cash and cash equivalents	$	78,306	$	4,234	Net increase in cash and cash equivalents	$	3,965	$	171,304

Operating Activities. Net cash provided by operating activities was ~~$9.4~~$57.6 million for the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, compared to ~~$22.5~~$5.1 million net cash used by operating activities in the same period in ~~2019.~~2020. The ~~decrease in~~improvement to net cash provided by operating activities for 2021 compared to 2020 was ~~due to an increase~~driven by higher sales and gross profit in ~~our operating~~2021, which resulted in a reduction in net loss ~~on higher operating~~when adjusted for non-cash expenses, particularly stock-based compensation expense, as well as working capital ~~changes primarily related to accounts payable and accrued expenses.~~changes. Working capital changes during the first ~~nine~~six months of ~~2020~~2021 primarily consisted of increases in ~~accounts receivable,~~ inventories, accounts payable and accrued expenses, deferred revenue and ~~other current~~employee related liabilities ~~all of which are~~ related to the growth in our ~~business.~~business, and a decrease in accounts receivable related to the timing of sales and cash collections. Accounts receivable ~~increased~~decreased to ~~$52.1~~$80.2 million at ~~September~~June 30, ~~2020~~2021 from ~~$46.6~~$82.2 million at December 31, ~~2019, as a result of higher sales in the third quarter of 2020 as compared to the fourth quarter of 2019.~~2020. Inventories increased to ~~$70.6~~$66.7 million at ~~September~~June 30, ~~2020~~2021 from ~~$49.1~~$63.7 million at December 31, ~~2019, primarily to support the growth in our business.~~2020.

Investing Activities. Net cash used in investing activities was ~~$236.4~~$70.9 million for the ~~nine~~six months ended ~~September~~June 30, 2021, which was primarily related to $385.6 million of purchases of short-term investments, $9.3 million cash paid for the acquisition of intangible assets and equity investments, and $5.3 million in purchases of property and equipment, offset by $329.4 million in proceeds from maturities and sales of short-term investments. Net cash used in investing activities was $98.6 million for the six months ended June 30, 2020, which was primarily related to ~~$332.0~~$167.0 million of purchases of short-term investments, ~~$23.3~~$16.6 million in purchases of property and equipment, and ~~$4.9~~$4.8 million cash paid for the acquisition of intangible assets, offset by ~~$123.7 million in proceeds from maturities and sales of short-term investments.~~Net cash used in investing activities was $36.1 million for the nine months ended September 30, 2019, which was primarily related to $126.3 million of purchases of short-term investments and $12.8 million in purchases of property and equipment, offset by $103.0$89.7 million in proceeds from maturities and sales of short-term investments.

Financing Activities. Net cash provided by financing activities was ~~$305.2~~$17.2 million for the ~~nine~~six months ended ~~September~~June 30, 2021, which primarily consisted of proceeds from the issuance of common stock under our stock plans. Net cash provided by financing activities was $275.3 million for the six months ended June 30, 2020, which primarily consisted of $278.7 million in proceeds from the issuance of the Convertible Senior Notes which was partially offset by $34.1 million in payments ~~for~~related to the ~~purchase of the related~~ Capped Call ~~Options,~~Transactions, and ~~$57.7~~$28.6 million in proceeds from the issuance of common stock under our stock plans. Net cash provided by financing activities was $17.8 million for the nine months ended September 30, 2019, which primarily consisted of proceeds from the issuance of common stock under our stock plans.

3839

Table of contents

Our liquidity position and capital requirements are subject to fluctuation based on a number of factors, including the following:

•our ability to generate sales, the timing of those sales, the mix of products sold and the collection of receivables from period to period;

•the relative mix of sales between domestic and international markets;

•the timing of any additional financings, and the net proceeds raised from such financings;

•the timing and amount of the exercise of outstanding warrants, and proceeds from the issuance of equity awards pursuant to employee stock plans;

•fluctuations in gross margins and operating margins;

•fluctuations in working capital, including changes in accounts receivable, inventories, accounts payable, employee-related liabilities, and operating lease liabilities; and

•the impacts and disruptions caused by the COVID-19 global pandemic.

Our primary short-term capital needs are expected to include expenditures related to:

•support of our commercialization efforts related to our current and future products;

•expansion of our customer support resources for our growing installed customer base;

•research and product development efforts, including clinical trial costs;

•acquisitions, leasing or licensing of equipment, technology, intellectual property and other assets;

•additional facilities leases and related tenant improvements, and manufacturing equipment to support business growth and increase manufacturing capacity; and

•payments under licensing, development and commercialization agreements.

Although we believe the foregoing items reflect our most likely uses of cash in the short-term, we cannot predict with certainty all of our particular cash uses or the timing or amount of cash used. In addition, from time to time we may consider opportunities to acquire or license other products or technologies that may enhance our product platform or technology, expand the breadth of our markets or customer base, or advance our business strategies. Any such transaction may require short-term expenditures that may impact our capital needs. If for any reason our cash and cash equivalents balances, or cash generated from operations is insufficient to satisfy our working capital requirements, we may in the future be required to seek additional capital from public or private offerings of our equity or debt securities, or we may elect to borrow capital under new credit arrangements or from other sources. We may also seek to raise additional capital from such offerings or borrowings on an opportunistic basis when we believe there are suitable opportunities for doing so. If we issue equity or debt securities to raise additional funds, our existing stockholders may experience dilution, we may incur significant financing or debt service costs, and the new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders. There can be no assurance that financing will be available on acceptable terms, or at all. Our ability to raise additional financing may be negatively impacted by a number of factors, including our recent and projected financial results, recent changes in and volatility of our stock price, perceptions about the dilutive impact of financing transactions, the competitive environment in our industry, uncertainties regarding the regulatory environment in which we operate and conditions impacting the capital markets more generally, including economic weakness, inflation, political instability, war and terrorism, natural disasters, incidence of illness or disease, or other events beyond our control.

3940

Table of contents

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The preparation of these consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes as of the date of the consolidated financial statements. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about our financial condition and results of operations that are not readily apparent from other sources. Actual results may differ from these estimates.

There have been no material changes to our critical accounting policies and estimates from the information provided in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies Involving Management Estimates and Assumptions,” included in our Annual Report on Form 10-K for the year ended December 31, ~~2019, with~~2020, other than the ~~exception~~adoption of ~~policies put~~ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in ~~place with regards to the Convertible~~an Entity’s Own Equity effective January 1, 2021(see Note 7, “Convertible Senior ~~Notes.~~

Notes”).

~~Table of contents~~

Off-Balance Sheet Arrangements

As of ~~September~~June 30, ~~2020,~~2021, we did not have any off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk

We invest our excess cash primarily in commercial paper, corporate debt securities, U.S. ~~Government-sponsored enterprise~~Treasury securities and U.S. ~~Treasury~~Government-sponsored enterprise securities. The primary objectives of our investment activities are to maintain liquidity and preserve principal while maximizing the income we receive from our financial instruments without significantly increasing risk. We have established guidelines regarding approved investments and maturities of investments, which are primarily designed to maintain liquidity and preserve principal.

Some of the financial instruments in which we invest subject us to market risk, in that a change in prevailing interest rates may cause the principal amount of the instrument to fluctuate. Other financial instruments in which we invest subject us to credit risk, in that the value of the instrument may fluctuate based on the issuer’s ability to pay. As a result of the COVID-19 global pandemic and the perceived increased credit risks associated with certain securities, credit rating agencies have issued downgrades ~~and~~or revised outlooks to negative for ~~a number of~~certain issuers of the debt securities held in our short-term investments portfolio. Unrealized losses on available-for-sale debt securities at ~~September~~June 30, ~~2020~~2021 were not significant. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and our current estimates of future cash flows to be collected from those securities, we believe the unrealized losses are not credit losses (see Note 3, “Short-Term Investments”).

Because of the short-term maturities of our financial instruments, we do not believe that an increase or decrease in market interest rates would have ~~any~~a significant impact on the realized value of our investment portfolio. If a 10% change in interest rates were to have occurred on ~~September~~June 30, ~~2020,~~2021, this change would not have had a material effect on the fair value of our investment portfolio as of that date.

In May 2020, ~~the~~ we issued $287.5 million principal amount of Convertible Senior Notes, which bear interest at a fixed rate of 1.50% per year. Accordingly, we are not subject to interest rate risk as a result of the Convertible Senior Notes (see Note 7, “Convertible Senior Notes”).

Table of contents

Foreign Currency Exchange Rate Risk

Our operations are primarily located in the United States, and nearly all of our sales since inception have been made in U.S. dollars. With the exception of a portion of our sales in Canada, our sales outside of the United States are currently made to independent distributors under agreements denominated in U.S. dollars. Accordingly, we believe ~~we do not currently have any material~~our exposure to foreign currency rate ~~fluctuations. As our business in markets outside of the United States increases, we may be exposed to foreign currency exchange risk. We believe this~~fluctuations is currently limited to our operations in Canada, where fluctuations in the rate of exchange between the U.S. dollar and the Canadian dollar could adversely affect our financial results. ~~In addition, from time~~We may be exposed to ~~time, we may have~~further foreign currency exchange risk ~~related to existing assets and liabilities, committed transactions and forecasted future cash flows.~~as we expand our operations in markets outside the United States. In certain circumstances, we may seek to manage such foreign currency exchange risk by using derivative instruments such as foreign currency exchange forward contracts to hedge our risk. In general, we may hedge material foreign currency exchange exposures up to 12 months in advance. However, we may choose not to hedge some exposures for a variety of reasons, including prohibitive economic costs.

4142

Table of contents

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act) that are designed to ensure that information required to be disclosed in the periodic and current reports we file with the Securities and Exchange Commission (SEC) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management ~~necessarily~~ is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Control systems can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As of ~~September~~June 30, ~~2020,~~2021, we carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of ~~September~~June 30, ~~2020.~~2021.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the quarter ended ~~September~~June 30, ~~2020~~2021 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

4243

Table of contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

In April 2020, we were named as a defendant in four federal class action lawsuits relating to a data breach we experienced in January 2020, each of which was subsequently dismissed.

In addition, in May 2020 we were named as a defendant in three California state court class action lawsuits arising from the same data breach. Collectively, these lawsuits seek statutory, compensatory, actual, and punitive damages; equitable relief, including restitution; pre- and post-judgment interest; injunctive relief; and attorney fees, costs, and expenses from us. On July 24, 2020, these three pending lawsuits were consolidated into a single case in the Superior Court of the State of California in the County of San Bernardino entitled Joseph Deluna et al v. Tandem Diabetes Care, Inc. The consolidated case alleges violations of the Confidentiality of Medical Information Act (CMIA), California Consumer Privacy Act (CCPA), California’s Unfair Competition Law (UCL), and breach of contract. We filed a demurrer seeking dismissal of all claims, which was heard by the Court on October 27, 2020, and which resulted in the following outcome: (i) the demurrer of the CMIA claim was denied; ~~and~~ (ii) the demurrer of the CCPA claim was sustained; and (iii) the demurrer of the UCL and contract claims were sustained with leave to amend the pending complaint. A second demurrer was heard by the Court on March 29, 2021 with the following outcome: (i) the demurrer of the CMIA claim was denied; and (ii) the demurrer of the UCL and contract claims were narrowed in scope to dismiss three plaintiffs for failing to allege cognizable damages or injuries-in-fact, resulting in two remaining plaintiffs. Although we intend to vigorously defend against these claims, there is no guarantee that we will prevail. We are presently unable to determine the ultimate outcome of these lawsuits or determine the amount (or range) of possible losses associated with the lawsuits.

In September 2020, we were named as a defendant in a lawsuit entitled Buck Walsh, individually and on behalf of others similarly situated v. Tandem Diabetes Care, Inc., which was filed in the Superior Court of the State of California in the County of San ~~Diego County.~~Diego. The alleged violations include business and professions code and labor code violations for failure to compensate wages, unpaid meal and rest periods, and failure to reimburse for necessary business-related expenses. The ~~proposed~~ class of plaintiffs includes hourly paid or non-exempt employees of the Company who were employed from April 6, 2016 through the date of adjudication.

~~Although we intend~~ The parties recently agreed to resolve the matter on a class-wide basis. The settlement is intended to resolve the claims of the individual plaintiff, as well as the remaining members of the class, unless an individual class member submits a timely request for exclusion. The material terms of the settlement are set forth in a binding Memorandum of Agreement dated as of July 1, 2021, which is subject to the completion of a number of conditions, as well as final approval by the court. There is no guarantee that the conditions will be met or that court approval will be obtained. If the court does not approve the settlement, or if other conditions to approval of the settlement are not met, the case will continue and the Company will continue to vigorously defend against ~~these claims, there is no guarantee that we will prevail. Accordingly, we are unable to determine~~ the ~~ultimate outcome of these lawsuits or determine the amount and range of potential losses associated with the lawsuits.~~claims.

From time to time, we are involved in various other legal proceedings, ~~disputes~~regulatory matters, and other disputes or claims arising infrom or related to the ~~ordinary~~normal course of our business activities, including actions with respect to intellectual property, data privacy, employment, regulatory, product liability and contractual matters. Although the results of legal proceedings, disputes and other claims cannot be predicted with certainty, we believe we are not currently ~~believe that the final outcome of these ordinary course matters will not,~~a party to any legal proceeding(s) which, if determined adversely to us, would, individually or ~~in the aggregate,~~taken together, have a material adverse effect on our business, operating results, financial ~~position, results of operations,~~condition or cash ~~flows or future prospects.~~flows. However, regardless of the merit of the claims raised or the outcome, legal proceedings ~~disputes and other claims can~~may have an adverse impact on us ~~because~~as a result of ~~legal~~defense and settlement costs, diversion of management time and resources, and other factors.

4344

Table of contents

Item 1A. Risk Factors

An investment in our common stock, or in ~~other~~securities convertible ~~securities~~into or exchangeable for our common stock, involves ~~risks.~~a high degree of risk. You should carefully consider the risks described below, together with all of the other information included in this Quarterly Report, as well as in our other filings with the SEC, in evaluating our business. If any of the following risks actually occur, our business, financial condition, operating results and future prospects could be materially and adversely affected. In that case, the trading price of our common stock may decline and you might lose all or part of your investment. The risks described below are not the only ones we face. Additional risks that we currently do not know about or that we currently believe to be immaterial may also impair our business, financial condition, operating results, liquidity, and future prospects. Certain statements below are forward-looking statements. For additional information, see Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations of this Quarterly Report.

The risk factors set forth below marked with an asterisk (*) next to the title contain changes to the description of the risk factors previously disclosed in Part I, Item IA1A of our Annual Report.

Summary of Risk Factors

An investment in our common stock, or in securities convertible into or exchangeable for our common stock, involves a high degree of risk. Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, as well as other risks that we face, can be found below, after this summary.

Risks Related to Our Business and Our Industry

•We have incurred significant operating losses since inception and may not achieve sustained profitability.

•We currently rely on sales of insulin pump products to generate a significant portion of our revenue, and any factors that negatively impact sales of these products may adversely affect us.

•Public health threats, such as the COVID-19 global pandemic, have had a material adverse effect on our business.

•Our ability to maintain and grow our revenue depends on retaining a high percentage of our customer base.

•We operate in a very competitive industry.

•Competitive products or other technological developments may render our products obsolete or less desirable.

•The failure of our insulin pump and related products to achieve and maintain market acceptance could result in us achieving sales below our expectations.

•Failure to secure or retain adequate coverage or reimbursement for our products by third-party payors could adversely affect our business.

•We may face unexpected challenges in marketing and selling our products, and training new customers on the use of our products.

•We may fail to meet our sales forecasts if we are unable to maintain our existing sales, marketing, clinical and customer service infrastructure.

•If we are unable to maintain or expand our network of independent distributors, our sales may be negatively affected.

•The third parties on which we rely to assist us with our pre-clinical development or clinical trials may not perform as expected.

•Our failure to successfully complete clinical trials and development-stage testing could prevent us from obtaining regulatory approvals for or commercializing our products.

•If assumptions about the potential market for our products are inaccurate our business may be adversely affected.

•Our ability to achieve profitability has dependencies on our ability to reduce the per-unit cost of our products.

•Manufacturing risks may adversely affect our ability to manufacture products.

•We depend on a limited number of third-party suppliers for certain components and products.

•Any disruption at one of our facilities could adversely affect our business and operating results.

•We may not experience the anticipated operating efficiencies from the transition of our manufacturing and warehousing operations.

•If we do not enhance our product portfolio to meet the demands of our market, we may fail to effectively compete.

•Concerns regarding the safety and efficacy of our products could limit sales and cause negative effects to our business.

•We may enter into collaborations or partnerships with third parties that may not result in commercially viable products or the generation of significant revenues.

Table of contents

•We operate our business in regions subject to natural disasters and other catastrophic events.

•A security breach or other significant disruption to our information technology systems could materially disrupt our operations or result in the unauthorized disclosure of sensitive information.”

•If we are found to have violated laws concerning the privacy and security of patient health information or other personal information, civil or criminal penalties could increase our liabilities and harm our business.

•We may be unable to retain and motivate our senior management or recruit additional qualified personnel.

•We may experience a variety of risks associated with international operations.

•Our failure to successfully manage the integration of acquisitions could have an adverse effect on our business.

Risks Related to Our Future Financings and Financial Results

•We may need to raise additional funds in the future and funds may not be available on commercially reasonable terms.

•Our operating results may fluctuate significantly from quarter to quarter.

Risks Related to Our Intellectual Property and Potential Litigation

•Our ability to comprehensively protect our intellectual property and proprietary technology is uncertain.

•Patent litigation is not uncommon in the medical device industry, and we may be subject to such litigation.

•We may be subject to damages resulting from claims that we have wrongfully used or disclosed patient health information or trade secrets, or are in breach of non-competition or non-solicitation agreements.

•We may incur product liability losses, and insurance coverage may be inadequate or unavailable to cover these losses.

Risks Related to Our Legal and Regulatory Environment

•Our products and operations are subject to extensive governmental regulation, and regulatory approvals could be denied or delayed.

•New products or modifications to our existing products may require new regulatory approvals, or require us to cease marketing or recall modified products.

•If we or our third-party suppliers, contract manufacturers or service providers fail to comply with manufacturing regulations, it could impair our ability to market our products.

•A recall of our products, or the discovery of safety issues with our products, could have a negative impact on us.

•Our failure to comply with foreign, U.S. federal and state fraud and abuse laws could have an adverse impact on us.

•We may be liable if we engage in the promotion of the off-label use of our products.

•Legislative or regulatory healthcare reforms may result in downward pressure on the price of and decrease reimbursement for our products.

Risks Related to Our Common Stock

•The price of our common stock may continue to fluctuate significantly.

•Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

•We may fail to maintain an effective system of internal control over financial reporting.

•We may be at increased risk of securities class action litigation.

Risks Related to Our Convertible Senior Notes

•The Notes could adversely affect our financial condition.

•We may not have sufficient cash flow from our business to service the Notes.

•We may take actions which could limit our ability to make payments on the Notes.

•We may not be able to raise the funds necessary to repurchase or settle conversions of the Notes.

•Conversion of the Notes may dilute the ownership interest of existing stockholders.

•The Capped Call Transactions may affect the value of the Notes and our common stock.

•We are subject to counterparty risk with respect to the Capped Call Transactions.

Table of contents

Risks Related to Our Business and Our Industry

We have incurred significant operating losses since inception and cannot assure you that we will achieve sustained profitability.*

Since our inception in January 2006, we have incurred a significant net loss. As of ~~September~~June 30, ~~2020,~~2021, we had an accumulated deficit of ~~$676.2~~$651.2 million. To date, we have funded our operations primarily through cash collected from product sales, private and public offerings of our equity securities, and debt financing. We have devoted substantially all of our resources to the design, development and commercialization of our products, the scaling of our manufacturing and business operations, and ~~commercial organization,~~ the research and development of our current products and products under ~~development, and the assembly of a management team to manage our business.~~development.

We began commercial sales of our first product, t:slim, in August 2012 and our current flagship pump platform, t:slim X2, in October 2016. The t:slim X2 insulin pump now represents 100% of new pump shipments. Until the third quarter of 2018 we were selling our products only in the United States and have since launched our products in select international geographies.

Since the first quarter of 2013, we have been able to manufacture and sell our insulin pump products at a cost and in volumes sufficient to allow us to achieve a positive overall gross margin. For the years ended December 31, ~~2019~~2020 and ~~2018,~~2019, our gross profit was $194.2 million and $89.8 million, respectively. Although we have achieved a positive overall gross margin and have substantially reduced our operating loss, we still operate at a net loss on an annual basis and expect that we may continue to do so for the foreseeable future.

To implement our business strategy and achieve consistent profitability, we need to, among other things, increase sales of our products and the gross profit associated with those sales, maintain an appropriate customer service, training and support infrastructure, fund ongoing R&D activities, create additional efficiencies in our manufacturing processes while adding to our capacity, and obtain regulatory clearance or approval to commercialize our products currently under development both domestically and internationally. We expect our expenses will continue to increase as we pursue these objectives and make investments in our business. Additional increases in our expenses without commensurate increases in sales could significantly increase our operating losses.

The extent of our future operating losses and the timing of our profitability are highly uncertain in light of a number of factors, including the timing of the launch of new products and product features by us and our competitors, market acceptance of our products and competitive products by people with insulin-dependent diabetes, their caregivers and healthcare providers, the timing of regulatory approval of our products and the products of our competitors, the actual efficiencies gained in our manufacturing processes, and the scope and duration of the impacts caused by the COVID-19 global pandemic. Any additional operating losses will have an adverse effect on our stockholders’ equity, and we cannot assure you that we will be able to sustain profitability.

~~Table of contents~~

We currently rely on sales of insulin pump products to generate a significant portion of our revenue, and any factors that negatively impact sales of these products may adversely affect our business, financial condition and operating results.*

We generate nearly all of our revenue from the sale of t:slim X2 insulin pumps and the related insulin cartridges and infusion sets. Sales of these products may be negatively impacted by many factors, including:

•market acceptance of the insulin pumps and related products manufactured and sold by our key competitors, including ~~Medtronic MiniMed, a division of Medtronic plc;~~Medtronic;

•the potential that breakthroughs for the monitoring, treatment or prevention of diabetes may render our insulin pumps obsolete or less desirable;

•adverse regulatory or legal actions relating to our products, or similar products or technologies of our competitors;

•failure of our Tandem Device Updater to accurately and timely provide customers with remote access to new product features and functionality as anticipated, or our failure to obtain regulatory approval for any such updates;

•changes in reimbursement rates or policies relating to insulin pumps or similar products or technologies by third-party payors;

Table of contents

•our inability to enter into contracts with third-party payors on a timely basis and on acceptable terms;

•problems arising from the expansion of our manufacturing capabilities and commercial operations, or destruction, loss, or temporary shutdown of our manufacturing facilities;

•concerns regarding the perceived safety or reliability of any of our products, or any component thereof; and

•claims that any of our products, or any component thereof, infringes on patent rights or other intellectual property rights of third parties.

In addition, sales of any of our current or future insulin pump products with CGM integration are subject to the continuation of our applicable agreements with Dexcom, Abbott, or other third parties which, under some circumstances, may be subject to termination, with or without cause, on relatively short notice. Sales of our current or future products may also be negatively impacted in the event of any regulatory or legal actions relating to CGM products that are compatible with our pumps, or in the event of any disruption to the availability of the applicable CGM-related supplies, such as sensors or transmitters, in a given market in which our products are sold. Sales of our products may also be adversely impacted if the CGM products that are compatible with our pumps are not viewed as superior to competing CGM products in markets where our products are sold, or if the price of these products is not competitive with similar products available in the market.

Because we currently rely on sales of our t:slim X2 insulin pump and related products to generate a significant majority of our revenue, any factors that negatively impact sales of these products (or negatively impact the products or components integrated with these products), or result in sales of these products increasing at a lower rate than expected, could adversely affect our business, financial condition and operating results. We believe the COVID-19 global pandemic has had, and that it may continue to have, ~~a material~~an adverse impact on sales of our ~~products as it could result in~~products. For instance, we have seen examples of customers delaying their purchasing decisions or physicians pausing prescriptions for our products. It could also have the effect of magnifying the negative impact of any of the factors described above.

~~Table of contents~~

Public health threats, such as the COVID-19 global pandemic, have had and could continue to have a material adverse effect on our operations, the operations of our business partners, and the global economy as a whole.*

Public health threats and other highly communicable diseases and outbreaks could adversely impact our operations, the operations of our customers, suppliers, distributors and other business partners, as well as the healthcare system in general. For example, the COVID-19 global pandemic, which is currently affecting numerous countries throughout the world, ~~has~~ resulted in a rapid and sustained rise in unemployment rates and ~~a sudden decrease~~decreases in global economic activity. While economic activity ~~and~~in the United States began to increase during the second quarter of 2021, the overall scope of the COVID-19 global pandemic and its impacts ~~is continuing~~continue to fluctuate, and in some instances worsen, in various regions worldwide. ~~While we experienced only a modest~~The overall negative impact from the COVID-19 global pandemic ~~during the first quarter of 2020, the negative impact during the second and third quarters of 2020 was more pronounced, and~~is difficult to estimate; however, we anticipate that our sales and operating results will continue to be adversely impacted in future periods and subject to unpredictable ~~variability.~~variability even if travel and social distancing restrictions are lifted. In addition, the ~~recent~~ rise in unemployment and ~~decrease~~decreases in economic activity in various regions worldwide due to the COVID-19 global pandemic may negatively impact the affordability of our products for certain customers, which could reduce demand for our products. Further, ~~the initiation of~~ certain ~~programs~~development activities originally planned ~~for the second and third quarter,~~to occur during 2020, such as human factors studies associated with our product development efforts ~~have been~~and activities to support the manufacturing scale-up for new products, were modified or delayed due to impacts of the COVID-19 global pandemic, which has impacted our development timelines and regulatory strategies and also could have a negative impact on our product commercialization efforts and the future demand for our products.

Table of contents

The COVID-19 global pandemic, or other similar outbreaks or epidemics, may have an adverse effect on the overall productivity of our workforce, and we ~~may be required~~expect to continue to take ~~extraordinary~~appropriate measures to protect the health and safety of our employees and our business partners and reduce the risk of disruptions to our operations. For example, ~~since in March 2020,~~ we ~~have restricted non-essential~~continue to restrict employee travel ~~banned~~and limit visitors ~~from all of~~to our facilities, and ~~transitioned those~~many of our employees who are able to perform their job function outside of our facilities toremain in a remote work environment. For our field-based sales and clinical employees, we initially discontinued all in-person activities and began utilizing technology to remotely engage healthcare providers and customers. Where permitted, in-person activities for our field-based sales and clinical employees have resumed on a limited basis and are gradually increasing, though the scope and scale ~~have been limited~~vary by geography and we still rely heavily on remote engagement. For our employees in manufacturing and warehousing positions involved in production and fulfillment operations, we have implemented ~~preventative measures to comply~~health and safety protocols in compliance with ~~physical distancing requirements~~applicable government orders and ~~have taken measures to help ensure safety, including requiring temperature checks for our employees before each shift.~~expert agency guidance. We ~~have also~~temporarily increased our staffing in certain operations in order to mitigate potential risks associated with increases in unplanned employee absences or illness. Our adoption of these preventive measures has resulted in incremental costs that have negatively impacted our gross margin, and ~~the impacts~~ could ~~be greater in~~impact future periods. In addition, for the duration of the COVID-19 global pandemic, some of our employees may be required to continue to operate within a remote work environment for extended periods of time due to illness, travel restrictions, government-imposed orders, school closures or for other reasons, any of which could result in reduced productivity of our workforce. As the COVID-19 global pandemic improves, we anticipate that more of our employees will return to working in our facilities under modified conditions. We are implementing protocols and safety measures and for the time being are continuing to limit the number of employees allowed in our facilities while planning for increased occupancy at a later date.

In addition to the foregoing impacts, disruptions from the COVID-19 global pandemic, or other similar outbreaks or epidemics, could result in delays in or the suspension of our manufacturing operations, research and product development activities, regulatory work streams, clinical development programs and other important commercial functions. In particular, if we ~~were~~or our third-party manufacturers are required to delay or suspend our manufacturing operations, we may encounter severe product shortages, which would adversely affect our results of operations and harm our reputation. We are also dependent upon our third-party suppliers for many of our product components and for our manufacturing-related equipment, and the COVID-19 global pandemic could have a material adverse impact on the operations of one or more of our suppliers, which could prevent them from delivering products to us or supporting our requirements for manufacturing-related equipment on a timely basis, or at all. For example, we continue to focus on increasing our cartridge inventory to targeted levels, but there can be no assurance that we or our third-party cartridge manufacturer will be able to manufacture cartridges in the quantities we require to meet product demand. In addition, ~~in the second quarter of~~at various times since 2020 our primary infusion set manufacturer experienced certain inventory constraints. There can be no assurance our supplier will be able to provide infusion sets in the quantities we require to meet customer demand. Additionally, global shortages of semiconductors and copper could limit our insulin pump manufacturing capacity in the future. If we experience these or similar manufacturing challenges in the future, it could have a negative impact on product sales and harm our reputation.

The full extent of the impact of the COVID-19 global pandemic on our business and operations is highly uncertain and subject to change, and will continue to depend on a number of factors, including the scope and duration of the pandemic. ~~We expect any further~~Further spread or escalation of the COVID-19 global pandemic, a resurgence of the pandemic in the United States, or even the threat or perception that this could occur, or any protracted duration of decreased economic activity, could have a material adverse impact on our business, operations and financial ~~results.~~

~~Table of contents~~

results and could negatively impact or disrupt our plans to have employees return to our facilities.

Our ability to maintain and grow our revenue depends in part on retaining a high percentage of our customer base.*

A key to maintaining and growing our revenue is the retention of a high percentage of our customers due to the potentially significant revenue generated from ongoing purchases of disposable infusion sets, insulin cartridges and other supplies. In addition, our pumps are designed and tested to remain effective for at least four years and a ~~satisfied~~ customer may consider purchasing another product from us when the time comes to replace the pump. We have developed retention programs aimed at our customers, their caregivers and healthcare providers, which include training specific to our products, ongoing support by our sales and clinical employees, and technical support and customer service. Demand for our products from our existing customers could decline or could fail to increase ~~in line with our projections~~as anticipated or projected as a result of a number of factors, including the introduction of competitive products, breakthroughs for the monitoring, treatment or prevention of diabetes, changes in reimbursement rates or policies, manufacturing problems, perceived safety or reliability issues with our products or components or the products of our competitors, the failure to secure regulatory clearance or approvals for products or product features in a timely manner or at all, product development or commercialization delays, the impacts and disruptions caused by the COVID-19 global pandemic, or for other reasons.

Table of contents

Further, the COVID-19 global pandemic has resulted in substantial restrictions on our engagement efforts with customers and healthcare providers, including ~~through~~ the cancellation or postponement of company-sponsored educational events, as well as third-party conferences, trade shows and similar events. The impact continues even as some third-party conferences, trade shows and events are being held remotely from time to time, which restricts our engagement with customers and healthcare providers. These restrictions have negatively impacted, and are likely to continue negatively ~~impact~~impacting, our ability to promote our new products and features to customers and healthcare providers, which could adversely impact our product sales and customer retention rates, as well as the strength of our brand.

The failure to retain a high percentage of our customers and increase sales to these customers consistent with our forecasts would have a material adverse effect on our business, financial condition and operating results.

We operate in a very competitive industry and if we fail to compete successfully against our existing or potential competitors, ~~many of whom have greater resources than us,~~or if the competitive environment harms our ~~sales~~business partners, our financial condition and operating results may be negatively affected.*

The medical device industry is intensely competitive, subject to rapid change and highly sensitive to the introduction of new products, treatment techniques or technologies, as well as other activities of industry participants. We believe our products compete, and will continue to compete, directly with a number of traditional insulin pumps, as well as other methods for the treatment of diabetes, including multiple daily injection (MDI) therapy.

Our primary competitors are major medical device companies that are publicly traded companies or divisions or subsidiaries of publicly traded companies, including Insulet and ~~Medtronic MiniMed.~~Medtronic. In addition, Eli Lilly ~~& Co. is developing~~has announced a collaboration to commercialize an insulin ~~pump.~~pump currently under development by a third party. There are also a number of other companies developing and marketing their own insulin delivery systems and/or related software applications, including insulin pumps and Bluetooth-enabled insulin pens to support MDI therapy. While these industry changes are significant, it is difficult to know how they will impact our business or the competitive landscape in which we operate. Our key competitors, most notably Medtronic, enjoy several competitive advantages over us, including:

•greater financial and human resources for sales and marketing, product development, customer service and clinical resources;

•greater ability to respond to competitive pressures, regulatory uncertainty, or challenges within the financial markets;

•established relationships with healthcare providers, third-party payors and regulatory agencies;

•established reputation and name recognition among healthcare providers and other key opinion leaders in the medical industry generally and the diabetes industry in particular;

•~~greater market share and established base of customers;~~

•larger and more established distribution networks;

•greater ability to cross-sell products or provide incentives to healthcare providers to use their products; and

•more experience in conducting R&D, manufacturing, clinical trials, and obtaining regulatory approval or clearance.

~~Table of contents~~

In some instances, our competitors offer products that include features that we do not currently offer. For instance, Insulet offers an insulin pump with a tubeless delivery system that does not utilize an infusion set and Medtronic recently ~~announced~~completed the acquisition of a connected insulin pen delivery device. Additionally, Medtronic recently announced the launch in select European countries of an infusion set that can be worn for up to seven days.

Table of contents

In addition, the competitive environment in which we operate has resulted and may continue to result in competitive pressures on our manufacturers, suppliers, distributors, collaboration partners and other business constituents. For example, we have entered into development agreements with Dexcom, which provide us non-exclusive licenses to integrate various generations of Dexcom CGM technology with our insulin pump products. ~~Since 2017~~ Abbott ~~has launched new blood~~also offers glucose sensors which compete with Dexcom CGMs. In June 2020, we entered into an agreement with Abbott to develop and commercialize integrated diabetes ~~solutions.~~solutions using Abbott’s glucose sensor. There can be no assurance that our ~~collaboration~~collaborations with Dexcom and Abbott will be successful or that we will not experience delays, business disputes, or other unanticipated ~~challenges or delays.~~challenges. Competitive pressures within our industry, as well as the impacts and disruptions associated with the COVID-19 global pandemic, could negatively impact the financial condition of our business partners and impact their ability to fulfill contractual obligations to us, which could negatively impact our product sales, result in delays in obtaining regulatory approvals for new products, harm our reputation, and result in harm to our financial condition and operating results.

For these and other reasons, we may not be able to compete successfully against our current or potential future ~~competitors. As a result, our product sales may be negatively affected,~~competitors, which could have a material adverse impact on our financial condition and operating results.

Competitive products or other technological developments and breakthroughs for the monitoring, treatment or prevention of diabetes may render our products obsolete or less desirable.*

Our ability to grow our business and achieve our strategic objectives will depend, among other things, on our ability to develop and commercialize products for the treatment of diabetes that offer distinct features and functionality, are easy-to-use, provide superior treatment outcomes, receive adequate coverage and reimbursement from third-party payors, and are otherwise more appealing than available alternatives. Our primary competitors, as well as a number of other companies and medical researchers are pursuing new delivery devices, delivery technologies, sensing technologies, treatment techniques, procedures, drugs and other therapies for the monitoring, treatment and prevention of diabetes. Any breakthroughs in diabetes monitoring, treatment or prevention could reduce the potential market for our products or render our products obsolete altogether, which would significantly reduce our sales or cause our sales to grow at a slower rate than we currently expect. In addition, even the perception that new products may be introduced, or that technological or treatment advancements could occur, could cause consumers to delay the purchase of our products.

Because the insulin-dependent diabetes market is large and growing, we anticipate companies will continue to dedicate significant resources to developing competitive products and technologies. The introduction by competitors of products that are or claim to be superior to our products may create market confusion that may make it difficult to differentiate the benefits of our products over competitive products. In addition, some of our competitors employ aggressive pricing strategies, including the use of discounts, rebates, low cost product upgrades or other financial incentives that could adversely affect sales of our products. If a competitor develops a product that competes with or is perceived to be superior to our products, or if competitors continue to utilize strategies that place downward pressure on pricing within our industry, our sales may decline, our operating margins could be reduced and we may fail to meet our financial projections, which would materially and adversely affect our business, financial condition and operating results.

Moreover, we have designed our hardware products to resemble modern consumer electronic devices to address certain embarrassment and functionality concerns consumers have raised with respect to traditional pumps. Similarly, our newer mobile software applications are being designed to incorporate features and functions that are common to other consumer-oriented applications. These consumer industries are themselves highly competitive, and characterized by continuous new product introductions, rapid developments in technology, and subjective and changing consumer preferences. If, in the future, consumers cease to view our products as contemporary or convenient as compared to then-existing consumer technology, our products may become less desirable.

4851

Table of contents

The failure of our insulin pump and related products to achieve and maintain market acceptance could result in us achieving sales below our expectations, which would cause our business, financial condition and operating results to be materially and adversely affected.*

Our current business and growth strategy is highly dependent on our insulin pump and related products achieving and maintaining market acceptance. In order for us to sell our products to people with insulin-dependent diabetes, we must convince them, their caregivers and healthcare providers that our products are an attractive alternative to competitive products for the treatment of diabetes, including traditional insulin pump products and MDI therapies, as well as alternative diabetes monitoring, treatment or prevention methodologies. Market acceptance and adoption of our products depends on educating people with diabetes, as well as their caregivers and healthcare providers, about the distinct features, ease-of-use, beneficial treatment outcomes, and other perceived benefits of our products as compared to competitive products. If we are not successful in convincing existing and potential customers of the benefits of our products, or if we are not able to achieve the support of caregivers and healthcare providers for our products, our sales may decline or we may achieve sales below our expectations.

Market acceptance of our products could be negatively impacted by many factors, including:

•the failure of our products to achieve and maintain wide acceptance among people with insulin-dependent diabetes, their caregivers, healthcare providers, third-party payors and key opinion leaders in the diabetes treatment community;

•lack of evidence supporting the safety, ease-of-use or other perceived benefits of our products over competitive products or other currently available insulin treatment methodologies;

•perceived risks or uncertainties associated with the use of our products, or components thereof, or of similar products or technologies of our competitors;

•adverse regulatory or legal actions relating to our insulin pump products or similar products or technologies; and

•results of clinical studies relating to our existing products or products under development or similar competitive products.

In addition, the rapid evolution of technology and treatment options within our industry may cause consumers to delay the purchase of our products in anticipation of advancements or breakthroughs, or the perception that advancements or breakthroughs could occur, in our products or the products offered by our competitors. It is also possible that consumers interested in purchasing any of our future products currently under development may delay the purchase of one of our current products. We anticipate that customers may continue to delay their purchasing decisions, or physicians may continue to pause prescriptions of our products, as a result of the COVID-19 global pandemic.

If our insulin pump products do not achieve and maintain widespread market acceptance, we may fail to achieve sales consistent with our projections, in which case our business, financial condition and operating results could be materially and adversely affected.

Failure to secure or retain adequate coverage or reimbursement for our current products and our potential future products by third-party payors could adversely affect our business, financial condition and operating results.*

A substantial portion of the purchase price of an insulin pump is typically paid for by third-party payors, including private insurance companies, preferred provider organizations and other managed care providers. Future sales of our current and future products will be limited unless our customers can rely on third-party payors to pay for all or part of the associated purchase cost. Access to adequate coverage and reimbursement for our current and future products by third-party payors, both domestically and internationally, is essential to the acceptance of our products by customers.

4952

Table of contents

As guidelines in setting their coverage and reimbursement policies, many third-party payors in the United States use coverage decisions and payment amounts determined by the Centers for Medicare and Medicaid Services (CMS), which administers the U.S. Medicare program. Medicare periodically reviews its reimbursement practices for diabetes-related products, and there is uncertainty as to the future Medicare reimbursement rate for our products. Effective January 1, 2020, in addition to the existing reimbursement code for insulin pumps, CMS established additional reimbursement codes for insulin pumps with AID and CGM integration and associated supplies. In light of complexities surrounding use and payment of the codes, CMS subsequently determined the new codes will not be valid for Medicare submission at this time. It is also possible that CMS may continue to review and modify the current coverage and reimbursement of diabetes-related products in connection with anticipated changes to the regulatory approval process for insulin pumps and related products, software applications and services. In addition, third-party payors that do not follow the CMS guidelines may adopt different coverage and reimbursement policies for our current and future products. Further, it is possible that some third-party payors will not offer any coverage for our current or future products. For instance, it is possible that third-party payors may adopt policies in the future that designate one or more of our competitors as their preferred, in-network durable medical equipment provider of insulin pumps and that such policies would discourage or prohibit the payors’ members from purchasing our products, which would adversely impact our ability to sell our products.

We currently have contracts establishing reimbursement for our insulin pump products with a number of national and regional third-party payors in the United States. While we may enter into additional contracts both domestically and internationally with third-party payors and add coverage for future products under our current agreements, we cannot guarantee that we will succeed in doing so or that the reimbursement contracts that we are able to negotiate will enable us to sell our products on a profitable basis. In particular, we have limited experience securing reimbursement in international markets. Government involvement in funding healthcare may limit access to or reimbursement for the Company’s products. In addition, existing contracts with third-party payors generally include numerous quality and compliance related requirements, including audit rights, and can be modified or terminated by the third-party payor without cause and with little or no notice to us. ~~Moreover,~~Our compliance with the administrative procedures or requirements ~~of third-party payors~~ may result in increased costs for us and delays in processing approvals by those third-party payors for customers to obtain coverage for our ~~products.~~products, and any payor audits of our compliance obligations may result in requests for refunds or other costs. Failure to secure or retain adequate coverage or reimbursement for our current and future products by third-party payors, or delays in processing approvals by those payors, could result in the loss of sales, which could have a material adverse effect on our business, financial condition and operating results.

Further, the healthcare industry in the United States is increasingly focused on cost containment as government and private insurers seek to control healthcare costs by imposing lower payment rates and negotiating reduced contract rates with third-party payors. If third-party payors deny coverage or reduce their current levels of payment, or if our production costs increase faster than increases in reimbursement levels, we may be unable to sell our products on a profitable basis.

We may face unexpected challenges in marketing and selling our products, and training new customers on the use of our products, which could harm our ability to achieve our sales forecasts.*

We have limited experience marketing and selling our newer products as well as training new customers on their use, particularly in international markets. In addition, the vast majority of our existing customers are individuals with type 1 diabetes, and we have limited experience marketing and selling our products to customers with type 2 diabetes. We anticipate that selling our products to customers with higher insulin requirements, including customers with type 2 diabetes, may be even more difficult following our decision to discontinue sales of new t:flex pumps in the third quarter of 2018.

In addition, due to the current COVID-19 global pandemic, starting in March 2020 we temporarily discontinued in-person activities for our field-based sales and clinical employees and are utilizing technology to remotely engage healthcare providers and customers. While we have authorized limited in-person activities to resume, many restrictions persist that have been imposed by state and local ~~governments,~~governmental authorities or expert agencies, as well as by the health systems and professional organizations with which we interact. The scope and duration of these restrictions on our field-based employees remains highly uncertain, and it is difficult to predict the extent of any adverse impacts on the demand for our products resulting from these restrictions.

Our financial condition and operating results are and will continue to be highly dependent on our ability to adequately promote, market and sell our ~~t:slim X2~~ insulin pump and related products, and the ability of our diabetes educators to train new customers on the use of our products. If our sales and marketing representatives or diabetes educators continue to be restricted in their ability to interact with healthcare providers and customers, our sales could decrease or may not increase at levels that are in line with our forecasts.

5053

Table of contents

If we are unable to maintain our existing sales, marketing, clinical and customer service infrastructure, we may fail to increase our sales to meet our forecasts.*

A key element of our business strategy involves our sales, marketing, clinical and customer service personnel driving adoption of our products. We have significantly increased the number of sales, marketing, clinical and customer service personnel employed by us since we commenced commercial ~~sales in 2012.~~sales. However, we have faced considerable challenges in growing and managing these resources, including with respect to recruiting, training and assimilation of sales territories. We expect to continue to face significant challenges as we seek to further increase the number of our sales, clinical and customer service personnel in order to optimize the coverage of our existing sales territories, as well as expand the number and scope of our existing sales territories. These challenges may be even greater in connection with our commercial expansion outside of the United States, where we have limited experience. Unexpected turnover among our sales, marketing, clinical and customer service personnel, or unanticipated challenges in recruiting additional personnel, would have a negative impact on our ability to achieve our sales projections. Further, if a sales, marketing or clinical representative was to depart and be retained by one of our competitors, we may fail to prevent him or her from helping competitors solicit business from our existing customers, which could adversely affect our sales. Similarly, if we are not able to recruit and retain a network of diabetes educators and customer service personnel, we may not be able to successfully train and service new customers, which could delay new sales and harm our reputation. These risks may be greater now than in the past due to current general labor shortages in the United States, and in particular in our office locations in San Diego, California and Boise, Idaho.

We expect the oversight of our sales, marketing, clinical and customer service personnel will continue to place significant burdens on our management ~~team. These burdens~~team, which may be ~~even higher while~~compounded as we ~~seek to~~ manage ~~and expand a~~ remote ~~workforce~~employees during ~~the duration of~~ the COVID-19 global ~~pandemic.~~pandemic and as we work towards returning personnel to our facilities. If we are unable to retain our personnel in line with our strategic plans, we may not be able to effectively commercialize our existing products or products under development, or enhance the strength of our brand, either of which could result in the failure of our sales to increase in line with our projections or cause sales to decline.

Our sales and marketing efforts are dependent on independent distributors who are free to market products that compete with our products. If we are unable to maintain or expand our network of independent distributors, our sales may be negatively affected.

~~For the year ended December 31, 2019, sales to approximately 55 independent distributors represented approximately 76% of our sales.~~ We believe a majority of our sales will continue to be to independent distributors for the foreseeable future, and it is possible that the percentage of our sales to independent distributors could increase, particularly in light of our reliance on independent distributors outside of the United States. For example, our dependence upon independent distributors domestically could increase if third-party payors decide to contract with independent distributors directly in lieu of contracting with us to supply our products to their members directly. Our dependence upon independent distributors could also increase if customers prefer to purchase all of their diabetes supplies through a single source, instead of purchasing pump-related products through us and other diabetes supplies through other suppliers. None of our independent distributors domestically has been required to sell our products exclusively and each of them may freely sell the products of our competitors. Our distributor agreements in the United States generally have one-year initial terms with automatic one-year renewal terms, and are terminable in connection with a party’s material breach. Our distributor agreements outside of the United States generally have longer initial terms and, in addition to being terminable in connection with a party’s material breach, include provisions that allow us to terminate those agreements prior to their ordinary expiration in specified circumstances. If we are unable to maintain or expand our network of independent distributors, our sales may be negatively affected.

For the year ended December 31, ~~2019,~~2020, our two largest independent distributors in the United States collectively comprised approximately ~~31%~~29% of our worldwide sales, and our three largest independent international distributors collectively comprised approximately ~~60%~~53% of our international sales. If any of our key independent distributors were to cease to distribute our products or reduce their promotion of our products as compared to the products of our competitors, our sales could be adversely affected. In that case, we may need to seek alternative independent distributors or increase our reliance on our other independent distributors or our direct sales representatives, which may not prevent our sales from being adversely affected. Additionally, to the extent we enter into additional arrangements with independent distributors to perform sales, marketing or distribution services, the terms of the arrangements could result in our product margins being lower than if we directly marketed and sold our products.

5154

Table of contents

If the third parties on which we increasingly rely to assist us with our current and anticipated pre-clinical development or clinical trials do not perform as expected, we may not be able to obtain regulatory clearance or approval or commercialize our products.

As our clinical infrastructure expands, we expect to increasingly rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct some of our current and anticipated pre-clinical investigations and clinical trials. If we are not able to reach mutually acceptable agreements with these third parties on a timely basis, these third parties do not successfully carry out their commitments or regulatory obligations or meet expected deadlines, or the quality or accuracy of the data they obtain is compromised due to the failure to adhere to agreed-upon clinical protocols or regulatory requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory clearance or approval for, or successfully commercialize, our products on a timely basis, if at all, and our business, operating results and prospects may be adversely affected.

We are increasingly dependent on clinical investigators and clinical sites to enroll ~~patients~~participants in our current and anticipated clinical trials and human factors studies, and the failure to successfully complete ~~the clinical~~those trials and studies could prevent us from obtaining regulatory approvals for or commercializing our products.*

As part of our product development efforts, we expect to increasingly rely on clinical investigators and clinical sites to enroll ~~patients~~participants in our clinical trials or users in our human factors testing and other third parties to manage such trials and testing and to perform related data collection and analysis. However, we may not be able to control the amount and timing of resources that clinical sites may devote to our clinical ~~trials.~~trials or other studies. If these clinical investigators and clinical sites fail to enroll a sufficient number of patients, fail to ensure compliance by patients with clinical protocols, or fail to comply with regulatory requirements, we may be unable to successfully complete our clinical trials or other studies, which could prevent us from obtaining regulatory approvals for our products and commercializing our products, which would have an adverse impact on our business.

If important assumptions about the potential market for our products are inaccurate, or if we have failed to understand what people with insulin-dependent diabetes are seeking in an insulin pump, our business and operating results may be adversely affected.*

Our business strategy was developed based on a number of important assumptions about the diabetes industry in general, and the insulin-dependent diabetes market in particular, any one or more of which may prove to be inaccurate or may change over time. For example, we believe that the benefits of insulin pump therapy as compared to other common insulin treatment alternatives will continue to drive growth in the market for insulin pump therapy. In addition, we believe the incidence of diabetes in the United States and worldwide is increasing. Further, our view is that diabetes management can vary greatly from person to person, creating multiple market segments based on clinical needs and personal preferences. However, each of these assumptions may prove to be inaccurate and limited sources exist to compare treatment alternatives and obtain reliable market data. The actual incidence of diabetes, and the actual demand for our products or competitive products, could differ materially from our projections if our assumptions are incorrect. In addition, our strategy of focusing exclusively on the insulin-dependent diabetes market may limit our ability to increase sales or achieve profitability.

Another key element of our business strategy is utilizing market research to understand what people with diabetes are seeking to improve in their diabetes therapy management. This strategy underlies our entire product design, marketing and customer support approach and is the basis on which we developed our current products and are pursuing the development of new products. However, our market research is based on interviews, focus groups and online surveys involving people with insulin-dependent diabetes, their caregivers and healthcare providers, which represent only a small percentage of the overall insulin-dependent diabetes market. As a result, the responses we receive may not be reflective of the broader market and may not provide us accurate insight into the desires of people with insulin-dependent diabetes. In addition, understanding the meaning and significance of such market research responses necessarily requires that analysis be conducted and conclusions be drawn. We may not be able perform an analysis that yields meaningful results, or the conclusions we draw from the analysis could be misleading or incorrect. Moreover, even if our market research has allowed us to better understand the features and functionality consumers are seeking in an insulin pump to improve management of their diabetes therapy, there can be no assurance that consumers will actually purchase our products or that our competitors will not develop products with similar features.

5255

Table of contents

We expect to face complexities frequently encountered by companies in competitive and rapidly evolving markets, which may make it difficult to evaluate our business and forecast our future sales and operating results.*

We operate in a competitive and rapidly evolving market. Important industry changes, such as the FDA approval and launch of new products by our competitors, as well as changes specific to our business, such as the timing of our launch of new products currently in development, increasing reliance on digital health products and connected devices, and our potential expansion of commercial sales in international markets, combine to make it more difficult for us to predict our future sales and operating results, as well as our expected timeframe to achieve profitability. The significant uncertainty resulting from the COVID-19 global pandemic ~~will~~has made, and may continue to make, it more difficult for us to accurately forecast our financial results and achieve sustained profitability. In assessing our business prospects, you should consider these factors as well as the various risks and difficulties frequently encountered by companies in competitive and rapidly evolving markets, particularly those companies that manufacture and sell medical devices.

These risks include our ability to:

•implement and execute our business strategy;

•manage and improve the productivity of our sales, marketing, clinical and customer service infrastructure to grow sales of our existing and proposed products, and enhance our ability to provide service and support to our customers;

•achieve and maintain market acceptance of our products and increase awareness of our brand among people with insulin-dependent diabetes, their caregivers and healthcare providers;

•comply with a broad range of regulatory requirements within a highly regulated industry;

•enhance our manufacturing capabilities, increase production of products efficiently while maintaining quality standards, and adapt our manufacturing facilities to the production of new products;

•respond effectively to competitive pressures and developments;

•enhance our existing products and develop proposed products;

•manage cybersecurity and other technological risks associated with our expanding portfolio of digital health products, and align these products to a dynamic threat landscape.

•obtain and maintain regulatory clearance or approval to enhance our existing products and commercialize proposed products;

•perform clinical trials and other studies with respect to our existing products and proposed products; and

•attract, retain and motivate qualified personnel in various areas of our business.

As a result of these or other risks, we may not be able to execute key components of our business strategy, and our business, financial condition and operating results may suffer.

Our ability to achieve profitability will depend, in part, on our ability to reduce the per-unit cost of our products while also increasing production volume.*

We believe our ability to reduce the per-unit cost of our insulin pumps and related products will have a significant impact on our ability to achieve profitability. Our cost of sales includes raw materials and component parts, labor costs, product training expenses, freight, reserves for expected warranty costs, royalties, scrap and charges for excess and obsolete inventories. It also includes manufacturing overhead costs, including expenses relating to quality assurance, manufacturing engineering, material procurement and inventory control, facilities, equipment, information technology and operations supervision and management. Our warranty reserve requires a significant amount of judgment and ~~are~~is primarily estimated based on historical experience. Recently released versions of our pump may not incur warranty costs in a manner similar to previously released pumps and the launch of our mobile app also may result in unanticipated changes in historical trends.

5356

Table of contents

In response to the COVID-19 global pandemic, we have taken steps to prioritize the health and safety of our employees and customers, while working to maintain a continuous supply of products, training and customer support. For example, we have implemented preventative safety measures for our employees involved in production and fulfillment operations as well as for any field-based employees. For employees in other functions, we have adopted measures designed to help employees remain effective in a work-from-home ~~environment.~~environment and we are implementing safety measures and protocols as employees transition back into our facilities. We ~~have~~ also temporarily increased our staffing in certain operations in order to mitigate potential risks associated with increases in unplanned employee absences or illness. Each of these measures has resulted in unanticipated expenses that will negatively impact our gross margin and may adversely impact our ability to achieve profitability. We may also incur additional incremental expenses to help us support our ongoing operations during a period of unpredictable variability in the demand for our products, including throughout the duration of the COVID-19 pandemic.

If we are unable to increase our production volumes while sustaining or reducing our overall cost of sales, including through arrangements such as volume purchase discounts, negotiation of pricing and cost reductions with our suppliers, more efficient training programs for customers, improved warranty performance or fluctuations in warranty estimates, it will be difficult to reduce our per-unit costs and our ability to achieve profitability will be constrained.

In addition, the per-unit cost of our products is significantly impacted by our overall production volumes, and any factors that prevent our products from achieving market acceptance, cause our production volumes to decline, alter our product mix, result in our sales growing at a slower rate than we expect, or result in the closure of our manufacturing facilities, would significantly impact our expected ~~per unit~~per-unit costs, which would adversely impact our gross margins. Further, we may not achieve anticipated improvements in manufacturing efficiency as we undertake actions to expand our manufacturing capacity. If we are unable to effectively manage our overall costs while increasing our production volumes and lowering our per-unit costs, we may not be able to achieve or sustain profitability, which would have an adverse impact on our business, financial condition and operating results.

Manufacturing risks may adversely affect our ability to manufacture products, which could negatively impact our sales and operating margins.*

Our business strategy depends on our ability to manufacture our current and proposed products in sufficient quantities and on a timely basis ~~so as~~ to meet consumer demand, while adhering to product quality standards, complying with regulatory requirements and managing manufacturing costs. We are subject to numerous risks related to our manufacturing capabilities, including:

•quality or reliability defects in product components that we source from third-party suppliers;

•our inability to secure product components in a timely manner due to shipping delays at ports of entry or exit, the impact of the COVID-19 global pandemic, or other issues, in sufficient quantities and on commercially reasonable terms;

•difficulty identifying and qualifying alternative suppliers for components in a timely manner;

•implementing and maintaining acceptable quality systems while experiencing rapid growth;

•our failure to increase production of products to meet demand;

•our inability to modify production lines and expand manufacturing facilities to enable us to efficiently produce future products or implement changes in current products in response to consumer demand or regulatory requirements;

•our inability to manufacture multiple products simultaneously while utilizing common manufacturing equipment;

•government-mandated or voluntary closures of, or operational limitations impacting, our manufacturing facilities; and

•potential damage to or destruction of our manufacturing equipment or manufacturing facilities.

5457

Table of contents

As demand for our products increases, and as the number of our commercial products expands, we will have to invest additional resources to purchase components, hire and train employees, and enhance our manufacturing processes and quality systems. We may also increase our utilization of third parties to perform contracted manufacturing services for us, and we may need to acquire additional custom designed equipment to support the expansion of our manufacturing capacity. In addition, although we expect some of our products under development to share product features and components with our current products, manufacturing of these products may require modification of our production lines, hiring of specialized employees, identification of new suppliers for specific components, qualifying and implementing additional equipment and procedures, obtaining new regulatory approvals, or developing new manufacturing technologies. Ultimately, it may not be possible for us to manufacture these products at a cost or in quantities sufficient to make these products commercially viable.

In response to the COVID-19 global pandemic, in early 2020 we initiated discussions with our key suppliers regarding their abilities to fulfill existing orders and we have continued to regularly assess their capacity. ~~In the second quarter of 2020,~~At various times, our primary infusion set manufacturer experienced certain inventory constraints which resulted in ~~our having to ask~~us requesting some customers to accept substitutions of similar products to prevent delays in order fulfillment. Additionally, at various times our cartridge inventory was below our targeted stocking levels. We ~~now~~ have ~~pump~~acquired finished goods and ~~infusion set~~raw material inventory ~~on hand that meets~~for our products in order to meet targeted stocking levels ~~and continue to focus on increasing our cartridge inventory level.~~in the near-term. Currently, we do not anticipate a significant disruption in our ability to manufacture insulin pumps and cartridges, nor do we anticipate our third-party manufacturers will be unable to provide sufficient quantities to meet product ~~demand.~~demand, however we continue to monitor factors that could negatively impact our longer-term supply chain, such as global shortages of semiconductors and copper that are needed to manufacture our insulin pumps and accessories. If we experience these or similar manufacturing challenges in the future, it could have a negative impact on product sales and harm our reputation.

If we and our suppliers fail to increase our production capacity to meet consumer demand while also maintaining product quality standards, obtaining and maintaining regulatory approvals, and efficiently managing costs, our sales and operating margins could be negatively impacted, which would have an adverse impact on our financial condition and operating results.

We depend on a limited number of third-party suppliers for certain components and products, and the loss of any of these suppliers, their inability to provide us with an adequate supply of components or products, or our ability to adequately forecast customer demand, could harm our business.*

We currently rely, and expect to continue to rely, on third-party suppliers to supply components of our current products and our potential future products, including our disposable cartridges. For example, we rely on plastic injection molding companies to provide plastic molded components, electronic manufacturing suppliers to provide electronic assemblies, and machining companies to provide machined mechanical components. We also purchase all of our infusion sets and pump accessories from third-party suppliers. For our business strategy to be successful, our suppliers must be able to provide us with components and products in sufficient quantities, in compliance with regulatory requirements and quality control standards, in accordance with agreed-upon specifications, at acceptable costs and on a timely basis.

Although we have long-term supply agreements with many of our suppliers, these agreements do not include long-term capacity commitments. Under most of our supply agreements, we make purchases on a purchase order basis and have no obligation to buy any given quantity of components or products until we place written orders, and our suppliers have no obligation to manufacture for us or sell to us any given quantity of components or products until they accept an order. In addition, our suppliers may encounter problems that limit their ability to manufacture components or products for us, including financial difficulties, damage to their manufacturing equipment or facilities, inability to obtain raw materials or other components, or problems with their own suppliers. As a result, our ability to purchase adequate quantities of our components or products may be limited. If we fail to obtain sufficient quantities of high-quality components to meet demand on a timely basis, we could lose customer orders, our reputation may be harmed, and our business could suffer.

5558

Table of contents

We generally use a small number of suppliers for our components and products, some of which are located outside the United States, including in China, Mexico and ~~Mexico.~~Costa Rica. Depending on a limited number of suppliers exposes us to risks, including limited control over costs such as tariffs, availability, quality and delivery schedules. Moreover, in some cases we do not have long-standing relationships with our manufacturers and may not be able to convince suppliers to continue to make components available to us unless there is demand for such components from their other customers. As a result, there is a risk that certain components could be discontinued and no longer available to us. We have in the past been, and we may in the future be, required to make significant “last time” purchases of component inventories that are being discontinued by the manufacturer to ensure supply continuity. If any one or more of our suppliers cease to provide us with sufficient quantities of components in a timely manner or on terms acceptable to us, we would have to seek alternative sources of supply. Because of factors such as the proprietary nature of our products, our quality control standards and applicable regulatory requirements, we cannot quickly engage additional or replacement suppliers for some of our critical components. These risks associated with the procurement of critical components from a limited number of suppliers may be increased as a result of the COVID-19 global pandemic. Failure of any of our suppliers to deliver products at the level our business requires could harm our reputation and limit our ability to meet our sales projections, which could have a material adverse effect on our business, financial condition and operating results.

We place orders with our suppliers using our forecasts of customer demand, which are based on a number of assumptions and estimates, in advance of purchase commitments from our customers. As a result, we incur inventory and manufacturing costs in advance of anticipated sales, which sales ultimately may not materialize or may be lower than expected. If we overestimate customer demand, we may experience higher inventory carrying costs and increased excess or obsolete inventory, which would negatively impact our results of operations. By the same token, if we underestimate future demand we may be unable to meet future production requirements or our inventory of critical materials may be below our targeted stocking levels. We expect it will be particularly difficult to accurately forecast demand during the global ~~pandemic.~~pandemic and even for some time while travel and social-distancing restrictions are lifted.

We may also have difficulty obtaining components from other suppliers that are acceptable to the FDA or other regulatory agencies, and the failure of our suppliers to comply with regulatory requirements could expose us to regulatory action including warning letters, product recalls, termination of distribution, product seizures or civil penalties. Such a failure by our suppliers could also require us to cease using the components, seek alternative components or technologies, and modify our products to incorporate alternative components or technologies, which could necessitate additional regulatory approvals. Any disruption of this nature, or any increased expenses associated with any such disruption, could negatively impact our ability to manufacture our products on a timely basis, in sufficient quantities, or at all, which could harm our commercialization efforts and have a material adverse impact on our operating results.

If we cannot reliably manufacture our proprietary infusion set connector, or if it does not achieve market acceptance, we may not achieve our financial projections.*

In September 2017, we began commercial sales in the United States of products with our customized t:lock connector, which is used to connect our pump cartridge to our infusion set offerings. Our t:lock connector replaced the standard luer-lock connector that historically joined an infusion set to our proprietary disposable insulin cartridges. Concurrently, we began selling infusion sets that are compatible with our t:lock connector. Starting in 2018, we initially offered standard luer-lock cartridges and infusion sets in select international markets, and transitioned to our t:lock connector in international markets during 2019.

We believe the transition to the t:lock connector, for our direct customers and distributors in the United States and international markets, is substantially complete. However, during 2020 there may be limited circumstances where we continue offering both styles of cartridges and infusion sets in international markets to facilitate the transition of customer supplies. Due to the variability in purchasing patterns, standard luer-lock inventories may not be consumed at the predicted rates and we may be required to offer both styles of insulin cartridges and infusion sets for a longer period than anticipated or we may be left with excess quantities of standard luer-lock inventories that we cannot sell at standard prices or at all, which would negatively impact our results of operations.

While the t:lock connector was designed based on customer feedback, and all standard luer-lock infusion sets that we recently offered are now available with the t:lock connector, it is possible that t:lock may not continue to gain market acceptance by current or potential customers, their caregivers, or healthcare providers. Any negative market response to the t:lock connector may impact a current customer’s decision to purchase a new pump from us at the time of renewal. In addition, potential customers may decide not to purchase our insulin pumps if they do not prefer the t:lock connector or t:lock compatible infusion sets, which could have a material adverse impact on our business, financial condition and operating results.

~~Table of contents~~

~~Our business operations areprimarily located in San Diego, California, and any~~ disruption at one of our facilities could adversely affect our business and operating results.*

~~Substantially all~~Although we operate in multiple locations, most of our current operations are still conducted in San Diego, California, including our final pump assembly, some manufacturing processes, ~~R&D activities~~ and the majority of our research and development, management and administrative functions. In addition, the majority of our inventories of component supplies and finished goods is stored at two facilities in San Diego. InOver the ~~second half of 2019,~~past year we ~~commenced~~substantially expanded various quality and customer and technical support activities in Boise, Idaho. ~~We expect our operations in Boise to expand substantially over the next 12 months.~~ We take precautions to safeguard our facilities, including by acquiring insurance, employing back-up generators, adopting health and safety protocols and utilizing off-site storage of computer data. However, vandalism, terrorism or a natural disaster, such as an earthquake, fire or flood, or other catastrophic event, could damage or destroy our manufacturing equipment or our inventories of component supplies and finished goods, cause substantial delays in our operations, result in the loss of key information, result in reduced sales, and cause us to incur additional expenses. Our insurance coverage may not be sufficient to provide coverage with respect to the damages incurred in any particular case, and our insurance carrier may deny coverage with respect to all or a portion of our claims. Regardless of the level of insurance coverage or other precautions taken, damage to our facilities may have a material adverse effect on our business, financial condition and operating results.

Table of contents

We may not experience the anticipated operating efficiencies from the transition of our manufacturing and warehousing operations.*

At the beginning of 2018 we completed the transition of our manufacturing operations to a facility located on Barnes Canyon Road in San Diego, and during the fourth quarter of 2019 we commenced operations at a ~~new~~ logistics warehouse in San Diego. We expect that both of these actions will allow for future capacity for product manufacturing and warehousing expansion. However, we may not experience the anticipated operating efficiencies at either ~~facility.~~facility as we continue to scale our business operations and add manufacturing requirements for products currently under development. In addition, beginning in 2020 we outsourced a portion of our cartridge manufacturing demand to an experienced third-party contract ~~manufacturer.~~manufacturer and we expect to increase our reliance on this third party cartridge manufacturer over the next 24 months while reducing our own internal t:slim cartridge manufacturing capacity in our existing facility. We may consider outsourcing other aspects of our operations in the future. If we fail to achieve the operating efficiencies that we anticipate, our manufacturing and operating costs may be greater than expected, which would have a material adverse impact on our operating results. In addition, we or our third-party contract manufacturers may encounter problems during manufacturing for a variety of reasons, including failure to follow specific protocols and procedures, failure to comply with applicable regulations, equipment malfunction, component part supply constraints and environmental factors, any of which could delay or impede our ability to meet customer demand and have a material adverse impact on our business, financial condition and operating results. Further, because of the custom nature of our cartridge manufacturing process and product components, and the highly regulated nature of our products overall, in the event of any problems with ~~our~~a contract manufacturer, we may not be able to quickly establish additional or alternative arrangements.

We expect that the management and support of our ~~new~~ facilities, increasing reliance on third-party contract manufacturers and the increase of our manufacturing volumes will place significant burdens on our management team, particularly in areas relating to operations, quality, regulatory, facilities and information technology. We may not be able to effectively manage our ongoing manufacturing operations and we may not achieve the operating efficiencies that we anticipate, either from our own facilities or from our use of contract manufacturing. Further, additional increases in demand for our products may require that we further expand our business operations, which may require that we obtain additional facilities, make additional investments in capital equipment or increase our utilization of ~~external third parties to perform contracted manufacturing services for us.~~third-party contract manufacturing.

If we do not enhance our product portfolio to meet the demands of our market, we may fail to effectively compete, which may impede our ability to become profitable.*

In order to increase our sales and market share in the insulin-dependent diabetes market, we must enhance and broaden our product portfolio in response to the evolving demands of people with insulin-dependent diabetes, their caregivers and healthcare providers, as well as competitive pressures and technologies. We may not be successful in developing, obtaining regulatory approval for, or marketing our proposed products when anticipated, or at all. In addition, notwithstanding our market research efforts, our future products may not be accepted by people with insulin-dependent diabetes, their caregivers, healthcare providers or third-party payors. The success of any proposed product offerings will depend on numerous factors, including our ability to:

•identify the product features and functionality that people with insulin-dependent diabetes, their caregivers and healthcare providers are seeking in an insulin pump, and successfully incorporate those features into our products;

•develop and introduce products in sufficient quantities and in a timely manner;

~~Table of contents~~

•offer products at a price that is competitive with other products then available;

•work with third-party payors to obtain reimbursement for our products;

•adequately protect our intellectual property and avoid infringing upon the intellectual property rights of third parties;

•demonstrate the safety and efficacy of proposed products; and

•obtain the necessary regulatory approvals for proposed ~~products.~~products on a timely basis.

Table of contents

If we fail to generate demand by continuing to develop products that incorporate features and functionality requested by people with insulin-dependent diabetes, their caregivers or healthcare providers, or if we do not obtain regulatory clearance or approval for proposed products in time to meet market demand, we may be unable to compete and may fail to generate sales sufficient to achieve or maintain profitability. We have in the past experienced, and may in the future experience, delays in various phases of product development and commercialization, including during research and development, manufacturing, limited release testing, marketing and customer education efforts. We have also recently experienced delays in the regulatory review and approval process, including due to the impacts of the current global pandemic. Any delays in our anticipated regulatory submissions or approvals, or subsequent product launches, may significantly impede our ability to successfully compete in our markets. In particular, such delays could cause customers to delay or forego purchases of our products, or to purchase our competitors’ products. Even if we are able to successfully develop proposed products when anticipated, these products may not produce sales in excess of the costs of development, and they may be quickly rendered obsolete by changing consumer preferences or the introduction by our competitors of products embodying new technologies or features, or alternative methods for the treatment of diabetes.

Any concerns regarding the safety and efficacy of our products could limit sales and cause unforeseen negative effects to our business prospects and financial results.*

Studies to evaluate the safety or effectiveness of our latest products in a controlled setting are only recently available. As a result, people with insulin-dependent diabetes and healthcare providers may not be familiar with our studies and may be slower to adopt or recommend our products. Further, even with data from controlled studies third-party payors may not be willing to provide coverage or reimbursement for our ~~products and we~~products. We remain subject to regulatory and product liability ~~risks. These~~risks, and these and other factors could slow the adoption of our products and result in our sales being lower than anticipated. In addition, future studies or clinical experience may indicate that treatment with our products is not superior to treatment with competitive products. Such results could slow the adoption of our products and significantly reduce our sales, which could prevent us from achieving our forecasted sales targets or achieving or sustaining profitability.

If the results of clinical studies or other experience, such as our monitoring or investigation of customer complaints, indicate that our products may cause or create an unacceptable risk of unexpected or serious complications or other unforeseen negative effects, we could be required to inform our customers of these risks or complications or, in more serious circumstances, we could be subject to mandatory product recalls, suspension or withdrawal of FDA clearance or approval, which could result in significant legal liability, harm to our reputation, and a decline in our product sales.

Any alleged illness or injury associated with any of our products or product recalls may negatively impact our financial results and business prospects depending on a number of factors, including the scope and seriousness of the problem, degree of publicity, reaction of our customers and healthcare professionals, competitive response, and consumer perceptions generally. Even if such an allegation or product liability claim lacks merit, cannot be substantiated, is unsuccessful or is not fully pursued, the negative publicity surrounding any assertion that our products caused illness, injury or death could adversely affect our reputation with customers, healthcare professionals, third-party payors, and existing and potential collaborators, and could adversely affect our operating results and cause a decline in our stock price. Furthermore, general concerns regarding the perceived safety or reliability of any of our products, or any component thereof, may have a similar adverse effect on us.

~~Table of contents~~

We may enter into collaborations, licensing arrangements, joint ventures, strategic alliances or partnerships with third parties that may not result in the development of commercially viable products or the generation of significant future revenues.*

In the ordinary course of our business, we may enter into collaborations, licensing arrangements, joint ventures, strategic alliances or partnerships to develop proposed products or technologies, pursue new markets, or protect our intellectual property assets. We may also elect to amend or modify similar agreements that we already have in place. Proposing, negotiating and implementing collaborations, licensing arrangements, joint ventures, strategic alliances or partnerships may be a lengthy and complex process, and may subject us to business risks. For example, other companies, including those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these opportunities, or may be the counterparty in any such arrangements. We may not be able to identify or complete any such collaboration in a timely manner, on a cost-effective basis, on acceptable terms or at all. In addition, we may not realize the anticipated benefits of any such collaborations that we do identify and complete. In particular, these collaborations may not result in the development of products or technologies that achieve commercial success or result in positive financial results, or may otherwise fail to have the intended impact on our business.

Table of contents

Additionally, we may not be in a position to exercise sole decision-making authority regarding a collaboration, licensing or other similar arrangement, which could create the potential risk of creating impasses on decisions. Further, our collaborators and business partners may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators and other business partners, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any agreement, such as those related to financial obligations, termination rights or the ownership or control or other licenses of intellectual property rights. If any conflicts arise with our current or future collaborators, they may act in their self-interest, which may be adverse to our best interest, and they may breach their obligations to us. In addition, we have limited control over the amount and timing of resources that our current collaborators, such as Dexcom and ~~TypeZero,~~Abbott, or any future collaborators devote to our arrangement with them or our future products. Disputes between us and our current, future or potential collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements are contractual in nature and may be terminated or dissolved under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium.

For example, we have entered into multiple development and commercialization agreements with Dexcom, which provide us non-exclusive licenses to integrate various currently available and future generations of ~~Dexcom~~Dexcom’s CGM technology with our insulin pump products. ~~Our agreements with Dexcom related to G5 and G6 CGM currently run until June 2021 with automatic one-year renewals unless a party provides prior notice to the contrary.~~ Under certain circumstances, these agreements may be terminated by either party without cause or on short notice. Our current agreements with Dexcom do not grant us rights to integrate future generations of Dexcom CGM technology, other than G7 CGM devices, with any of our current or future products. Termination of any of our agreements with Dexcom would require us to redesign certain current products and products under development, and attempt to integrate an alternative CGM system into our insulin pump systems, which would require significant development and regulatory activities that could result in an interruption or substantial delay in the availability of the product to our customers. The termination of our existing commercial agreements with Dexcom would disrupt our ability to commercialize our existing products and our development of future products, which could have a material adverse impact on our financial condition and results of operations, negatively impact our ability to compete and cause our stock price to decline.

We operate our business in regions subject to natural disasters and other catastrophic events, and any disruption to our business resulting from natural disasters will adversely affect our revenue and results of operations.*

We operate our business, and our third-party contract manufactures are located, in regions subject to natural disasters, including earthquakes, hurricanes, floods, fires and other catastrophic events. For example, a portion of our office facilities located in San Diego are in an area that is prone to flooding, which has occasionally temporarily disrupted our business operations. Any natural disaster could adversely affect our ability to conduct business and provide products and services to our customers, and the insurance we maintain may not be adequate to cover our losses resulting from any business interruption resulting from a natural disaster or other catastrophic events. Any future disruptions to our operations could have a material adverse impact on our financial condition and results of operations in future periods.

~~Table of contents~~

A security breach or other significant disruption to our information technology systems, or failures of our pumps’ software to perform as we anticipate, could materially disrupt our operations or result in the loss, theft, misuse, unauthorized disclosure, or unauthorized access to sensitive information relating to our customers, suppliers, employees or other individuals, which could damage our relationships, expose us to litigation or regulatory proceedings, or harm our reputation, any of which could have an adverse and material effect on our business, financial condition and operating results.*

The efficient operation of our business depends on our information technology and communication systems, as well as those of our third-party business partners. We rely on such systems to effectively store, process and transit proprietary sales and marketing data, accounting and financial functions, manufacturing and quality records, inventory management, product development tasks, research and development data, customer service and technical support functions. Our information technology systems, including those that support our t:connect uploader software and cloud-based web application, our current and future mobile applications, our Tandem Source data management platform, as well as those involved in the operation of our Tandem Device Updater, are vulnerable to damage or interruption from a number of causes, including earthquakes, fires, floods and other natural disasters, terrorist attacks, attacks by computer viruses or hackers, malware, ransomware or other destructive software, cyber-attacks, power losses, and computer system or data network failures. Should any of those risks occur, it could adversely impact the availability, confidentiality and integrity of information assets contained in those systems.

Table of contents

Our business also involves the storage and transmission of a substantial amount of confidential, personal, or other sensitive information, including health information and other personal information relating to our customers, the personal information of our employees and other individuals, and our proprietary, financial, operational or strategic information. Should any of the foregoing risks occur, it could also result in the loss, theft, misuse, unauthorized disclosure, or unauthorized access of such sensitive information, which could lead to significant reputational or competitive harm, litigation involving us or our business partners, regulatory proceedings, or substantial liabilities, fines, penalties or expenses. As a result, we strive to maintain and regularly update reasonable security measures, and to respond quickly and effectively if and when data security incidents do occur. Like many businesses, we are subject to numerous data privacy and security risks, including threats arising from computer viruses or hackers, cyber-attacks and ransomware attacks, as well as the risk that one or more of our employees may fail to comply, whether knowingly or accidentally, with established security measures, or with internal policies relating to the use, storage or transmission of confidential or sensitive information. We are unable to predict the direct or indirect impact of any such incidents to our business. Further, many of our third-party service providers are subject to similar risks. Whether or not our security measures and those of our third-party service providers are ultimately successful, our expenditures on those measures could have an adverse impact on our financial condition and results of operations, and divert management’s attention from pursuing our strategic objectives.

In addition to the risks regarding information technology systems and processing of sensitive information, our insulin pumps and other products rely on software, some of which is developed by third-party service providers, that could contain unanticipated vulnerabilities, which could make our products subject to computer viruses, cyber-attacks, or failures. These risks significantly increased ~~after July 2016,~~ when we received FDA clearance of our Tandem Device Updater, which enables customers to remotely update software on their insulin pumps and may be higher following the launch of our new mobile application in the second half of 2020. We may also face new risks relating to our information technology systems as we continue to commercialize our products outside of the United States and are subject to additional regulations relating to the use and protection of personal information and as we launch new mobile applications or new features to our existing applications.

The failure of our or our service providers’ information technology systems or our pumps’ software or other mobile applications to perform as we anticipate, or our failure to effectively implement new information technology systems and privacy policies and controls, could disrupt our entire operation or adversely affect our software products. For example, we market our Tandem Device Updater as having the unique capability to deploy software updates to our pumps, which may allow customers remote access to new and enhanced features. The failure of our Tandem Device Updater to provide software updates as we anticipate, including as a result of our inability to secure and maintain necessary regulatory approvals, the inability of our pumps to properly receive software updates, errors or viruses embedded within the software being transmitted, or the failure of our customers to properly utilize the system to complete the update, could result in decreased sales, increased warranty costs, and harm to our reputation, any of which could have a material adverse effect on our business, financial condition and operating results.

~~Table of contents~~

We experienced a breach of our information technology systems in January 2020.*

On January 17, 2020, we learned that an unauthorized person gained access to an employee’s email account through a cyber-attack commonly known as “phishing.” We investigated the incident, and learned that a limited number of our employee email accounts may have been accessed by an unauthorized user in a similar manner between January 17, 2020 and January 20, 2020. Our ~~continued~~ investigation indicated that customer information, as well as proprietary Company information, may have been contained in one or more of the employee email accounts affected by the incident. Our investigation has not determined whether an unauthorized person viewed any such information. As a result of this incident, we ~~were named~~are presently defending a ~~defendant in three California state court putative class action lawsuits. The three cases were recently combined into a single~~ class action lawsuit entitled Joseph Deluna et alal. v. Tandem Diabetes Care, Inc., which is pending in the Superior Court of the State of California in the County of San Bernardino.

The risks posed by this lawsuit and any future related matters include civil monetary damages, attorney fees and costs, other legal penalties, reputational damage, loss of goodwill, and competitive harm.

Table of contents

If we are found to have violated laws concerning the privacy and security of patient health information or other personal information, we could be subject to civil or criminal penalties, which could increase our liabilities and harm our reputation or our business.*

There are a number of domestic and international laws protecting the privacy and security of personal information. These laws include the U.S. Health Insurance Portability and Accountability Act of 1996 (HIPAA) and related regulations, U.S. state laws (such as the California Consumer Privacy Act (CCPA)), Canada’s Personal Information and Electronic Documents Act (PIPEDA) or the applicable provincial alternatives, the EU’s General Data Protection Regulation (GDPR), EU member states directives, or similar applicable laws. These laws place limits on how we may collect, use, share and store medical information and other personal information, and they impose obligations to protect that information against unauthorized access, use, loss, and disclosure. The putative class action ~~lawsuits~~lawsuit described above ~~allege~~alleges violations of some of these laws.

If we, or any of our service providers who have access to the personal data for which we are responsible, are found to be in violation of the privacy or security requirements of HIPAA, PIPEDA, GDPR, or applicable foreign, U.S. state and Canadian provincial laws, we could be subject to civil or criminal penalties, which could increase our liabilities, harm our reputation and have a material adverse effect on our business, financial condition and operating results. In addition, entities operating in the healthcare industry have increasingly become targets for hackers. Although we utilize a variety of measures to secure the data that we control, even compliant entities can experience security breaches or have inadvertent failures despite employing reasonable practices and safeguards.

We may also face new risks relating to data privacy and security as the United States, individual U.S. states or Canadian provinces, E.U. member states, and other international jurisdictions adopt or implement new data privacy and security laws and regulations as we continue to commercialize our products worldwide. For example, amendments to privacy and security laws (such as the ~~California Consumer Privacy Act, which took effect on January 1, 2020,~~CCPA) may impose additional requirements on us and increase our regulatory and litigation risk. As we continue to expand, our business will need to adapt to meet these and other similar legal requirements.

We depend on the knowledge and skills of our senior management and other key employees, and if we are unable to retain and motivate them or recruit additional qualified personnel, our business may suffer.

We have benefited substantially from the leadership and performance of our senior management, as well as certain key employees. For example, key members of our management have experience successfully scaling an early stage medical device company to achieve profitability. Our success will depend on our ability to retain our current management and key employees, and to attract and retain qualified personnel in the future. Competition for senior management and key employees in our industry is intense and we cannot guarantee that we will be able to retain our personnel or attract new, qualified personnel. The loss of the services of certain members of our senior management or key employees could prevent or delay the implementation and completion of our strategic objectives, or divert management’s attention to seeking qualified replacements. Each member of senior management, as well as our key employees may terminate employment without notice and without cause or good reason. The members of our senior management are not subject to non-competition agreements. Accordingly, the adverse effect resulting from the loss of certain members of senior management could be compounded by our inability to prevent them from competing with us.

~~Table of contents~~

We depend upon key employees in a competitive market, and if we are unable to provide meaningful equity incentives to retain key personnel, it could adversely affect our ability to execute our business strategy.

We are highly dependent upon the members of our management team, as well as other key employees. In our industry, it is common to attract and retain executive talent and other employees with compensation packages that include a significant equity component. We have issued, and may continue to issue, additional equity incentives that we believe will enhance our ability to retain our current key employees and attract the necessary additional executive talent. It may be more difficult to continue to incentivize employees during a period of rapid growth in our overall headcount while limiting the utilization of the share reserve under our current stock incentive plans. However, even if we issue significant additional equity incentives, there can be no assurance that we will be able to attract and retain key executive talent. A loss of any of our key personnel, or our inability to hire new personnel, may have a material adverse effect on our ability to execute our business strategy.

Table of contents

We began commercialization of our products outside of the United States, which may result in a variety of risks associated with international operations that could materially adversely affect our business.*

During 2018, we began commercialization of the t:slim X2 insulin pump in select geographies outside of the United States. We have limited experience commercializing our products outside of the United States and expect that we will be subject to additional risks related to international business markets, including:

•different regulatory requirements for product approvals in foreign countries;

•differing U.S. and foreign medical device import and export rules;

•more restrictive privacy laws relating to personal information of end-users and employees, including ~~GDPR;~~GDPR and other EU member state directives;

•reduced protection for our intellectual property rights in foreign countries;

•unexpected changes in tariffs, trade barriers and regulatory requirements;

•different reimbursement systems;

•economic weakness, including inflation, or political instability in particular foreign economies and markets;

•compliance with tax, employment, immigration and labor laws for employees living or traveling abroad or with U.S. regulations that would apply to activities in such foreign jurisdictions, such as the Foreign Corrupt Practices Act;

•foreign taxes, including withholding of payroll taxes;

•foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country; and

•business interruptions resulting from geopolitical actions, including war and terrorism, natural disasters, or incidence of disease, including as a result of the COVID-19 global pandemic.

In addition, entry into international markets may require significant financial resources, impose additional demands on our manufacturing, quality, regulatory, customer support and other general and administrative personnel, and could divert management’s attention from managing our core business. We have limited experience with regulatory environments and market practices internationally, and we may not be able to penetrate or successfully operate in new markets. ~~Accordingly, if~~If we are unable to expand internationally, manage the complexity of our global operations successfully or if we incur unanticipated expenses, we may not achieve the expected benefits of this expansion and our financial condition and results of operations could be materially and adversely impacted.

~~Table of contents~~

We may seek to grow our business through acquisitions of ~~complementary~~ products or technologies, or investments in businesses, and the failure to successfully manage these acquisitions or investments, or the failure to integrate them with our existing business, could have a material adverse effect on our business, financial condition and operating results.*

From time to time, we may consider opportunities to acquire or invest in other companies, products or technologies that may enhance our product platform or technology, expand the breadth of our markets or customer base, or otherwise advance our business strategies. Potential and completed acquisitions ~~both~~and investments involve numerous risks, including:

•problems assimilating the acquired products or technologies;

•issues maintaining uniform standards, procedures, controls and policies;

•unanticipated costs, impairment charges or write-offs associated with ~~acquisitions;~~acquisitions or investments;

•diversion of management’s attention from our existing business;

Table of contents

•risks associated with entering new markets in which we have limited or no experience; and

•increased legal and accounting costs relating to the acquisitions or to comply with regulatory requirements or other compliance matters.

We may experience one or more or of ~~those~~these risks in connection with our ~~recent~~ acquisition of ~~Sugarmate.~~Sugarmate, which was completed in 2020. We do not know if we will be able to identify future acquisitions or investments we deem suitable, whether we will be able to successfully complete any such acquisitions or investments on favorable terms or at all, or whether we will be able to successfully integrate any acquired products or technologies into our business. Our potential inability to integrate any acquired products or technologies effectively may adversely affect our business, operating results and financial condition.

Risks Related to Our Future Financings and Financial Results ~~and Need for Financing~~

We may need or otherwise determine to raise additional funds in the future and if we are unable to raise additional funds when necessary or desirable, we may not be able to achieve our strategic objectives.*

At ~~September~~June 30, ~~2020,~~2021, we had ~~$464.5~~$545.3 million in cash, cash equivalents and short-term investments. Our management expects the continued growth of our business, including the expansion of our customer service infrastructure to support our growing base of customers, our plans to expand commercial sales of our products outside of the United States, the growth of our manufacturing and warehousing operations, ~~increase~~increasing the size of our facility footprint due to ~~increasing~~increases in headcount and additional R&D activities, will continue to increase our expenses. In addition, the amount of our future product sales is difficult to predict and actual sales may not be in line with our forecasts. Accordingly, our future capital requirements will depend on many factors, including:

•the revenue generated by sales of our insulin pump products, and the related insulin cartridges and infusion sets, and any other future products that we may develop and commercialize;

•the gross profits and gross margin we realize from the sales we generate;

•the costs associated with maintaining and expanding an appropriate sales, marketing, clinical and customer service infrastructure;

•the expenses we incur or other capital expenditures we make to maintain or enhance our manufacturing operations and distribution capabilities, including leasing additional property, hiring additional personnel, and purchasing additional ~~manufacturing equipment and other measures taken to add manufacturing capacity;~~equipment;

•the expenses associated with developing and commercializing our proposed products or technologies;

•
~~the costs associated with maintaining and expanding our customer service infrastructure;~~

~~Table of contents~~

•the cost of obtaining and maintaining regulatory clearance or approval for our products and our manufacturing facilities;

•the cost of ongoing compliance with legal and regulatory requirements;

•the expenses we incur in connection with potential litigation or governmental investigations;

•expenses we may incur or other financial commitments we may make in connection with current and potential new acquisitions, investments, business or commercial collaborations, development agreements or licensing arrangements;

•anticipated or unanticipated capital expenditures;

•unanticipated general and administrative expenses; and

•impacts and disruptions resulting from geopolitical actions, including war and terrorism, natural disasters, or incidence of disease, including as a result of the impacts from the COVID-19 global pandemic.

Table of contents

As a result of these and other factors we may in the future seek additional capital from public or private offerings of our equity or debt securities, or from other sources. If we issue equity or debt securities to raise additional funds, our existing stockholders may experience dilution, we may incur significant financing or debt service costs, and the new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders. In addition, if we raise additional funds through collaborations, licensing, joint ventures, strategic alliances, partnership arrangements or other similar arrangements, it may be necessary to relinquish valuable rights to our potential future products or proprietary technologies, or grant licenses on terms that are not favorable to us.

If we are unable to raise additional capital when necessary, we may not be able to maintain our existing sales, marketing, clinical and customer service infrastructure, enhance our current products or develop new products, take advantage of future opportunities, respond to competitive pressures, changes in supplier relationships, or unanticipated changes in customer demand. Any of these events could adversely affect our ability to achieve our strategic objectives, which could have a material adverse effect on our business, financial condition and operating results.

Our operating results may fluctuate significantly from quarter to quarter.*

There has been and may continue to be meaningful variability in our operating results from quarter to quarter, as well as within each quarter, especially around the time of anticipated new product launches or regulatory approvals by us or our competitors, and as a result of the commercial launch of our products in geographies outside of the United States. Our operating results, and the variability of these operating results, will be affected by numerous factors, including:

•our ability to commercialize and sell our current and future products and our ability to increase sales and gross profit from our ~~insulin pump~~ products, including insulin pumps and the related insulin cartridges and infusion ~~sets, and to commercialize and sell our future products;~~sets;

•the number and mix of our products sold in each quarter;

•acceptance of our products by people with insulin-dependent diabetes, their caregivers, healthcare providers and third-party payors;

•the pricing of our products and competitive products, including the use of discounts, rebates or other financial incentives by us or our competitors;

•the effect of third-party coverage and reimbursement policies;

•our ability to maintain our existing infrastructure;

•the amount of, and the timing of the payment for, insurance deductibles required to be paid by our customers and potential customers under their existing insurance plans;

•interruption in the manufacturing or distribution of our products;

~~Table of contents~~

•our ability to simultaneously manufacture multiple products that meet quality, reliability and regulatory requirements;

•seasonality and other factors affecting the timing of purchases of our products;

•timing of new product offerings, acquisitions, licenses or other significant events by us or our competitors;

•results of clinical research and trials on our existing and future products;

•the ability of our suppliers to timely provide us with an adequate supply of components that meet our requirements for product quality and reliability;

•regulatory clearance or approvals affecting our products or those of our competitors; and

•the timing of revenue and expense recognition associated with our product sales pursuant to applicable accounting standards.

~~Each~~

Table of ~~these factors may be negatively impacted by the COVID-19 global pandemic, which could have the effect of causing greater fluctuations in our operating results in future periods.~~contents

In addition, we expect our operating expenses will continue to increase as we expand our business, which may exacerbate the quarterly fluctuations in our operating results. If our quarterly or annual operating results fall below the expectation of investors or securities analysts, the price of our common stock could decline substantially. Further, any quarterly or annual fluctuations in our operating results may, in turn, cause the price of our common stock to fluctuate substantially, and these price fluctuations could result in further pressure on our stock price. We believe quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.

Risks Related to Our Intellectual Property and Potential Litigation

Our ability to comprehensively protect our intellectual property and proprietary technology is uncertain.*

We rely primarily on patent, trademark and trade secret laws, as well as confidentiality and non-disclosure agreements, to protect our proprietary technologies. As of ~~September~~June 30, ~~2020,~~2021, our patent portfolio consisted of approximately 99110 issued U.S. patents and 7274 pending U.S. patent applications. Of these, our issued U.S. patents expire between approximately 2021 and ~~2038. We are also seeking~~2039. Our foreign patent ~~protection for our proprietary technologies~~portfolio consisted of approximately 32 issued patents and 19 pending patent applications in other countries throughout the world. Of these, our issued foreign patents expire between approximately 2025 and 2033. In addition, we also have 4389 trademark registrations, including 19 U.S. trademark registrations and 2470 foreign trademark registrations.

We have applied for patent protection relating to certain existing and proposed products and processes. If we fail to file a patent application timely in any jurisdiction, ~~we may be precluded from doing so at a later date.~~it could result in us forfeiting certain patent rights in that jurisdiction. Further, we cannot assure you that any of our patent applications will be ~~approved~~granted in a timely manner or at all. The rights granted to us under our patents, and the rights we are seeking to have granted in our pending patent applications, may not ~~be meaningful or~~ provide us with any commercial advantage. In addition, those rights could be opposed, contested or circumvented by our competitors, or be declared invalid or unenforceable in judicial or administrative proceedings. The failure of our patents to adequately protect our technology might make it easier for our competitors to offer the same or similar products or technologies. Even if we are successful in receiving patent protection for certain products and processes, our competitors may be able to design around our patents or develop products that provide outcomes which are comparable to ours without infringing on our intellectual property rights. Due to differences between foreign and U.S. patent laws, our patented intellectual property rights may not receive the same degree of protection in foreign countries as they would in the United States. Even if patents are granted outside of the United States, effective enforcement in those countries may not be available.

We rely on our trademarks and trade names to distinguish our products from the products of our competitors, and have registered or applied to register many of these trademarks. We cannot assure you that our current or future trademark applications will be approved in a timely manner or at all. From time to time, third parties oppose our trademark applications, or otherwise challenge our use of ~~the~~ trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition, and could require us to devote additional resources to marketing new brands. Further, we cannot assure you that competitors will not infringe upon our trademarks, or that we will have adequate resources to enforce our trademarks.

~~Table of contents~~

We have entered into confidentiality agreements and intellectual property assignment agreements with our officers, employees, temporary employees and consultants regarding our intellectual property and proprietary technology. We also enter into confidentiality agreements with potential collaborators and other counterparties, and the terms of our collaboration agreements typically contain provisions governing the ownership and control of intellectual property. In the event of unauthorized use or disclosure or other breaches of those agreements, we may not be provided with meaningful protection for our trade secrets or other proprietary information.

Table of contents

If a competitor infringes ~~upon~~ one of our patents, trademarks or other intellectual property rights, enforcing those patents, trademarks and other intellectual property rights may be difficult, expensive and time consuming. Patent law relating to the scope of claims in the industry in which we operate is subject to rapid change and constant evolution and, consequently, patent ~~positions~~protection in our industry can be uncertain. Even if successful, litigation to defend our patents and trademarks against challenges or to enforce our intellectual property rights could divert management’s attention from managing our business. Moreover, we may not have sufficient resources or incentive to defend our patents or trademarks against challenges or to enforce our intellectual property rights. Litigation also puts our patents at risk of being invalidated or narrowly interpreted ~~narrowly~~ and our patent applications at risk of not issuing. Additionally, pursuing litigation may provoke third parties to assert counterclaims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially valuable. The occurrence of any of these events may have a material adverse effect on our business, financial condition and operating results.

~~The~~Patent litigation in the medical device industry is ~~characterized by patent litigation,~~not uncommon, and from time to time, we may be subject to litigation that could be costly, result in the diversion of management’s time and efforts, or require us to pay damages.*

Our success will depend in part on not infringing the patents or violating the other proprietary rights of third parties. Significant litigation regarding patent rights exists in our industry. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made ~~substantial~~considerable investments in competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make and sell our products. The large number of patents, the rapid rate of new patent issuances, and the complexities of the technology involved increase the risk of patent litigation.

From time to time, we may receive communications from third parties alleging our infringement of their intellectual property rights or offering a license to their intellectual property ~~that is alleged to relate~~relating to products that we are currently developing. Any intellectual property-related discussions, disputes or litigation could force us to do one or more of the following:

•stop selling our products or using technology that ~~contains the~~ allegedly ~~infringing~~infringes third-party intellectual property;

•prevent or limit our ability to sell a product that we are currently developing;

•incur significant legal expenses;

•pay substantial damages to the party whose intellectual property rights we are allegedly infringing;

•redesign those products that ~~contain the~~ allegedly ~~infringing~~infringe third-party intellectual property; or

•attempt to obtain a license to the relevant intellectual property from third parties, which may not be available on reasonable terms or at all.

We do not currently maintain insurance to cover the expense or any liability that may arise from an intellectual property dispute with a third party. Any litigation or claim against us, even those without merit, or even preparing for a potential dispute or litigation before it arises, may cause us to incur substantial costs, and could place a significant strain on our financial resources and divert the attention of management from our core business. Any litigation or claim against us may also harm our reputation. Further, as we launch new products and increase our sales, and the number of participants in the diabetes market increases, we believe the possibility of our involvement in intellectual property disputes will increase.

Table of contents

We may be subject to damages resulting from claims that we, or our employees, have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.

Many of our employees were previously employed at other medical device companies, including those that are our direct competitors or could potentially become our direct competitors. In some cases, those employees joined our company recently. We may be subject to claims that we, or our employees, have inadvertently or otherwise used or disclosed trade secrets

~~Table of contents~~

or other proprietary information of these former employers or competitors. In addition, we have been and may in the future be subject to allegations that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement. Litigation may be necessary to defend against these claims. Even if we successfully defend against these claims, litigation could cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our core business and harm our reputation. If our defense to those claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. We cannot guarantee that this type of litigation will not continue, and any future litigation or the threat thereof may adversely affect our ability to hire additional direct sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize proposed products, which could have an adverse effect on our business, financial condition and operating results.

We may incur product liability losses, and insurance coverage may be inadequate or unavailable to cover these losses.*

Our business exposes us to potential product liability claims that are inherent in the design, manufacture, testing, inspection, and sale of medical devices. We are subject to product liability lawsuits alleging that component failures, manufacturing flaws, manufacturing defects, negligence in manufacturing, design defects, negligence in design, or inadequate disclosure of product-related risks, warnings, or product-related information resulted in an unsafe condition, injury or death to customers. The risk of one or more product liability claims or lawsuits may be even greater after we launch new products with new features or enter new markets where we have no prior experience selling our products and rely on newly-hired staff or new independent distributors or contractors to provide new customer training and customer support. In addition, the misuse of our products or the failure of customers to adhere to operating guidelines could cause significant harm to customers, including death, which could result in product liability claims. We may also identify deficiencies in our products that we determine are immaterial and do not pose safety risks, and therefore decide not to initiate a voluntary recall. However, any such deficiency may be more significant than we expect and lead to product liability claims. Product liability lawsuits and claims, safety alerts or product recalls, with or without merit, could cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our core business, harm our reputation and adversely affect our ability to attract and retain customers, any of which could have a material adverse effect on our business, financial condition and operating results.

Although we maintain third-party product liability insurance coverage, it is possible that claims against us may exceed the coverage limits of our insurance policies. Even if any product liability loss is covered by an insurance policy, these policies typically have substantial deductibles for which we are responsible. In addition, we expect the cost of our product liability insurance will increase as our product sales increase and we may also increase the amount of our deductibles over time. Product liability claims in excess of applicable insurance coverage could have a material adverse effect on our business, financial condition and operating results. In addition, any product liability claim brought against us, with or without merit, could result in further increases of our product liability insurance premiums. Insurance coverage varies in cost and can be difficult to obtain, and we cannot guarantee that we will be able to obtain insurance coverage in the future on terms acceptable to us or at all. Our inability to obtain sufficient insurance coverage to protect ~~again~~against potential product liability claims could prevent or limit our commercialization of current products or products currently under development.

Risks Related to Our Legal and Regulatory Environment

Our products and operations are subject to extensive governmental regulation, and failure to comply with applicable requirements could cause our business to suffer.*

The medical device industry is regulated extensively in the United States by governmental authorities, principally the FDA and corresponding state regulatory agencies. The regulations are very complex and are subject to rapid change and varying interpretations. Regulatory restrictions or changes could limit our ability to carry on or expand our operations or result in higher than anticipated costs or lower than anticipated sales. The FDA and other U.S. governmental agencies and international regulatory authorities regulate numerous elements of our business, including:

•product design and development;

Table of contents

•pre-clinical and clinical testing and trials;

•product safety;

•establishment registration and product listing;

•labeling and storage;

~~Table of contents~~

•marketing, manufacturing, sales and distribution;

•pre-market clearance or approval;

•servicing and post-market surveillance;

•advertising and promotion; and

•recalls and field safety corrective actions.

Before we can market or sell a new regulated product or a significant modification to an existing product in the United States, we must obtain either clearance under Section 510(k) of the ~~FDCA~~Food, Drug and Cosmetic Act or approval of a pre-market approval (PMA) application from the FDA, unless an exemption from pre-market review applies. In the 510(k) clearance process, the FDA must determine that a proposed device is “substantially equivalent” to a device legally on the market, known as a “predicate” device, with respect to intended use, technology and safety, and effectiveness, in order to clear the proposed device for marketing. Clinical data is sometimes required to support substantial equivalence. The PMA pathway requires an applicant to demonstrate the safety and effectiveness of the device based on extensive data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices. Products that are approved through a PMA application generally need FDA approval before they can be modified. Similarly, some modifications made to products cleared through the 510(k) clearance process may require a new 510(k) submission. The process of obtaining regulatory clearances or approvals to market a medical device can be costly and time-consuming, and we may not be able to obtain these clearances or approvals on a timely basis or at all for our proposed products.

If the FDA or other regulatory authority requires ~~us to go through~~ a more rigorous examination for our future products or modifications to existing products than we had expected, our product introductions or modifications could be delayed or canceled, which could cause our sales to decline or to not increase in line with our forecasts.

The FDA or other regulatory authority can delay, limit or deny clearance or approval of one of our devices for many reasons, including:

•our inability to demonstrate that our products are safe and effective for their intended users;

•the data from our pre-clinical studies or clinical trials may be insufficient to support clearance or approval; and

•failure of the manufacturing process or facilities we use to meet applicable requirements.

In addition, the FDA or other regulatory authority may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance of our products under development or impact our ability to modify our currently cleared or approved products on a timely basis. More recently, the FDA has stated that the review process for new submissions may take longer than normal due to the impact of the COVID-19 global pandemic.

Any delay in, or failure to receive or maintain, clearance or approval for our products under development could prevent us from generating revenue from these products or achieving profitability. Moreover, customers may defer purchasing our existing products in anticipation of a new product launch. Additionally, the FDA and other regulatory authorities have broad enforcement ~~powers. Regulatory~~powers, and regulatory enforcement or inquiries, or other increased scrutiny on us, could dissuade some customers from using our products and adversely affect our reputation and the perceived safety and efficacy of our products.

Table of contents

Failure to comply with applicable regulations could jeopardize our ability to sell our products and result in enforcement actions such as fines, civil penalties, injunctions, warning letters, recalls of products, delays in the introduction of products into the market, refusal of the FDA or other regulators to grant future clearances or approvals, delays by the FDA or other regulators in granting clearances or approvals, and the suspension or withdrawal of existing approvals by the FDA or other regulators. Any of these sanctions could result in higher than anticipated costs, lower than anticipated sales, and diversion of management time and resources, any of which could have a material adverse effect on our reputation, business, financial condition and operating results.

~~Table of contents~~

Further, we commenced commercial sales of our products in select international markets during the third quarter of 2018. As we expand our operations outside of the United States and launch new products, we will become subject to various additional regulatory and legal requirements ~~under the applicable laws and regulations of~~in the international markets we enter. These additional legal and regulatory requirements may result in our incurring significant costs and expenditures. We have limited experience complying with applicable laws and regulations in international markets generally, and in particular when we enter new markets, and if we are not able to comply with any such requirements, our international expansion and business could be significantly harmed.

~~Modifications~~New products or modifications to our existing products may require new 510(k) clearances or PMAs, or may require us to cease marketing or recall the modified products until clearances are obtained.*

Any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design, or manufacture, requires a new 510(k) clearance or, possibly, a PMA. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer’s decision. The FDA may not agree with our decisions regarding whether new clearances or approvals are necessary for changes that we have made to our products. If the FDA disagrees with our determination and requires us to submit new 510(k) notifications or PMAs for modifications to our previously cleared or approved products, for which we concluded that new clearances or approvals were not necessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties.

Further, the FDA’s ongoing review of and potential changes to the 510(k) program may make it more difficult for us to modify our previously cleared products, either by imposing stricter requirements on when a new 510(k) for a modification to a previously cleared product must be submitted, or by applying more onerous review criteria to such submissions.

If we or our third-party suppliers, contract manufacturers and service providers fail to comply with the FDA’s good manufacturing practice regulations, this could impair our ability to market our products in a cost-effective and timely manner.*

We and our third-party suppliers, contract manufacturers and service providers are required to comply with the FDA’s Quality System Regulation (QSR), which covers the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of our products. The FDA audits compliance with the QSR through periodic announced and unannounced inspections of manufacturing and other ~~facilities. The FDA~~facilities which may ~~impose inspections or audits~~occur at any time. We cannot assure you that our facilities or our contract manufacturer or ~~component~~third-party suppliers’ facilities would pass any ~~future~~ quality system inspection or audit. If we or our suppliers, contract manufacturers and service providers have significant non-compliance issues or if any corrective action plan that we or our suppliers, contract manufacturers or service providers propose in response to observed deficiencies is not sufficient, the FDA could take enforcement action against us and the manufacturing or distribution of our devices could be interrupted and our operations disrupted.

If we, or our third-party suppliers, contract manufacturers and service providers, fail to adhere to QSR requirements, this could delay production of our products and lead to fines, difficulties in obtaining regulatory clearances, recalls, enforcement actions, including injunctive relief or consent decrees, or other consequences, which could, in turn, have a material adverse effect on our financial condition or results of operations.

Table of contents

A recall or suspension of our products, or the discovery of serious safety issues with our products, could have a significant negative impact on us.*

The FDA and equivalent foreign regulatory authorities have the authority to require the recall or suspension, either temporarily or permanently, of commercialized products in the event of material deficiencies or defects in quality systems, product design or manufacture or in the event that a product poses an unacceptable risk to health. Regulatory authorities have broad discretion to require the recall or suspension of a product or to require that manufacturers alert customers of safety risks, and may do so even in circumstances where we do not believe our product poses an unacceptable risk to health. In addition, manufacturers may, under their own initiative recall a product or suspend sales if any material deficiency in a product is found or alert customers of unanticipated safety risks. A government-mandated or voluntary recall or suspension by us, one of our distributors or any of our other third-party suppliers could occur as a result of an unacceptable risk to health, component failures, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls, suspensions or other notices relating to any products that we distribute would divert managerial and financial resources, and have an adverse effect on our reputation, financial condition and operating results.

~~Table of contents~~

Further, under the FDA’s Medical Device Reporting regulations and equivalent regulations in other geographies, we are required to maintain appropriate quality systems and report incidents in which our product may have caused or contributed to ~~a death or~~ serious injury or death in which our product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to ~~death~~serious injury or ~~serious injury.~~death. Repeated product malfunctions may result in a voluntary or involuntary product recall or suspension of product sales, which could divert managerial and financial resources, impair our ability to manufacture our products in a cost-effective and timely manner and have an adverse effect on our reputation, financial condition and operating results. We have initiated product recalls in the past, and our risk of future product recalls may increase as we launch new products or offer new software updates for existing products.

Any adverse event involving any products that we distribute, either domestically or internationally, could result in future voluntary corrective actions, such as recalls or customer notifications, or regulatory agency action, which could include inspection, mandatory recall or other enforcement action. For example, ~~earlier this year we received a notice from~~ the Australian Therapeutic Goods Administration ~~TGA, proposing to suspend the sale of~~(TGA) temporarily suspended our ~~insulin~~ pump ~~products. Most of our historical pump~~product sales in Australia ~~were of our t:slim X2 with Dexcom G5 CGM and more recently we commenced~~commencing November 24, 2020, however sales of pump-related supplies were allowed to continue. Effective April 1, 2021, following discussions with the TGA, the temporary suspension was lifted for our t:slim X2 with Basal-IQ ~~technology. To~~technology, subject to certain post-market surveillance obligations and other conditions. We have discontinued sales of earlier generation products in Australia and to date we have not offered our Control-IQ technology in ~~Australia. Although we provided a response~~Australia but may elect to ~~this initial regulatory inquiry,~~do so in ~~October 2020 we were informed~~the future. There can be no assurance that the TGA ~~intends to suspend~~will not reimpose the suspension of our pump product sales or impose other regulatory restrictions in ~~Australia commencing November 24, 2020. We intend to work with~~the future. Any regulatory challenges we encounter could have a negative impact on our ~~local independent distributor to meet with the TGA~~product sales and ~~if necessary, seek a review of this action; however, unless the decision is reversed or delayed we will be unable to continue to sell~~harm our ~~pump products in Australia for at least six months.~~reputation. Any corrective actions we take in response to this action or future matters with the TGA or other regulatory bodies, whether voluntary or involuntary, will require the dedication of our time and capital, may distract management from operating our business, may harm our reputation and financial results or could result in additional regulatory scrutiny in other geographies.

Our failure to comply with U.S. federal and state fraud and abuse laws, including anti-kickback laws and other U.S. federal and state anti-referral laws, could have a material, adverse impact on our business.*

There are numerous U.S. federal and state laws pertaining to healthcare fraud and abuse, including anti-kickback laws, physician self-referral laws, and false claims laws. Our relationships with healthcare providers and other third parties are subject to scrutiny under these laws. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, imprisonment and exclusion from participation in federal and state healthcare programs, including the Medicare, Medicaid and Veterans Administration health programs.

Healthcare fraud and abuse regulations are complex and evolving, and even minor irregularities can potentially give rise to claims that a statute or prohibition has been violated. The laws that may affect our ability to operate include:

•the federal healthcare programs’ Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, paying or providing remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind in exchange for or to induce either the referral of an individual for, or the purchase, lease, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and state Medicaid programs;

Table of contents

•federal and state false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, state Medicaid programs, or other third-party payors that are false or fraudulent;

•federal and state physician ~~referral~~self-referral laws, such as the Stark Law, that prohibit a physician from referring Medicare or Medicaid patients to an entity providing “designated health services,” including a company that furnishes durable medical equipment, with which the physician has a financial relationship unless that financial relationship meets an ~~exception;~~exception under the applicable law;

•federal and state laws, such as the Civil Monetary Penalties Law, that prohibit an individual or entity from offering or transferring remuneration to any person eligible for benefits under a federal or state health care program which such individual or entity knows or should know are likely to influence such eligible individual’s choice of provider, practitioner or supplier of any item or service for which payment may be made under federal health care programs such as Medicare and state Medicaid programs;

~~Table of contents~~

•federal criminal laws enacted as part of HIPAA that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;

•federal disclosure laws, such as the Physician Payments Sunshine Act, which require certain manufacturers, including medical device manufacturers, to submit annual data pertaining to payments or other transfers of value to covered recipients, including physicians;

•the Federal Trade Commission Act and similar laws regulating advertisement and consumer protections;

•federal and state laws governing the use, disclosure and security of personal information, including protected health information, such as HIPAA and the Health Information Technology for Economic and Clinical Health; and

•foreign and U.S. state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial ~~insurers; and~~

Possible sanctions for violation of these laws include monetary fines, civil and criminal penalties, exclusion from Medicare, Medicaid and other federal healthcare programs, and forfeiture of amounts collected in violation of those prohibitions and in some circumstances, treble damages. Any violation of these laws, or any action against us for violation of these laws, even if we successfully defend against it, could result in a material adverse effect on our reputation, business, financial condition and operating results. ~~Recently,~~The reporting requirements under the Physician Payments Sunshine Act have been expanded, and we will need to implement additional processes and controls in order to comply with these new tracking and disclosure obligations. Any failure to submit the required data in an accurate and timely manner may result in the imposition of civil monetary penalties. Federal government agencies have issued final rules making modifications to the Anti-Kickback Statute “safe harbors” and the Stark Law regulations, and the full impact of such modifications on the health care industry and our business operations is not yet known. Further, the federal government ~~agencies have~~has published proposed rules for public comment which would make material modifications to ~~several of these laws, including but not limited to the Anti-Kickback Statute, the Stark Law and~~ HIPAA. It is unknown if or when these proposed rules may be adopted and what final form the proposed rules may take and how they may impact our business operations.

To enforce compliance with the federal laws, the U.S. Department of Justice (DOJ) in conjunction with other federal agencies, has increased its scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Dealing with investigations can be ~~time-~~time and resource-consuming and can divert management’s attention from our core business. Additionally, if a healthcare company settles an investigation with the DOJ or other law enforcement agencies, we may be forced to agree to additional onerous compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.

Table of contents

The scope and enforcement of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal or state regulatory authorities might challenge our current or future activities under these laws. Any of these challenges could have a material adverse effect on our reputation, business, financial condition and operating results. Any state or federal regulatory review of us, regardless of the outcome, would be costly and time-consuming. Additionally, we cannot predict the impact of any changes in these laws and whether ~~or not~~they might be retroactive.

We may be liable if we engage in the promotion of the off-label use of our products.*

Our promotional materials and training methods must comply with FDA and other applicable laws and regulations, including the prohibition against the promotion of the off-label use of our products or the pre-promotion of unapproved products. Healthcare providers may use our products off-label, as the FDA does not restrict or regulate a physician’s choice of treatment within the practice of medicine. However, if the FDA determines that our promotional materials or training constitutes promotion of an off-label use or the pre-promotion of an unapproved product, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil ~~fine~~fines and criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties. Although our policy is to refrain from statements that could be considered off-label promotion of our products or pre-promotion of an unapproved product, the FDA or another regulatory agency could disagree and conclude that we have engaged in improper promotional activities. In addition, the off-label use of our products may increase the risk of product liability claims, which are expensive to defend and could result in substantial damage awards against us and harm our reputation.

~~Table of contents~~

Legislative or regulatory healthcare reforms may result in downward pressure on the price of and decrease reimbursement for our products, and uncertainty regarding the healthcare regulatory environment could have a material adverse effect on our business.*

The sales of our products depend in part on the availability of coverage and reimbursement from third-party payors such as government health administration authorities, private health insurers, health maintenance organizations and other healthcare-related organizations. Both the federal and state governments in the United States continue to propose and pass new legislation and regulations designed to, among other things, expand healthcare coverage to more individuals, contain or reduce the cost of healthcare, and improve the quality of healthcare outcomes. This legislation and regulation may result in decreased reimbursement for medical devices, which may create additional pressure to reduce the prices charged for medical devices. Reduced reimbursement rates could significantly decrease our revenue, which in turn would place significant downward pressure on our gross margins and impede our ability to become profitable.

The ~~Patient Protection and~~ Affordable Care Act ~~(PPACA)~~(ACA), substantially changed the way healthcare is financed by both governmental and private insurers, encourages improvements in the quality of healthcare items and services, and significantly impacts the medical device industry. However, a number of legislative changes have been proposed and adopted since the ~~PPACA~~ACA was enacted, and legislation has also been and will likely continue to be proposed that could modify or repeal the ~~PPACA.~~ACA. In addition, the ACA continues to be the subject of various legal challenges. The uncertainties regarding the future of the ~~PPACA,~~ACA, and other healthcare reform initiatives, may have an adverse effect on our customers’ purchasing decisions regarding our products.

In the future, additional changes could be made to governmental healthcare programs that could significantly impact the success of our products. Cost control initiatives could decrease the price that we receive for our products. At this time, we cannot predict which, if any, additional healthcare reform proposals will be adopted, when they may be adopted or what impact they may have on the existing regulatory environment, or our ability to operate our business. Any of these factors could have a material adverse effect on our operating results and financial condition.

Our financial performance may be adversely affected by medical device tax provisions in the healthcare reform laws.*

The PPACA imposed, among other things, an excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States, starting January 1, 2013. In December 2019, the medical device excise tax was repealed. Prior to the repeal, the tax had been suspended for calendar years 2016, 2017, 2018 and 2019. As a result of the repeal and the prior moratorium, sales of taxable medical devices after December 31, 2015, are not subject to the tax. We do not believe that our products were subject to this tax based on the retail exemption under applicable Treasury Regulations. However, the availability of this exemption is subject to interpretation by the Internal Revenue Service (IRS) and the IRS may disagree with our analysis. Additionally, Congress could enact future legislation or further change the law related to the medical device tax in a manner that could adversely affect us. The financial impact such taxes could have on our business is unclear and there can be no assurance that our business would not be materially adversely affected.

Risks Related to Our Common Stock

The price of our common stock may continue to fluctuate significantly.*

The trading price of our common stock has been volatile in recent years. We believe our stock price has been, and will continue to be, subject to wide fluctuations in response to a variety of factors, including the following:

•actual or anticipated fluctuations in our financial and operating results from period to period;

•our actual or perceived need for additional capital to fund our operations;

Table of contents

•market acceptance of our current products and products under development, and the recognition of our brand;

•introduction of proposed products, technologies or treatment techniques by us or our competitors;

•announcements of significant contracts, acquisitions or divestitures by us or our competitors;

•regulatory approval of our products or the products of our competitors, or the failure to obtain such approvals on the projected timeline or at all;

~~Table of contents~~

•speculative trading practices of market participants;

•issuance of securities analysts’ reports or recommendations;

•threatened or actual litigation and government investigations;

•sales of shares of our common stock by our employees, directors or principal stockholders; and

•general political or economic conditions, including the impacts and disruptions caused by the COVID-19 global pandemic.

These and other factors might cause the market price of our common stock to fluctuate substantially. Fluctuations in our stock price may negatively affect the liquidity of our common stock, which could further impact our stock price.

In recent years, the stock market has experienced significant price and volume fluctuations. This volatility has had a significant impact on the market price of securities issued by many companies across many industries. These changes may occur without regard to the financial condition or operating performance of the affected companies. Accordingly, the price of our common stock could fluctuate based upon factors that have little or nothing to do with our company, and these fluctuations could materially reduce the market price of our common stock.

Anti-takeover provisions in our organizational documents and Delaware law may discourage or prevent a change of control, even if an acquisition would be beneficial to our stockholders, which could reduce our stock price and prevent our stockholders from replacing or removing our current management.

Our amended and restated certificate of incorporation and bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions:

•authorize the issuance of preferred stock with powers, preferences and rights that may be senior to our common stock, which can be created and issued by the board of directors without prior stockholder approval;

•provide for the adoption of a staggered board of directors whereby the board is divided into three classes each of which has a different three-year term;

•provide that the number of directors shall be fixed by the board;

•prohibit our stockholders from filling board vacancies;

•provide for the removal of a director only with cause and then by the affirmative vote of the holders of a majority of the outstanding shares;

•prohibit stockholders from calling special stockholder meetings;

•prohibit stockholders from acting by written consent without holding a meeting of stockholders;

•require the vote of at least two-thirds of the outstanding shares to approve amendments to the certificate of incorporation or bylaws; and

Table of contents

•require advance written notice of stockholder proposals and director nominations.

We are subject to the provisions of Section 203 of the Delaware General Corporation Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including a merger, tender offer or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.

~~Table of contents~~

Our board of directors is authorized to issue and designate shares of our preferred stock in additional series without stockholder approval.

Our amended and restated certificate of incorporation authorizes our board of directors, without the approval of our stockholders, to issue 5,000,000 shares of our preferred stock, subject to limitations prescribed by applicable law, rules and regulations and the provisions of our amended and restated certificate of incorporation, as shares of preferred stock in series, and to establish from time to time the number of shares to be included in each such series, and to fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations or restrictions thereof. The powers, preferences and rights of these additional series of preferred stock may be senior to or on parity with our common stock, and the issuance of such shares in the future may reduce the value of our common stock.

~~U.S. federal income tax reform could adversely affect us and our stockholders.~~

On December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act (2017 Tax Act) which significantly reforms the Internal Revenue Code of 1986, as amended (the Code). The 2017 Tax Act, among other things, includes changes to U.S. federal tax rates, imposes significant additional limitations on the deductibility of interest, allows for the expensing of capital expenditures, and puts into effect the migration from a “worldwide” system of taxation to a territorial system. We do not expect tax reform to have a material impact on our projection of minimal cash taxes. Our net deferred tax assets and liabilities were revalued at the newly enacted U.S. corporate rate, and the impact was recognized in our tax expense, offset by a full valuation allowance, in the year of enactment. We continue to examine the impact that this tax reform legislation may have on our business. The impact of this tax reform on holders of our common stock is uncertain and could be adverse.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.*

As of December 31, ~~2019,~~2020, we had accumulated federal and state net operating loss (NOL) carryforwards of approximately ~~$248.7~~$340.0 million, and $288.7 million, respectively, which ~~includes~~included the reduction recorded in 2019 discussed below. Of the total federal ~~net operating loss~~NOL carryforwards, approximately $131.5 million were generated after January 1, 2018, and therefore do not expire. NOL generated after January 1, 2018, is subject to 80% limitation in accordance with the Tax Cuts and Jobs Act of 2017. The remaining federal NOL carryforwards of $208.5 million will begin to expire in 2026, and state tax loss carryforwards begin to expire in 2021, unless previously utilized. If there is an “ownership change” with respect to our company, as defined under Section 382 of the Code, the utilization of our NOL and research credit carryforwards may be subject to substantial limitations imposed by the Code, and similar state provisions. Limitations imposed on our ability to utilize NOL carryforwards could cause U.S. federal income taxes to be paid earlier than would be paid if such limitations were not in effect and could cause NOL carryforwards to expire unused, in each case reducing or eliminating the benefit of our NOL carryforwards. In general, an ownership change occurs whenever there is a shift in ownership of our company by more than 50% by one or more 5% stockholders over a specified time period.

We have completed ~~an analysis~~analyses through December 31, ~~2018~~2020 to determine whether our net operating losses and credits are likely to be limited by Section 382. Based on ~~this~~the 2018 study completed in 2019, the Company determined that offerings of our securities caused an ownership change, as defined under Section 382, in 2018 and the resulting limitation significantly reduced the Company’s ability to utilize its net operating loss and credit carryovers before they expire. As a result, in 2019 the Company significantly reduced its deferred tax assets for the net operating loss and research credit carryforwards that ~~are~~were projected to expire unused. In addition, future ownership changes under Section 382 may further limit the Company’s ability to fully utilize any remaining tax benefits.

With respect to our NOLs generated in 2018 and thereafter, the 2017 Tax Act may reduce the tax benefit of our NOLs. Under the 2017 Tax Act, our ability to carry back NOLs incurred after December 31, 2017 to previous tax years is eliminated. Under prior law, we could carry back NOLs for two years and carry forward NOLs for 20 years. Under the 2017 Tax Act, NOL carryforwards may be carried forward indefinitely. However, for NOLs arising after December 31, 2017, NOL carryforwards will be limited to 80% of our taxable income. Our NOLs generated in 2017 and in prior years will not be subject to the limitations under the 2017 Tax Act.

In response to the COVID-19 global pandemic, ~~The~~the CARES Act was enacted on March 27, 2020, to provide aid and economic stimulus to the economy. Among other provisions, the CARES Act eliminates the 80% NOL limitation for tax years 2018, 2019, and 2020, and allows NOLs generated in those years to be carried back for five years. ~~Due to the recent enactment~~We believe that any impact of the CARES Act weprovisions are ~~currently unable~~not significant to ~~quantify the impact that the CARES Act will have on~~ our financial position, results of operations or cash ~~flows, although we do not anticipate the impact to be significant.~~

~~Table of contents~~

flows.

We do not intend to pay cash dividends.

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings for use in the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Accordingly, investors may have to sell some or all of their shares of our common stock in order to generate cash flow from their investment.

Table of contents

If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.

Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. For example, Mr. Sheridan, our principal executive officer, and Ms. Vosseller, our principal financial and accounting officer, are involved in a personal relationship and share a primary residence. While our board of directors is informed of the relationship and appropriate actions have been taken to ensure compliance with Company policies and procedures, the existence of this relationship could create additional risk, or the perception of additional risk, that our controls and procedures may not be effective. In addition, any testing by us conducted in connection with Section 404(a) of the Sarbanes-Oxley Act, or any testing conducted by our independent registered public accounting firm in connection with Section 404(b) of the Sarbanes-Oxley Act may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our consolidated financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.

We are required to disclose changes made to our internal control procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.

We may be at increased risk of securities class action litigation.

In the past, securities class action litigation has been instituted against companies following periods of volatility in the overall market and in the price of a company’s securities. We believe this risk may be particularly relevant to us as we have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business, financial condition and results of operations. Our stock price volatility and the increase in our market capitalization during the past year may also result in higher expenses associated with our directors’ and officers’ liability insurance program.

If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline.

The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. In addition, if our operating results fail to meet the forecasts of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our stock price and trading volume to decline.

Risks Related to ~~our~~Our Convertible Senior Notes

We have indebtedness in the form of convertible senior notes, which could adversely affect our financial condition and our ability to respond to changes in our business.*

In May 2020, we completed the offering of $287.5 million principal amount of 1.50% Convertible Senior Notes due 2025 (the Notes), which we refer to as the Note Offering. Holders of the Notes will have the right to require us to repurchase their Notes upon the occurrence of a fundamental change (as defined in the indenture governing the Notes) at a purchase price equal to 100% of the principal amount of the Notes to be purchased, plus accrued and unpaid interest, if any. In addition, upon conversion of the Notes, unless we elect to deliver solely shares of our common stock to settle such conversion, we will be

~~Table of contents~~

required to make cash payments in respect of the Notes being converted. Furthermore, the indenture governing the Notes provides that, in the event of an event of default (as defined in the indenture) for the Notes, ~~it may result in~~ the principal, premium, if any, and interest, if any, ~~becoming~~may become due prior to the maturity date for the Notes. There can be no assurance that we will be able to pay these amounts when due, or that we will be able to refinance this indebtedness on acceptable terms or at all.

As a result of our increased level of indebtedness ~~after the completion of~~due to the Notes Offering:

Table of contents

•our level of vulnerability to adverse economic conditions and competitive pressures ~~will~~may be heightened;

•we ~~will be~~are required to dedicate a portion of our liquidity position or cash flow from operations to interest payments, limiting the availability of cash for other purposes;

•our flexibility in planning for, or reacting to, changes in our business and industry may be more limited; and

•our ability to obtain additional financing in the future for working capital, capital expenditures, acquisitions, investments or general corporate ~~purposes or other~~ purposes may be impaired.

We cannot be sure that our leverage resulting from the completion of the Notes Offering will not materially and adversely affect our ability to finance our operations or capital needs or to engage in other business activities. In addition, we cannot be sure that additional financing will be available when required or, if available, will be on terms satisfactory to us.

Servicing the Notes will require a significant amount of cash, and we may not have sufficient cash flow from our business to repay the Notes.*

Our ability to make scheduled payments of the principal and interest on or to refinance the Notes depends on our future business operations and liquidity, which are subject, to some extent, on economic, financial, regulatory, competitive and other factors that are beyond our control, including, without limitation, market acceptance of our products, regulatory approval for our products under development, and the impacts and disruptions caused by the COVID-19 global pandemic. Our business may not generate or sustain a level of cash flow from operations sufficient to service the Notes and any future indebtedness we may incur, while operating our business and making necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as reducing or delaying capital expenditures, selling or licensing assets, refinancing indebtedness, or obtaining additional equity capital. These alternative measures may not be successful and may not permit us to meet our scheduled debt service obligations. Our ability to successfully engage in these activities will depend on a number of factors, including the value of our assets, our operating results and financial condition, the value of our common stock, and the status of the capital markets at such time. We may not be able to engage in any of these activities on commercially reasonable terms or at all, which could result in a default on the Notes or our future indebtedness.

We may incur substantial additional debt or take other actions which could diminish our ability to make payments on the Notes.*

We and our subsidiaries are not prevented by the terms of the indenture governing the Notes, or otherwise, from incurring substantial additional indebtedness in the future, which may include the issuance of secured debt. We are not restricted under the terms of the indenture governing the Notes from incurring additional indebtedness, securing existing or future indebtedness, or recapitalizing our indebtedness. We are similarly not restricted under the terms of the indenture from taking a number of other actions that could have the effect of diminishing our ability to make payments on the Notes when due.

We may not have the ability to raise the funds necessary to repurchase the Notes upon a fundamental change, or to settle conversions of the Notes, and our future indebtedness may contain limitations on our ability to pay cash upon repurchase or conversion of the Notes.*

Holders of the Notes have the right to require us to repurchase their Notes upon the occurrence of a fundamental change at a ~~fundamental change~~ repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any. In addition, upon conversion of the Notes, unless we elect to deliver solely shares of our common stock to settle such conversion, we will be required to make cash payments in respect of the Notes being converted. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of Notes surrendered therefor or Notes being converted. In addition, our ability to repurchase the Notes or to pay

~~Table of contents~~

cash upon conversions of the Notes may be limited by law, by regulatory authority or by agreements governing our future indebtedness. Our failure to repurchase Notes at a time when the repurchase is required by the indenture, or to pay any cash payable on future conversions of the Notes as required by the indenture, would constitute an event of default under the indenture. An event of default under the indenture, or the fundamental change itself, could also lead to an event of default under agreements governing any future indebtedness we may have issued. If the repayment of the related indebtedness were to be accelerated, we may not have sufficient funds to repay the indebtedness, while also repurchasing the Notes or making cash payments upon conversions thereof.

Table of contents

The conditional conversion feature of the Notes may adversely affect our liquidity.*

In the event the conditional conversion feature of the Notes is triggered, holders of the Notes will be entitled to convert the Notes at any time during specified periods at their option. If one or more holders elect to convert their Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock, we would be required to settle all or a portion of our conversion obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their Notes, we could be required, under applicable accounting rules, to reclassify all or a portion of the outstanding principal of the Notes as a current rather than long-term liability, which would adversely affect our liquidity.

The accounting method for convertible debt securities that may be settled in cash, such as the Notes, could have a material effect on our reported financial results.*

Under Accounting Standards Codification 470-20, Debt with Conversion and Other Options (“ASC 470-20”), an entity must evaluate the ability to separately account for the liability and equity components of the convertible debt instruments (such as the Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer’s economic interest cost. The determination of the effect of the guidance on the accounting for the Notes is that the equity component has been included in the additional paid-in capital section of stockholders’ equity on our consolidated balance sheet at the issuance date, and the value of the equity component has been treated as debt discount for purposes of accounting for the debt component of the Notes. As a result, we have recorded non-cash interest expense as a result of the amortization of the discounted carrying value of the Notes to their face amount over the term of the Notes. Accordingly, we have reported a greater net loss in our financial results because the guidance requires interest to include both the amortization of the debt discount and the instrument’s coupon interest rate, which could adversely affect the trading price of our common stock.

In addition, under certain circumstances, convertible debt instruments (such as the Notes) that may be settled entirely or partly in cash are currently accounted for utilizing the treasury stock method, the effect of which is that the shares issuable upon conversion of the Notes are not included in the calculation of diluted earnings (loss) per share except to the extent that the conversion value of the Notes exceeds their principal amount. Under the treasury stock method, for diluted earnings (loss) per share purposes, the transaction is accounted for as if the shares of common stock that would be necessary to settle such excess, if we elected to settle such excess in shares, are issued.

In July 2019, the FASB issued an exposure draft that proposes to change the accounting for convertible debt instruments that are similar to the Notes. Under the current exposure draft, an entity may no longer be required to separately account for the liability and equity components of convertible debt instruments. If the exposure draft is adopted in its current form, this could have the impact of reducing non-cash interest expense, and thereby reducing our net loss, or increasing our net income. Additionally, as currently proposed, the treasury stock method for calculating earnings (loss) per share will no longer be allowed for convertible debt instruments whose principal amount may be settled using shares. Rather, the if-converted method may be required, which would increase our diluted loss per share, or decrease our diluted earnings per share. We cannot be sure that this exposure draft will be issued, or will be issued in its current format. We also cannot be sure whether other changes may be made to the current accounting standards related to the Notes, or otherwise, that could have an adverse impact on our financial statements.

Conversion of the Notes will, to the extent we deliver shares upon conversion of such Notes, dilute the ownership interest of existing stockholders and may otherwise have a negative impact on the trading price of our common stock.*

The conversion of some or all of the Notes will dilute the ownership interests of existing stockholders, including holders who had previously converted their Notes, to the extent we deliver shares upon conversion of any of the Notes. Any sales in the public market of the common stock issued upon the conversion of the Notes could adversely affect prevailing market prices of our common stock. In addition, the perception that some or all of the Notes may be converted into shares of our common stock in the future could have a negative impact on the trading price of our common stock.

~~Table of contents~~

The fundamental change repurchase feature of the Notes may delay or prevent an otherwise beneficial takeover attempt.*

The terms of the Notes require us to repurchase the Notes in the event of a fundamental change. A takeover of the Company would trigger an option of the holders of the Notes to require us to repurchase the Notes. In addition, if a make-whole fundamental change (as defined in the indenture) occurs prior to the maturity date of the Notes, we will, in some cases, be required to increase the conversion rate of the Notes for a holder that elects to convert its Notes in connection with such make-whole fundamental change. These and other provisions set forth in the indenture may have the effect of delaying or preventing a takeover of the Company.

The Capped Call Transactions may affect the value of the Notes and our common stock.*

In connection with the issuance of the Notes, we entered into ~~the~~capped call transactions (the Capped Call ~~Transactions~~Transactions) with the option counterparties. The Capped Call Transactions are expected generally to reduce the potential dilution to our common stock upon any conversion of the Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to a cap.

The option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to our common stock and/or purchasing or selling our common stock or other securities of ours in secondary market transactions prior to the maturity of the Notes (and are likely to do so during any observation period related to a conversion of Notes). This activity could also cause or avoid an increase or a decrease in the market price of our common stock or the Notes, which could affect a Note holder’s ability to convert the Notes and, to the extent the activity occurs during any observation period related to a conversion of Notes, it could affect the number of shares and the value of the consideration that a Note holder will receive upon conversion of the Notes. In addition, if such Capped Call Transactions fail to become effective, the option counterparties or their respective affiliates may unwind their hedge positions with respect to our common stock, which could adversely affect the value of our common stock.

The potential effect, if any, of any of these transactions and activities on the market price of our common stock or the Notes will depend in part on market conditions and cannot be ascertained at this time, but any of these activities could adversely affect the value of our common stock and the value of the Notes and, under certain circumstances, the ability of the Note holders to convert the Notes.

We do not make any representation or prediction as to the direction or magnitude of any potential effect that the transactions described above may have on the value of the Notes or the trading price of our common stock. In addition, we do not make any representation that the option counterparties will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice.

Table of contents

We are subject to counterparty risk with respect to the Capped Call Transactions*Transactions.

The option counterparties are financial institutions, and we will be subject to the risk that any or all of them may default under the Capped Call Transactions. Our exposure to the credit risk of the option counterparties will not be secured by any collateral. ~~Recent global economic conditions, in particular those related to the COVID-19 global pandemic, have resulted in the failure or financial difficulties of many financial institutions.~~ If an option counterparty becomes subject to insolvency proceedings, we will become an unsecured creditor in those proceedings, with a claim equal to our exposure at that time under our transactions with that option counterparty. Our exposure will depend on many factors but, in general, an increase in our exposure will be correlated to an increase in the market price and volatility of our common stock. In addition, upon a default by an option counterparty, we may suffer more dilution than we currently anticipate with respect to our common stock. We can provide no assurances as to the financial stability or viability of the option counterparties.

7881

Table of contents

Item 6. Exhibits

Incorporated by Reference

Provided Herewith

Exhibit Number

Exhibit Description

Form

File No.

Date of First Filing

Exhibit Number

~~10.1~~

~~Second Amendment toLease Agreement~~by ~~andBetweenARE-11025/11075 ROSELLE STREET, LLC, and Tandem Diabetes Care, Inc.~~

~~10.2~~

~~Fifth Amendment to Lease Agreement by and Between ARE-11025/11075 ROSELLE STREET, LLC, and Tandem Diabetes Care, Inc.~~

31.1

Certification of John F. Sheridan, Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Leigh A. Vosseller, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**

Certification of John F. Sheridan, Chief Executive Officer, pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**

Certification of Leigh A. Vosseller, Chief Financial Officer, pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

XBRL Instance Document.

101.SCH

XBRL Taxonomy Extension Schema Document.

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB

XBRL Taxonomy Extension Label Linkbase Document.

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document.

104

Cover Page Interactive Data File (embedded within the Inline XBRL Document contained in Exhibit 101)

* ~~Indicates management contract or compensatory plan.~~

** This certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the registrant specifically incorporates it by reference.

7982

Table of contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Tandem Diabetes Care, Inc.

Dated: ~~November 5, 2020~~August 4, 2021	By:	/s/ John F. Sheridan
		John F. Sheridan President and Chief Executive Officer (on behalf of the registrant and as the registrant’s Principal Executive Officer)

Dated: ~~November 5, 2020~~August 4, 2021	By:	/s/ Leigh A. Vosseller
		Leigh A. Vosseller Executive Vice President, Chief Financial Officer and Treasurer (on behalf of the registrant and as the registrant’s Principal Financial and Accounting Officer)

8083


Years Ending December 31,
2020 (remaining)	$	2,314
2021	9,421
2022	8,710
2023	4,386
2024	1,881
Thereafter	3,975
Total undiscounted lease payments	30,687
Less: amount representing interest	(3,429)
Present value of operating lease liabilities	27,258
Less: current portion of operating lease liabilities	(9,365)
Operating lease liabilities - long-term	$	17,893